compound|predicate|object|pmid
bombesin|isa|tetradecapeptide|11996
bombesin|augments|gastric|11996
caerulein|affects|acidification|11996
caerulein|augments|pancreas|2717605
bombesin|causes|acute edematous pancreatitis|2717605
bombesin|part_of|rats|2717605
bombesin|augments|pancreas|2717605
caerulein|augments|pancreatic juice secretion|2717605
bombesin|isa|tetradecapeptide|2717605
bombesin|affects|growth|3438303
Bombesin|coexists_with|protein|3438303
Bombesin|coexists_with|RNA|3438303
caerulein|inhibits|amylase|3438303
bombesin|inhibits|amylase|3438303
bombesin|inhibits|lipase|3438303
caerulein|inhibits|lipase|3438303
exenatide|affects|pancreatitis|20923958
exenatide|administered_to|rats|20923958
exenatide|part_of|mice|20923958
caerulein|causes|pancreatitis|20923958
IL-1beta|isa|cytokines|20923958
IL-6|isa|cytokines|20923958
lipase|treats|rats|20923958
exenatide|inhibits|CRN|20923958
lipase|treats|rodents|20923958
exenatide|treats|pancreatitis|20923958
Exenatide|neg_causes|pancreatitis|20923958
melittin|isa|bee venom|21939783
melittin|causes|AP|21939783
cytokine|part_of|pancreatic|21939783
melittin|disrupts|cell death|21939783
melittin|disrupts|AP|21939783
bee venom|associated_with|pancreatitis|23918150
BV|interacts_with|apamin|23918150
apamin|affects|AP|23918150
apamin|associated_with|AP|23918150
apamin|stimulates|JNK|23918150
Apamin|disrupts|pancreatitis|23918150
Bombesin|treats|dogs|367854
bombesin|augments|gastric acid secretion|367854
bombesin|treats|dogs|367854
tetradecapeptide|disrupts|renal blood flow|1012339
Bombesin|augments|renin activity|1012339
bombesin|treats|dogs|1012339
bombesin|disrupts|renal blood flow|1012339
erythropoietin|treats|dog|1012339
bombesin|interacts_with|erythropoietin|1012339
Bombesin|isa|tetradecapeptide|1204836
bombesin|part_of|dogs|1204836
bombesin|causes|systemic hypertension|1204836
bombesin|causes|occlusion|1204836
bombesin|treats|dogs|1204836
bombesin|inhibits|bombesin receptors|1324941
Bombesin|causes|contraction|1324941
captopril|isa|peptidase inhibitors|1324941
bestatin|isa|peptidase inhibitors|1324941
ATP|interacts_with|purinoceptors|1324941
peptidase inhibitors|interacts_with|bombesin|1324941
bestatin|interacts_with|bombesin|1324941
captopril|interacts_with|bombesin|1324941
agonist|causes|contraction|1324941
agonist|inhibits|tachykinin|1324941
somatostatin analogues|coexists_with|agonists|1363977
somatostatin analogues|coexists_with|bombesin/GRP antagonists|1363977
RC-160|treats|prostate cancer|1363977
agonistic|treats|prostate cancer|1363977
substance P|isa|neurotransmitter|1373071
substance P|interacts_with|neuropeptide receptors|1373071
substance P|disrupts|DNA synthesis|1373071
agonist|interacts_with|luteinizing hormone-releasing hormone|1376910
bombesin antagonist|coexists_with|RC-160|1376910
EGF|isa|treatment|1376910
EGF|uses|bombesin antagonist|1376910
RC-160|coexists_with|agonists|1376910
RC-3095|disrupts|growth|1376910
bombesin|disrupts|prostate cancer|1376910
RC-3095|disrupts|growth|1460673
bombesin|interacts_with|bombesin|1460673
bombesin|interacts_with|gastrin-releasing peptide receptor|1460673
RC-3095|administered_to|mice|1460673
RC-3095|part_of|nucleolar organizer region|1460673
bombesin|disrupts|Growth|1460673
peptides|affects|neurones|1515936
peptides|interacts_with|bombesin|1515936
neuromedin C|compared_with|neuromedin B|1515936
peptides|interacts_with|neuromedin B|1515936
peptides|interacts_with|neuromedin C|1515936
agonist|stimulates|neuromedin C|1515936
Bombesin|treats|rat|1515936
luteinizing hormone-releasing hormone|disrupts|growth|1682039
bombesin antagonists|treats|hamsters|1682039
epidermal growth factor receptors|associated_with|pancreatic cancers|1682039
RC-160-II|affects|tumors|1682039
RC-3095|affects|experimental pancreatic tumors|1682039
RC-160|interacts_with|RC-3095|1682039
RC-3095|affects|tumor growth|1682040
bombesin antagonists|disrupts|colon cancer growth|1682040
bombesin/gastrin releasing peptide antagonist|disrupts|growth|1682040
cholecystokinin|part_of|pancreas|1715085
pentagastrin|part_of|pancreas|1715085
bombesin|part_of|pancreas|1715085
putrescine|isa|polyamine|1715085
spermine|isa|polyamine|1715085
spermidine|isa|polyamine|1715085
spermidine|isa|protein|1715085
putrescine|isa|protein|1715085
spermine|isa|protein|1715085
hormones|treats|rats|1715085
RNA|part_of|pancreatic|1715085
hormones|administered_to|rats|1715085
spermidine|part_of|Pancreatic|1715085
putrescine|part_of|pancreatic|1715085
CCK|treats|rats|1715085
pentagastrin|treats|rats|1715085
bombesin|treats|rats|1715085
cholecystokinin|affects|pancreas|1715085
pentagastrin|affects|pancreas|1715085
bombesin|affects|pancreas|1715085
bombesin|disrupts|food intake|1788139
BN|interacts_with|BN|1788139
BN receptor antagonist|interacts_with|BN|1788139
BN receptors|part_of|brainstem|1788139
BN|affects|food intake|1788139
bombesin|treats|rats|1923941
bombesin|affects|gastric acid output|1923941
GRP|treats|rats|1923941
pentagastrin|part_of|rats|1923941
bombesin|produces|GRP|1923941
bombesin antagonist|affects|gastric function|1923941
bombesin|neg_affects|gastric emptying|2033507
bombesin|disrupts|gastric emptying|2033507
gastrin releasing peptide|affects|gastric function|2033507
Bombesin|affects|gastric emptying|2033507
bombesin|treats|rats|2086245
bombesin|affects|core body temperature|2207705
bombesin|treats|rat|2207705
bombesin|causes|hypothermia|2217515
peptides|affects|autonomic functions|2217515
insulin|part_of|rat|2217515
Bombesin|neg_causes|hypothermia|2217515
saline|isa|injections|2356153
saline|uses|saline|2356153
CCK|treats|rats|2356153
BBS|treats|rats|2356153
bombesin|treats|dogs|2359987
peptide|affects|gastric|2359987
Bombesin|disrupts|gastric acid secretion|2409424
gastrin releasing peptide|disrupts|gastric acid secretion|2409424
bombesin|associated_with|toxicity|2409424
bombesin|disrupts|gastric acid secretion|2409424
bombesin|treats|mice|2409425
bombesin|disrupts|gastrointestinal transit|2409425
bombesin antagonist|interacts_with|peptide|2409425
peptide|augments|vagus nerve|2409425
bombesin|affects|gastrointestinal motility|2409425
ACTH|part_of|rats|2409426
Spantide|treats|rats|2409426
substance P|inhibits|bombesin receptor|2409426
CCK|interacts_with|peptide|2421268
secretin|interacts_with|peptide|2421268
bombesin|treats|rat|2421268
physalaemin|disrupts|small cell lung cancer|2436762
BN|augments|satiety|2485250
bombesin|affects|satiety|2485250
dopamine|interacts_with|BN|2526353
bombesin|isa|neuropeptides|2538576
bombesin|associated_with|CNS infection|2538576
bombesin|affects|CNS infection|2538576
bombesin receptor antagonist|inhibits|gastric acid secretion|2538918
agonist|inhibits|bombesin|2538918
bombesin antagonist|affects|gastric acid secretion|2538918
bombesin|causes|hypothermia|2664543
insulin|treats|rats|2664543
bombesin|affects|core body temperature|2664543
insulin|part_of|rats|2664543
Bombesin|causes|hypothermia|2664543
pentagastrin|augments|gastric acid secretion|2714571
baclofen|treats|rats|2714571
Bombesin|disrupts|gastric acid secretion|2714571
pentagastrin|treats|rats|2714571
pentagastrin|augments|basal gastric acid secretion|2714571
baclofen|augments|gastric acid secretion|2714571
baclofen|augments|basal gastric acid secretion|2714571
monoclonal bombesin antibody 2A11|inhibits|bombesin|2714571
pentagastrin|neg_interacts_with|bombesin|2714571
calcitonin gene-related peptide|part_of|rat|2714571
substance P|neg_affects|gastric acid secretion|2714571
bombesin|treats|rats|2714571
bombesin|disrupts|gastric acid secretion|2714571
bombesin|affects|food intake|2755870
bombesin|treats|rat|2760944
N-methyl-N'-nitro-N-nitrosoguanidine|causes|gastric cancers|2766293
bombesin|treats|Wistar rats|2766293
bombesin|treats|rats|2766293
norepinephrine|coexists_with|antral|2766293
bombesin|augments|carcinogenesis|2766293
N-methyl-N'-nitro-N-nitrosoguanidine|interacts_with|norepinephrine|2766293
N-methyl-N'-nitro-N-nitrosoguanidine|causes|carcinogenesis|2766293
bombesin|part_of|carcinogenesis|2766293
amino acid|augments|gastric|2838842
bombesin|produces|hormones|2838842
Bombesin|disrupts|growth|2838842
CCK-8|inhibits|gastric emptying|2862711
Bombesin|augments|gastric acid secretion|2862711
neuropeptides|affects|gut|2862711
ODT8-SS|interacts_with|bombesin|2864099
BBS|neg_affects|food intake|2923249
saline|isa|injection|2923249
saline|uses|saline|2923249
BBS|neg_affects|water intake|2923249
BBS|affects|food intake|2923249
bombesin|stimulates|intravenous glucose|3114028
peptide|stimulates|glucose|3114028
bombesin|augments|arterial pressure|3197861
bombesin|affects|peripheral blood flow|3197861
bombesin|affects|gastrointestinal functions|3197861
Bombesin|disrupts|food intake|3202231
BBS|treats|rats|3202231
bombesin|disrupts|food intake|3202231
epinephrine|associated_with|hyperglycemia|3215150
glucagon|associated_with|hyperglycemia|3215150
glucagon|augments|epinephrine secretion|3215150
calcitonin|isa|neuropeptides|3226951
receptors|interacts_with|peptides|3226951
bombesin|interacts_with|peptides|3226951
peptides|causes|anorexia|3226951
calcitonin|affects|Anorectic|3226951
bombesin|affects|Anorectic|3226951
neurotensin|affects|Anorectic|3226951
bombesin|treats|rats|3295797
BBS|interacts_with|BBS|3295797
atropine methylnitrate|neg_interacts_with|pressor|3384004
pentagastrin|augments|gastric|3393692
BBS|disrupts|acid secretion|3393692
BBS|compared_with|infusion|3393692
BBS|neg_affects|acid secretion|3393692
BBS|lower_than|infusion|3393692
BBS|affects|gastric acid secretion|3393692
bombesin|affects|acid secretion|3393692
bombesin|part_of|intraventricular|3430867
BS|causes|hypothermia|3430867
BS|disrupts|thermogenesis|3430867
bombesin|treats|rats|3430867
bombesin|affects|gastrointestinal transit|3432135
bombesin|affects|arterial pressure|3432135
bombesin|interacts_with|bombesin|3432135
Bombesin|neg_augments|gastric intraluminal pressure|3432135
bombesin|neg_affects|arterial pressure|3432135
bombesin|affects|gastric motility|3432135
bombesin|augments|gastric acid secretion|3437584
bombesin|affects|gastric acid secretion|3437584
bombesin|causes|gastric mucosal erosions|3513909
bombesin|compared_with|angiotensin II|3656507
bombesin|higher_than|angiotensin II|3656507
saralasin|isa|angiotensin II|3656507
bombesin|disrupts|water intake|3656507
bombesin|administered_to|sheep|3656507
Bombesin|disrupts|gastric acid secretion|3676774
bombesin|affects|gastric|3676774
bombesin|affects|gut|3676774
bombesin receptors|affects|gastric|3676774
glucagon|part_of|Pancreatic|3801925
CCK|administered_to|individual|3801925
PG|part_of|PG|3801925
CCK|augments|satiety|3801925
BBS|augments|satiety|3801925
PG|augments|satiety|3801925
glucagon|part_of|pancreatic|3801925
bombesin|affects|satiety|3801925
cholecystokinin|affects|satiety|3801925
glucagon|affects|satiety|3801925
bombesin|treats|rats|3956337
Bombesin|disrupts|gastric acid output|3956337
bombesin|augments|thoracic vertebrae|3956337
peptide|affects|hyperglycemic|3956337
bombesin|disrupts|gastric acid secretion|4007411
Bombesin|disrupts|acid secretion|4007411
peptides|affects|gastric|4007411
bombesin|disrupts|food intake|4010472
gastrin-releasing peptide|disrupts|food intake|4010472
bombesin|affects|intestinal motility|4043224
Bombesin|augments|intestinal motility|4043224
bombesin|isa|tetradecapeptide|6283491
BBS|administered_to|rats|6283491
BBS|affects|satiety|6283491
cholecystokinin|affects|food intake|6283491
BBS|affects|food intake|6283491
BBS|disrupts|food intake|6283491
BBS|treats|rat|6283491
vasoactive intestinal polypeptide|augments|gastric ulcerations|6302295
beta-endorphin|interacts_with|NT|6302295
beta-endorphin|interacts_with|bombesin|6302295
bombesin|treats|rats|6472575
bombesin|causes|cuts|6472575
bombesin|augments|gastric acid output|6472575
bombesin|causes|lesions|6472575
bombesin|causes|hypergastrinemia|6472575
bombesin|disrupts|drinking|6473174
bombesin|disrupts|gastric acid secretion|6482676
bombesin|treats|rats|6482676
bombesin|disrupts|gastrointestinal transit|6522645
bombesin|affects|gastrointestinal transit|6522645
bombesin|coexists_with|trypsin|6607137
bombesin|part_of|patients|6607137
enzymes|coexists_with|bombesin|6607137
lipase|stimulates|bombesin|6607137
alpha-amylase|stimulates|bombesin|6607137
trypsin|stimulates|bombesin|6607137
bombesin|treats|patients|6697850
bombesin|treats|chronic pancreatitis|6697850
bombesin|treats|pancreatic insufficiency|6697850
PP|treats|patients|6697850
PP|treats|chronic pancreatitis|6697850
secretin|stimulates|PP|6697850
secretin|treats|patients|6697850
secretin|treats|chronic pancreatitis|6697850
bombesin|isa|tetradecapeptide|6734843
bombesin|treats|rabbits|6734843
Bombesin|neg_affects|gastric acid secretion|6740496
CCK|treats|humans|6740496
bombesin|produces|CCK|6740496
cholecystokinin|treats|patients|6740496
bombesin|interacts_with|cholecystokinin|6740496
cholecystokinin|treats|persons|6740496
bombesin|causes|hypothermia|6855453
Bombesin|causes|hypothermia|6855453
bombesin|affects|gastric emptying|6862156
bombesin|affects|large bowel|6862156
Bombesin|disrupts|gastric emptying|6862156
bombesin|neg_affects|gastric emptying|6862156
insulin|part_of|hypothalamus|7021368
bombesin|interacts_with|insulin|7021368
bombesin|interacts_with|2-DG|7021368
bombesin|affects|secretory|7021368
bombesin|disrupts|gastric|7063751
gastrin-releasing peptide|disrupts|gastric|7063751
peptides|inhibits|2-dGlc|7063751
bombesin|treats|rats|7063751
gastrin-releasing peptide|treats|rats|7063751
bombesin|affects|food intake|7079366
met-enkephalin|interacts_with|met-enkephalin|7092351
bombesin|neg_interacts_with|naloxone|7092351
opiate receptor|interacts_with|naloxone|7092351
pancreatic polypeptide|interacts_with|opiate peptides|7092351
bombesin|disrupts|gastric|7154848
bombesin|augments|gastric|7154848
neurotensin|interacts_with|bombesin|7173320
bombesin|affects|duodenal ulcers|7173320
bombesin|augments|gastric acid secretion|7255766
bombesin|stimulates|gastrin|7255766
bombesin|affects|gastric|7255766
bombesin|stimulates|bombesin|7255766
BN|compared_with|GRP|7479333
BN|higher_than|GRP|7479333
GRP|treats|rats|7479333
bombesin|neg_affects|sympathetic nerve|7563982
bombesin|augments|nerve|7563982
neurotransmitters|part_of|gut|7569765
gastric inhibitory polypeptide|produces|PYY|7569765
TTX|neg_interacts_with|isoproterenol|7569765
TTX|neg_interacts_with|CGRP|7569765
TTX|neg_interacts_with|bethanechol|7569765
TTX|neg_interacts_with|PYY|7569765
gastrin releasing peptide|isa|peptides|7705441
bombesin|affects|physiological responses|7705441
bombesin|inhibits|peptide receptor|7705441
peptides|affects|neurons|7705441
peptides|affects|cells|7705441
antibody|part_of|rats|7716060
somatostatin|inhibits|basal GAS|7716060
pentagastrin|treats|rats|7716060
bombesin|disrupts|basal GAS|7716060
Bombesin|disrupts|basal GAS|7716060
somatostatin|inhibits|gastric acid secretion|7716060
bombesin|treats|patients|7778034
cholecystokinin|treats|patients|7778034
Bombesin|isa|tetradecapeptide|7809021
Bombesin|augments|growth|7809021
BBS|affects|growth|7809021
bovine serum albumin|part_of|Mice|7809021
Bombesin|disrupts|growth|7809021
glutamate|interacts_with|NMDA receptors|7813568
neuromedin C|affects|nociception|7813568
neuromedin C|augments|nociception|7813568
yohimbine|treats|dogs|7829539
medetomidine|treats|dogs|7829539
Nitric oxide|associated_with|hyperemia|7846293
pentagastrin|augments|secretion|7846293
L-arginine|treats|fall|7846293
nitric oxide|affects|gastric|7846293
nitric oxide|affects|blood flow|7846293
nitric oxide|affects|gastric acid secretion|7846293
gastrin-releasing peptide|affects|growth|7858155
epidermal growth factor|disrupts|tumor growth|7858155
bombesin/GRP antagonist|causes|down-regulation|7858155
luteinizing hormone-releasing hormone|disrupts|growth|7868940
gastrin-releasing peptide|disrupts|growth|7868940
EGF-receptors|associated_with|tumors|7868940
LH-RH|treats|pancreatic cancers|7868940
bombesin/GRP antagonist|treats|pancreatic cancers|7868940
bombesin|administered_to|patients|7944667
chemotherapeutic agents|causes|enterocolitis|7944667
Bombesin|isa|tetradecapeptide|7972291
Bombesin|affects|hypothermic|7972291
tetradecapeptide|affects|hypothermic|7972291
BBS|causes|hypothermia|7972291
bombesin|administered_to|rats|7972291
bombesin|part_of|intraventricular|7972291
gastrin-releasing peptide|associated_with|cancers|8170991
Bombesin|associated_with|cancers|8170991
RC-3095|disrupts|growth|8170991
RC-3095|stimulates|kinase|8170991
EGF|augments|phosphorylation|8170991
bombesin|augments|phosphorylation|8170991
EGF|interacts_with|ligands|8170991
RC-3095|associated_with|hepatoma|8170991
gastrin-releasing peptide|augments|cancer|8170991
bombesin|augments|growth|8170991
bombesin|part_of|tumors|8170991
Bombesin|affects|blood pressure|8191031
insulin|treats|rats|8221161
bombesin|disrupts|core body temperature|8221161
RC-3095|stimulates|LH-RH|8242552
LH-RH|treats|cancer model|8242552
LH-RH|produces|RC-3095|8242552
LH-RH|affects|tumor growth|8242552
EGF|isa|treatment|8242552
EGF|uses|RC-3095|8242552
gastrin-releasing peptides|stimulates|luteinizing hormone-releasing hormone|8242552
luteinizing hormone-releasing hormone agonists|treats|breast cancer|8313327
RC-3095|part_of|Uterine|8313327
epidermal growth factor receptors|disrupts|tumor|8313327
RC-3095|causes|down-regulation|8313327
RC-3095|interacts_with|RC-3095|8313327
RC-3095|affects|tumors|8313327
RC-3095|affects|growth|8313359
RC-3095|disrupts|growth|8313359
RC-3095|part_of|mice|8313359
Bombesin|augments|DNA synthesis|8313359
thymidine|coexists_with|bombesin|8313359
thymidine|disrupts|uptake|8313359
bombesin|disrupts|uptake|8313359
thymidine|compared_with|bombesin|8313359
bombesin|treats|rats|8322979
BBS|disrupts|food intake|8322979
gastrin-releasing peptide|part_of|pancreatic cancers|8387464
bombesin|neg_augments|growth|8387464
GRP|neg_augments|growth|8387464
GRP|disrupts|pancreatic tumors|8387464
bombesin|disrupts|pancreatic tumors|8387464
bombesin antagonists|affects|growth|8387464
bombesin|causes|down-regulation|8387464
GRP|disrupts|pancreatic cancer|8387464
bombesin|disrupts|pancreatic cancer|8387464
gastrin-releasing peptide|interacts_with|bombesin|8387464
bombesin|disrupts|food intake|8403798
cholecystokinin|associated_with|shake|8403798
loxiglumide|compared_with|saline|8403798
loxiglumide|lower_than|saline|8403798
loxiglumide|coexists_with|bombesin|8403798
saline|coexists_with|bombesin|8403798
Bombesin|disrupts|food intake|8403798
saline|administered_to|men|8447491
bombesin|compared_with|saline|8447491
bombesin|administered_to|men|8447491
bombesin|affects|satiety|8447491
bombesin|disrupts|food intake|8447491
serotonin|isa|hormones|8630226
somatostatin|isa|hormones|8630226
bombesin|isa|hormones|8630226
somatostatin|associated_with|prostate cancer|8630226
serotonin|associated_with|prostate cancer|8630226
bombesin|associated_with|prostate cancer|8630226
Bombesin|disrupts|food intake|8795081
CCK|stimulates|BBS|8795081
BBS|stimulates|BBS|8795081
bombesin|augments|immunoreactivity|8795081
bombesin|disrupts|food intake|8959745
Oxytocin|disrupts|food intake|8959745
BN|interacts_with|OX|8959745
OX|disrupts|receptor expression|8959745
OX|treats|adults|8959745
BN|treats|adults|8959745
BN antagonists|neg_affects|food intake|8959745
OX|neg_affects|food intake|8959745
bombesin|affects|ontogenic|8959745
oxytocin|affects|ontogenic|8959745
bombesin|interacts_with|somatostatin|9175202
Bombesin|produces|somatostatin|9175202
gastrin|interacts_with|gastrin|9175202
gastrin|interacts_with|somatostatin|9175202
Bombesin|disrupts|histamine release|9175202
BBS|affects|diabetic|9213356
bombesin|affects|diabetic|9213356
cholecystokinin|affects|diabetic|9213356
CCK|treats|rats|9213356
CCK|treats|diabetic|9213356
CGRP|neg_treats|rats|9213356
BBS|affects|anorectic|9213356
CCK|affects|anorectic|9213356
amylin|affects|anorectic|9213356
bombesin|interacts_with|CGRP|9213356
cholecystokinin|interacts_with|CGRP|9213356
epidermal growth factor|isa|growth factors|9254895
EGF|disrupts|tumor growth|9254895
LH-RH|disrupts|tumor growth|9254895
GRP|disrupts|tumor growth|9254895
RC-3940-II|affects|growth|9254895
BN/GRP antagonists|disrupts|growth|9254895
EGF receptors|affects|tumor growth|9254895
RC-3940-II|disrupts|growth|9254895
azoxymethane|causes|intestinal adenocarcinomas|9344044
azoxymethane|administered_to|rats|9344044
Bombesin|augments|intestinal tumors|9344044
Bombesin|augments|cancer metastasis|9344044
bombesin|neg_augments|carcinogenesis|9344044
RC-3940-II|affects|growth|9376196
agonist|administered_to|nude mice|9376196
RC-3940-II|treats|nude mice|9376196
LH-RH receptors|interacts_with|Cetrorelix|9376196
bombesin antagonists|inhibits|EHF|9376196
bombesin antagonists|disrupts|growth|9376196
Cetrorelix|disrupts|growth|9376196
RC-3940-II|disrupts|growth|9376196
sucrose|part_of|Wistar rats|9402609
BN|part_of|Wistar rats|9402609
sodium|interacts_with|peptide|9402609
BN|augments|depression|9402609
NaCl|part_of|rats|9402609
Bombesin|treats|rats|9402609
therapeutic agents|treats|patients|9486581
therapeutic agents|treats|RCC|9486581
RC-3940-II|affects|growth|9486581
RC-160|administered_to|nude mice|9486581
RC-160|administered_to|animals|9486581
RC-3940-II|disrupts|growth|9486581
bombesin|administered_to|patients|9539666
bombesin|treats|patients|9539666
gastrin-releasing peptide|part_of|scapular region|9650851
bombesin|affects|exocrine secretion|9657358
bombesin|stimulates|secretin|9657358
secretin|stimulates|bombesin|9657358
bombesin|affects|parameters|9657358
RC-3940-II|administered_to|nude mice|9713279
RC-3095|disrupts|tumour growth|9713279
RC-3940-II|disrupts|growth|9713279
gastrin-releasing peptide receptor|part_of|murine|9815798
mGRPr|part_of|mGRPr|9815798
gastrin-releasing peptide receptor|part_of|tumor|9815798
Bombesin|disrupts|food intake|10362739
BN-sensitive receptors|interacts_with|BN|10362739
BN|affects|anorexic|10362739
insulin|interacts_with|bombesin|10455316
nitric oxide|part_of|cerebral|10455316
L-NAME|part_of|DMN|10455316
pentagastrin|augments|acid secretion|10455316
bombesin|disrupts|acid secretion|10455316
bombesin|disrupts|gastric acid secretion|10455316
epidermal growth factor|associated_with|cancers|10480336
peptide hormone analogs|disrupts|tumor growth|10480336
RC-3095|part_of|hamsters|10480336
RC-3095|associated_with|pancreatic cancers|10480336
EGF receptors|associated_with|pancreatic cancers|10480336
EGF receptors|associated_with|cancers|10480336
peptide analogs|disrupts|pancreatic cancers|10480336
peptides|affects|gastric acid secretion|10619185
alpha-helical CRF|isa|CRF|10619185
oxytocin|disrupts|acid secretion|10619185
oxytocin|interacts_with|endotoxin|10619185
oxytocin|inhibits|gastric acid secretion|10619185
growth factors|predisposes|breast carcinoma|10717621
mRNA|interacts_with|RC-3095|10717621
RC-3940-II|part_of|human breast carcinoma|10717621
RC-3940-II|part_of|tumors|10717621
RC-3940-II|compared_with|RC-3940-II|10717621
BN/GRP antagonists|treats|breast tumors|10717621
RC-3095|disrupts|growth|10717621
growth factors|affects|prostate cancer|10881027
neuropeptides|affects|prostate cancer|10881027
gastrin-releasing peptide|interacts_with|growth hormone-releasing hormone|10881027
RC-3940-II|coexists_with|JV-1-38|10881027
IGF-II|disrupts|tumor growth|10881027
MZ-5-156|coexists_with|IGF-I|10881027
RC-3940-II|disrupts|tumor|10881027
RC-3940-II|inhibits|IGF-II|10881027
RC-3940-II|inhibits|RC-3940-II|10881027
RC-3940-II|inhibits|BN/GRP|10881027
bombesin antagonists|affects|prostate cancer|10881027
cholecystokinin|affects|pancreatic cancer|10982627
bombesin|affects|pancreatic cancer|10982627
gastrin|affects|pancreatic cancer|10982627
receptors|augments|carcinogenesis|10982627
gastrointestinal hormones|associated_with|pancreatic cancer|10982627
bombesin (BN) receptors|associated_with|cancers|11058885
carboxylesterases|affects|tumors|11058885
mRNA|interacts_with|BN|11058885
bombesin|disrupts|cancer|11058885
bombesin|interacts_with|BN|11111013
BN|disrupts|food intake|11111013
BN|interacts_with|neuropeptide Y|11111013
BN|interacts_with|NPY|11111013
bombesin|disrupts|food intake|11111013
RC-3095|disrupts|growth|11485826
peptide YY|neg_interacts_with|TFF3|11495677
bombesin|treats|nude mice|11953892
bombesin|compared_with|DO3A-amide-betaAla-BBN|12031877
bombesin|administered_to|rats|12047914
nuclear antigen|part_of|cell|12592625
nuclear antigen|part_of|rats|12592625
BN receptors|associated_with|hypothermia|12676368
BN|causes|hypothermia|12676368
NMB|causes|hypothermia|12676368
GRP|causes|hypothermia|12676368
BN|inhibits|GRP receptor|12676368
BN receptor|associated_with|hypothermia|12676368
bombesin receptor|associated_with|hypothermia|12676368
Bombesin|affects|gastrointestinal motility|12678868
BBS|associated_with|tumor growth|12678868
BBS|associated_with|inflammation|12678868
peptides|inhibits|BBS receptor|12678868
bombesin|produces|somatostatin|12692184
PRL-2903|interacts_with|bombesin|12692184
bombesin|disrupts|acid secretion|12692184
antibody|part_of|mice|12692184
bombesin|neg_affects|gastric acid secretion|12692184
bombesin|disrupts|gastric acid secretion|12692184
hormones|part_of|gastric|12711834
Bombesin|interacts_with|mitogenic|12711834
cholecystokinin (CCK) receptors|interacts_with|bombesin|12711834
bombesin|associated_with|stress ulcers|12711834
cholecystokinin receptors|associated_with|gastric injury|12711834
bombesin|associated_with|gastric injury|12711834
bombesin|administered_to|mice|12807697
Bombesin|causes|cell proliferation|12807697
gastrin-releasing peptide|causes|cell proliferation|12807697
NMB|causes|cell proliferation|12807697
NMB|causes|chemotaxis|12807697
bombesin receptor subtype 3|causes|cell proliferation|12807697
bombesin receptor subtype 3|causes|chemotaxis|12807697
gastrin-releasing peptide|causes|chemotaxis|12807697
Bombesin|causes|chemotaxis|12807697
peptides|affects|growth|14499286
peptides|affects|cell proliferation|14499286
RC-3095|affects|memory|14499286
GRP receptor|affects|memory|14499286
RC-3940-II|affects|small cell lung carcinoma|14660794
RC-3940-II|inhibits|mutant p53 protein|14660794
EGF receptor|associated_with|tumors|14660794
IGF receptor|associated_with|tumors|14660794
GRP|augments|cells|14660794
BN/GRP antagonist|disrupts|growth|14660794
Tp53|augments|cell growth|14660794
growth hormone-releasing hormone|inhibits|p53|14660794
bombesin|inhibits|p53|14660794
BN|interacts_with|GRPR|15068608
analogues|interacts_with|GRPR|15068608
peptides|associated_with|pathogenesis|15165713
Bombesin|causes|disorders|15165713
Bombesin|causes|schizophrenia|15165713
dizocilpine|treats|rodents|15165713
RC-3095|affects|stereotypy|15165713
RC-3095|neg_affects|stereotyped behavior|15165713
GRP|interacts_with|drug|15165713
RC-3095|inhibits|apomorphine|15165713
BBS|associated_with|obstructive jaundice|15177937
NT|disrupts|injury|15177937
neurotensin|disrupts|oxidative stress|15177937
bombesin|affects|gut|15204957
Bombesin|associated_with|short bowel syndrome|15204957
somatostatin|interacts_with|receptors|15350601
somatostatin|disrupts|growth|15350601
hormone receptors|part_of|tumoral|15350601
peptide receptors|part_of|cancers|15653654
octreotide|part_of|neuroendocrine tumors|15653654
CCK2|part_of|neuroendocrine tumors|15653654
BN|causes|anorexia|15680182
L-nitro-arginine|inhibits|PKG|15680182
BN|disrupts|food intake|15680182
gastrin-releasing peptide|disrupts|food intake|15746304
BBS|augments|GH secretion|15746304
BBS|augments|PSS-II|15746304
BBS|augments|PSS|15746304
ghrelin|part_of|goldfish|15746304
BBS|inhibits|ghrelin|15746304
ghrelin|interacts_with|GRP|15746304
GRP|disrupts|ovarian tumors|15788692
bombesin|disrupts|ovarian cancers|15788692
chemotherapeutic agents|disrupts|toxicity|15853664
cytotoxic agents|treats|tumors|15853664
radiopharmaceuticals|treats|tumors|15853664
receptors|associated_with|cancers|15853664
somatostatin|isa|hypothalamic hormones|15853664
gastrin-releasing peptide receptor|affects|memory|16023260
RC-3095|administered_to|Rats|16023260
RC-3095|neg_affects|locomotion|16023260
GRPR|affects|memory|16023260
GRPR|affects|anxiety|16023260
peptides|augments|sensitivity|16040630
bombesin|interacts_with|bombesin|16040630
bombesin|interacts_with|gastrin-releasing peptide|16040630
GRP|part_of|neurons|16040630
bombesin|part_of|neurons|16040630
ATP|coexists_with|bombesin|16040630
ATP|coexists_with|GRP|16040630
bombesin|augments|sensitivity|16040630
GRP|augments|sensitivity|16040630
GRP|augments|excitability|16040630
bombesin|augments|excitability|16040630
multidrug resistance proteins|affects|endometrial cancers|16051478
bombesin|part_of|endometrial cancers|16051478
bombesin|affects|respiratory center|16117171
BBN|treats|diseases|16243649
pituitary hormones|affects|autonomic pathways|16264389
bombesin|affects|physiological functions|16264389
pituitary hormones|treats|Wistar-Kyoto rats|16264389
bombesin|interacts_with|pituitary hormones|16264389
trypsinogen activation peptide|neg_augments|pancreatic|16293654
TAP|part_of|pancreatic|16293654
TAP|stimulates|trypsin|16293654
TAP|stimulates|TAP|16293654
TAP|stimulates|chymotrypsin|16293654
bombesin|part_of|acinar cell|16293654
bombesin antagonist|inhibits|GRP receptors|16322338
GRP|disrupts|breast cancers|16322338
bombesin|disrupts|breast cancers|16322338
cell surface receptors|augments|growth|16505950
gastrin-releasing peptides|interacts_with|cell surface receptors|16505950
RC-3095|treats|murine|16505950
RC-3095|treats|patients|16505950
RC-3095|treats|malignancies|16505950
RC-3095|administered_to|patients|16505950
RC-3095|treats|individual|16505950
RC-3095|treats|hypergastrinemic|16505950
RC-3095|treats|syndrome|16505950
GRP|part_of|patient|16505950
peptides|augments|lung development|16603607
mammalian bombesin|treats|newborns|16603607
mammalian bombesin|treats|bronchopulmonary dysplasia|16603607
antibodies|disrupts|injury|16603607
bombesin|treats|mice|16603607
GRP|affects|alveolar|16603607
Bombesin|affects|lung|16603607
GRP|interacts_with|bombesin|16603607
GRPR|interacts_with|bombesin|16603607
Bombesin|predisposes|pulmonary fibrosis|16603607
radical|neg_affects|tumor growth|16801542
luteinizing hormone-releasing hormone|treats|ovarian cancers|16801542
somatostatin|treats|ovarian cancers|16801542
FK506|prevents|atrophy|16908293
bombesin|isa|neuropeptide|16908293
CCK-8|part_of|Mice|16963158
gut satiety hormones|neg_causes|hyperphagia|16963158
gastrin releasing peptide|part_of|amygdala|17208656
neuromedin C|disrupts|consumption|17208656
Leu|interacts_with|Neuromedin C|17208656
neuromedin C|stimulates|bombesin receptors|17208656
bombesin|administered_to|rabbits|17308247
Bombesin|augments|lymphoid cells|17308247
MZ-J-7-118|interacts_with|epidermal growth factor receptor|17332943
peptide analogues|part_of|NSCLC|17332943
RC-3940-II|causes|tumors|17332943
GHRH|treats|NSCLC|17332943
growth hormone releasing|interacts_with|EGFR|17332943
bombesin|interacts_with|EGFR|17332943
bombesin|associated_with|non-small cell lung cancer|17332943
growth hormone releasing|associated_with|non-small cell lung cancer|17332943
radiopharmaceuticals|treats|tumors|17372572
gastrin-releasing peptide receptor|inhibits|GRPR|17629354
D-AMPH|treats|rats|17629354
bombesin|stimulates|D-AMPH|17629354
RC-3095|stimulates|NGF|17629354
RC-3095|stimulates|BDNF|17629354
BDNF|interacts_with|RC-3095|17629354
Bombesin|augments|growth|18003891
gastrin-releasing peptide|augments|growth|18003891
GRP|disrupts|cancers|18003891
GRP|disrupts|growth|18003891
RC-3940-II|affects|growth|18003891
RC-3940-II|affects|cell lines|18003891
lung resistance-related protein|associated_with|tumors|18003891
RC-3940-II|treats|NSCLC|18003891
BN/GRP antagonist|disrupts|non-small-cell lung carcinoma|18003891
luteinising hormone-releasing hormone|affects|tumours|18201818
LHRH|part_of|Tumoural|18201818
BN/GRP|inhibits|receptors|18201818
BN/GRP|inhibits|growth factors|18201818
GHRH|inhibits|growth factors|18201818
GHRH|inhibits|receptors|18201818
neuropeptides|associated_with|tumour growth|18201818
LHRH|treats|prostate cancer|18201818
peptides|associated_with|prostate cancers|18201818
somatostatin|treats|prostate cancer|18201818
peptides|associated_with|metastases|18201818
cytokines|interacts_with|peptides|18220954
neuropeptides|associated_with|pathogenesis|18220954
molecular target|treats|inflammatory diseases|18220954
LHRH|coexists_with|receptors|18454045
luteinizing hormone-releasing hormone|coexists_with|receptors|18454045
bombesin|coexists_with|receptors|18454045
somatostatin|coexists_with|receptors|18454045
luteinizing hormone-releasing hormone|associated_with|hepatic carcinoma|18454045
LHRH|associated_with|hepatic carcinoma|18454045
bombesin|associated_with|hepatic carcinoma|18454045
somatostatin|associated_with|hepatic carcinoma|18454045
LHRH|associated_with|cancers|18454045
bombesin|associated_with|cancers|18454045
somatostatin|associated_with|cancers|18454045
peptide analogs|disrupts|growth|18454045
LHRH|part_of|HCC|18454045
bombesin|part_of|HCC|18454045
somatostatin|part_of|HCC|18454045
peptide analogs|interacts_with|receptors|18454045
somatostatin|treats|hepatic cancers|18454045
luteinizing hormone-releasing hormone|treats|hepatic cancers|18454045
peptide analogs|part_of|hepatic cancers|18454045
peptide analogs|interacts_with|somatostatin|18454045
peptide analogs|interacts_with|luteinizing hormone-releasing hormone|18454045
peptides|affects|conditioned fear|18563394
BB|affects|conditioned fear|18563394
RC-3095|disrupts|freezing|18563394
GRP|affects|fear|18563394
Bombesin|isa|neuropeptides|18567096
neurotensin|isa|neuropeptides|18567096
neurotensin|associated_with|intestinal growth|18567096
Bombesin|associated_with|intestinal growth|18567096
bombesin|affects|pleiotropic|18567096
neurotensin|affects|pleiotropic|18567096
bombesin|affects|Pleiotropic|18567096
neurotensin|affects|Pleiotropic|18567096
Glutathione transferases|isa|enzymes|19019494
Glutathione transferases|affects|detoxification|19019494
enzymes|affects|detoxification|19019494
GSTs|affects|hydrolysis|19019494
bombesin|stimulates|GSTA1-1|19019494
bombesin|treats|rats|19032952
bombesin|augments|arterial blood pressure|19032952
bombesin|augments|ventilation|19032952
bombesin|affects|hypertensive|19032952
AMPH|treats|rats|20131069
NMB|neg_interacts_with|corticosterone|20233609
GRP|neg_interacts_with|corticosterone|20233609
NMB|affects|brain|20233609
GRP|affects|brain|20233609
gastrin-releasing peptide (GRP) receptors|part_of|prostate|20410458
gastrin-releasing peptide (GRP) receptors|part_of|breast|20410458
BBN|interacts_with|GRP receptors|20410458
BBN|associated_with|tumors|20410458
BBN|associated_with|acne|20410458
BBN|augments|uptake|20410458
cancer drugs|interacts_with|membrane proteins|20491631
neuromedin C|isa|bombesin|20727356
peptides|interacts_with|bombesin|20727356
bombesin|compared_with|NMB|20727356
bombesin|higher_than|NMB|20727356
NMB|disrupts|food intake|20727356
NMC|disrupts|food intake|20727356
pressor|treats|rat|21849634
peptide|interacts_with|bombesin|21849634
Bombesin|augments|excitation|21849634
bombesin|affects|blood pressure|21849634
bombesin|treats|rat|21849634
bombesin|part_of|Tumor|22050889
chloroquine|treats|mice|22329438
histamine|part_of|spinal cord|22329438
chloroquine|neg_treats|mice|22329438
BN|part_of|Liposomes|22619538
GRP|part_of|HT-29 cells|22751419
5-FU|isa|chemotherapeutic agents|22751419
growth hormone|interacts_with|bombesin-like peptides|22868212
GRP|coexists_with|NMC|22868212
peptides|augments|growth hormone secretion|22868212
gastrin-releasing peptide receptor|interacts_with|Bombesin|22868212
Bombesin|treats|cattle|22868212
RC-3940-II|affects|liver cancers|22926257
BN/GRP receptors|associated_with|tumors|22926257
RC-3940-II|affects|cell proliferation|22926257
RC-3940-II|disrupts|growth|22926257
BN/GRP antagonist|disrupts|growth|22926257
RC-3940-II|disrupts|cancers|22926257
RC-3940-II|treats|liver cancers|22926257
growth hormone-releasing hormone|disrupts|prostate cancer|22971474
luteinizing hormone-releasing hormone|disrupts|prostate cancer|22971474
somatostatin analogues|disrupts|prostate cancer|22971474
agonist|treats|prostate cancer|22971474
bombesin|inhibits|peptide|23451211
integrin alphavbeta3|part_of|tumor|23708872
Bombesin|interacts_with|Bombesin receptor|23863118
drug|disrupts|toxicity|23863118
PDC|isa|drug|23863118
PDC|disrupts|toxicity|23863118
polyglutamic acid|isa|polymers|23863118
solutions|causes|dysfunction|24247113
COX|interacts_with|S-nitrosothiol|24530741
bombesin|isa|neuropeptide|24530741
COX|part_of|brain|24530741
noradrenaline|interacts_with|COX|24530741
adrenaline|interacts_with|COX|24530741
COX-1|part_of|neurons|24530741
bombesin|stimulates|7-Nitroindazole|24530741
bombesin|treats|rat|24530741
nNOS|stimulates|COX-1|24530741
ancrod|treats|foot ischaemia|360366
Arvin|isa|ancrod|484913
ancrod|associated_with|rest pain|484913
Ancrod|affects|defibrination|492058
Ancrod|treats|patients|492058
Ancrod|treats|pain|492058
Kabikinase|isa|streptokinase|577626
Arvin|part_of|patients|577626
Arvin|isa|ancrod|577626
ancrod|part_of|patients|577626
streptokinase|treats|deep vein thrombosis|577626
ancrod|treats|deep vein thrombosis|577626
Arwin|isa|ancrod|651769
ancrod|treats|patients|651769
Arwin|treats|patients|651769
Arvin|isa|ancrod|725844
ancrod|treats|patients|725844
Arvin|treats|patients|725844
fibrinogen/fibrin degradation products|coexists_with|plasminogen|725844
ancrod|prevents|thromboembolism|725844
dextran|isa|glucose polymer|786606
dextran|isa|drug|786606
dextran|prevents|thromboembolism|786606
drugs|treats|thromboembolic disorders|786606
plasmin|isa|proteolytic enzymes|786606
streptokinase|isa|plasminogen activators|786606
plasmin|stimulates|plasminogen activator|786606
plasminogen activators|augments|lysis|786606
ancrod|associated_with|nephritis|794557
fibrin|associated_with|nephritis|794557
thrombin|interacts_with|fibrinogen|920833
ancrod|neg_interacts_with|fibrinogen|920833
bovine thrombin|administered_to|rabbits|920833
thrombin|coexists_with|fibrinogen|920833
ancrod|neg_interacts_with|thrombin|920833
thrombin|treats|rabbits|920833
thrombin|stimulates|fibrinogen|920833
thrombin|treats|afibrinogenemia|920833
heparin|administered_to|dogs|952568
Ancrod|treats|dogs|952568
ancrod|treats|arterial thrombosis|952568
ancrod|compared_with|heparin|952568
Ancrod|neg_affects|sensitivity|953985
streptokinase|coexists_with|fibrinogen|1017726
ancrod|treats|thrombosis|1017726
fibrinogen|affects|blood|1069443
snake venom|inhibits|fibrinogen|1069443
fibrinogen|part_of|blood|1078314
Ancrod|affects|blood|1078314
heparin|administered_to|rabbits|1212801
anticoagulants|affects|nephritis|1212801
heparin|disrupts|fibrin deposition|1212801
ancrod|administered_to|animals|1212801
anticoagulants|treats|nephritis|1212801
ancrod|affects|defibrination|1212811
urea|part_of|blood|1212811
ancrod|associated_with|defibrination|1212811
ancrod|affects|injury|1212811
Ancrod|treats|Dogs|1704437
Ancrod|isa|venom|1704437
ancrod|compared_with|recombinant tissue plasminogen activator|1768613
globulin|part_of|rabbits|1768613
globulin|part_of|sheep|1768613
rtPA|compared_with|ancrod|1768613
rtPA|same_as|ancrod|1768613
Ancrod|treats|humans|1839548
ancrod|treats|patients|1839548
Arvin|isa|ancrod|1839548
ancrod|treats|ischemic stroke|1839548
Arvin|treats|ischemic stroke|1839548
drug|treats|patients|1932741
ancrod|isa|drug|1932741
drug|treats|heparin-induced thrombocytopenia|1932741
ancrod|treats|heparin-induced thrombocytopenia|1932741
ancrod|treats|patients|1932741
heparin|administered_to|patients|1932741
Ancrod|isa|venom|2133215
ancrod|part_of|patients|2133215
ancrod|associated_with|intermittent claudication|2133215
ancrod|neg_treats|peripheral blood flow|2133215
fibrin|augments|fibrinolysis|2186630
fibrin|inhibits|plasminogen activator inhibitor|2186630
Ancrod|treats|patients|2186630
Ancrod|treats|acute stroke|2186630
heparin|treats|patients|2190683
heparin|treats|critically ill|2190683
mechlorethamine hydrochloride|isa|nitrogen mustard|2225555
ancrod|treats|patients|2225555
ancrod|treats|lupus nephritis|2225555
Ancrod|associated_with|systemic lupus erythematosus|2299806
PIF|stimulates|PCA|2299806
ancrod|affects|fibrin deposition|2299806
ancrod|affects|glomerulonephritis|2299806
PCA|predisposes|injury|2299806
fibrinolytic agent|treats|ischemic stroke|2643955
ancrod|isa|fibrinolytic agent|2643955
ancrod|treats|ischemic stroke|2643955
drug|treats|patients|2790577
Arvin|isa|ancrod|2818066
Ancrod|treats|peripheral vascular disease|3056131
d-dimers|inhibits|fibrinogen|3056131
Ancrod|administered_to|patients|3063776
ancrod|affects|fibrinolysis|3078212
ancrod|affects|immunologic findings|3078212
ancrod|affects|renal function|3078212
ancrod|converts_to|fibrin degradation products|3078212
alpha 2-antiplasmin|isa|treatment|3078212
ancrod|inhibits|Igs|3078212
ancrod|inhibits|gamma globulin|3078212
ancrod|inhibits|dsDNA antibody|3078212
ancrod|interacts_with|favorable|3078212
ancrod|treats|glomerulonephritis|3078212
ancrod|part_of|patients|3385879
ancrod|administered_to|dogs|3565240
plasminogen activator|inhibits|fibrinogen|3565240
Ancrod|isa|proteinase|3573090
Ancrod|prevents|vascular occlusion|3573090
Streptokinase|affects|fibrinolysis|3741774
Ancrod|treats|glomerulonephritis|3741774
Ancrod|treats|rabbits|3741774
Streptokinase|treats|injury|3741774
Ancrod|treats|fibrin deposition|3741774
Streptokinase|treats|fibrin deposition|3741774
Ancrod|treats|injury|3741774
Streptokinase|inhibits|fibrin|3741774
fibrinogen|neg_stimulates|factor XIII|3871465
Ancrod|administered_to|patients|3871465
plasminogen activator|part_of|vascular|3871465
plasminogen activator|stimulates|plasminogen|3871465
ancrod|part_of|patients|3871465
PI|coexists_with|serine protease inhibitors|3871465
drug|affects|glomerulonephritis|3968467
ancrod|part_of|patients|3968467
ancrod|associated_with|systemic lupus erythematosus|3968467
plasminogen activator|part_of|vascular|3968467
plasminogen activator|stimulates|plasminogen|3968467
ancrod|treats|thrombosis|3968467
alpha 2-antiplasmin|isa|plasmin inhibitor|3968467
Arvin|isa|ancrod|5485178
ancrod|compared_with|heparin|5485178
ancrod|lower_than|heparin|5485178
mannitol|treats|patients|6196006
low-molecular weight dextran|treats|patients|6196006
low-molecular weight dextran|treats|ischemic stroke|6196006
mannitol|treats|ischemic stroke|6196006
ancrod|associated_with|ischemic stroke|6196006
plasminogen activator|part_of|vascular|6229228
VPA|part_of|VPA|6229228
Ancrod|associated_with|systemic lupus erythematosus|6229228
plasmin|isa|proteolytic enzyme|6672998
batroxobin|isa|enzymes|6672998
ancrod|isa|enzymes|6672998
ancrod|treats|patient|6754189
ancrod|treats|renal allograft failure|6754189
ancrod|treats|necrosis|6754189
ancrod|treats|fibrin deposition|6754189
ancrod|treats|defibrination|6758185
prostacyclin|part_of|vascular|6758185
prostacyclin|treats|thrombi|6758185
prostacyclin|treats|patients|6758185
prostacyclin|treats|lupus nephritis|6758185
ancrod|administered_to|animals|6760667
Ancrod|affects|renal function|6816068
Ancrod|affects|fibrin deposition|6816068
Ancrod|causes|defibrination|6816068
ancrod|associated_with|glomerulonephritis|6816068
fibrinogen|coexists_with|fibrinogen degradation products|6948396
Arvin|isa|treatment|6948396
Arvin|uses|Arvin|6948396
Arvin|affects|red cells|6948396
Arvin|isa|ancrod|7038977
saline|isa|injections|7038977
saline|uses|saline|7038977
saline|administered_to|patients|7038977
ancrod|administered_to|patients|7038977
ancrod|isa|injections|7038977
ancrod|uses|ancrod|7038977
ancrod|prevents|deep vein thrombosis|7038977
venom|interacts_with|coagulant|7725330
venom|neg_affects|platelet function|7725330
Ancrod|treats|DVT/PE|7788603
ancrod|treats|patients|7788603
ancrod|neg_treats|patient|7788603
ancrod|treats|Patients|7788603
ancrod|treats|complications|7788603
ancrod|prevents|DVT/PE|7788603
venom|converts_to|Ancrod|7954782
Arvin|isa|ancrod|7979757
ancrod|treats|patient|7979757
Arvin|treats|patient|7979757
heparin|treats|patients|7979757
heparin|treats|syndrome|7979757
heparin|treats|heparin-induced thrombocytopenia|7979757
ancrod|treats|patients|8073455
ancrod|treats|ischemic stroke|8073455
ancrod|administered_to|patients|8073455
ancrod|part_of|patients|8073455
Ancrod|administered_to|patients|8073455
Ancrod|treats|brain infarction|8073455
Snake venoms|interacts_with|haemostatic|8075311
anticoagulants|stimulates|protein C|8075311
thrombin|isa|coagulants|8075311
thrombin|isa|anticoagulants|8075311
Defibrase|isa|enzymes|8075311
Ancrod|isa|enzymes|8075311
protein C|isa|haemostatic|8075311
venom|isa|toxins|8075311
Heparin|treats|thromboembolic disease|8156472
ancrod|isa|fibrinolytic agent|8156472
ancrod|treats|thrombosis|8156472
ancrod|causes|defibrination|8222694
snake toxin|causes|defibrination|8222694
heparin|administered_to|patients|8433424
Ancrod|compared_with|heparin|8433424
fibrinogen|interacts_with|fibrin|8457476
Ancrod|isa|venom|8457476
ancrod|part_of|patients|8457476
ancrod|associated_with|claudication|8457476
PAI-1|affects|defibrination|8457476
plasminogen activators|stimulates|plasminogen|8457476
tPA|stimulates|plasminogen|8457476
Fc gamma RII|part_of|platelet|8571730
tissue factor pathway inhibitor|part_of|recombinant|8571730
ancrod|disrupts|thrombus|8607122
snake venom|disrupts|cleavage|8607122
ancrod|treats|occlusive thrombus|8607122
hirudin|treats|occlusive thrombus|8607122
fibrinogen|interacts_with|GPIIb/IIIa receptors|8607122
porcine heparin|treats|patients|8740327
porcine heparin|treats|hypersensitivity|8740327
heparin|part_of|lung|8740327
heparin|treats|unstable angina|8740327
enoxaparin|treats|unstable angina|8740327
heparin|causes|hypersensitivity reaction|8740327
low-molecular-weight heparin|treats|short period|8740327
Enoxaparin|treats|unstable angina|8740327
protease|interacts_with|ancrod|8769943
ancrod|prevents|Adhesion|8769943
Ancrod|disrupts|thrombosis|8822133
ancrod|neg_prevents|thrombi|8822133
drug|administered_to|patients|8950124
Ancrod|treats|patients|8950124
Ancrod|treats|heparin-induced thrombocytopenia|8950124
ancrod|treats|rat|9296273
ancrod|affects|cerebral lesions|9296273
proteolytic|interacts_with|proteolytic|9360849
Ancrod|treats|deep-vein thrombosis|9360849
Ancrod|treats|patients|9360849
Ancrod|treats|stroke|9360849
Ancrod|treats|sickle-cell crisis|9360849
Ancrod|treats|priapism|9360849
Ancrod|treats|myocardial infarction|9360849
crotalase|administered_to|humans|9360849
heparin|part_of|blood|9360849
thrombin|coexists_with|fibrinogen|9360849
soluble fibrin|produces|fibrinogen|9360857
ancrod|part_of|patients|9360857
ancrod|associated_with|ischaemic stroke|9360857
ancrod|treats|patients|9360857
ancrod|treats|ischaemic stroke|9360857
Ancrod|treats|ischaemic stroke|9360857
ancrod|treats|cerebral ischaemia|9384248
heparin|neg_inhibits|SVTLEs|9425723
Prothrombin activators|coexists_with|snake venoms|9425723
Arg-Gly-Asp|coexists_with|snake venoms|9425723
TNF|causes|toxicity reactions|9619377
enzyme|interacts_with|fibrinogen|9619377
ancrod|part_of|Mice|9619377
ancrod|treats|mice|9619377
TNF|coexists_with|ancrod|9619377
Heparin|isa|anticoagulant|9725413
ancrod|associated_with|heparin-induced thrombocytopenia|9725413
heparin|treats|patients|9855180
heparin|treats|HIT|9855180
anticoagulant|treats|patients|9855180
anticoagulant|treats|HIT|9855180
Warfarin|treats|patients|9855180
Warfarin|treats|HIT|9855180
thrombin|treats|HIT|9855180
thrombin|associated_with|HIT|9855180
low-molecular-weight heparin|treats|thrombocytopenia|9855180
low-molecular-weight heparin|treats|patients|9855180
low-molecular-weight heparin|treats|HIT|9855180
low-molecular-weight heparin|treats|thrombosis|9855180
Anticoagulants|treats|patients|9932617
Anticoagulants|treats|ischemic stroke|9932617
heparin|prevents|stroke|9932617
ORG 10172|treats|patients|9932617
Anticoagulants|treats|cerebral venous thrombosis|9932617
Anticoagulant|treats|ischemic stroke|9932617
Anticoagulant|treats|cerebral venous thrombosis|9932617
fibrinogen|disrupts|blood viscosity|10796295
ancrod|treats|patients|10815082
ancrod|treats|ischemic stroke|10815082
ancrod|administered_to|Patients|10815082
ancrod|compared_with|placebo|10815082
Ancrod|isa|venom|11023513
Ancrod|produces|fibrinopeptide|11023513
desA-profibrin|produces|desA-profibrin|11023513
ancrod|coexists_with|fibrinogen|11023513
protamine|isa|perfusion procedures|11565896
Ancrod|isa|venom|11755954
cofactor|stimulates|plasminogen|11755954
Plasmin|augments|tPA|11755954
cofactor|stimulates|plasminogen|11755954
ancrod|stimulates|Plasminogen|11755954
ancrod|administered_to|patients|11882102
ancrod's|associated_with|disability|11882102
ancrod|treats|ischaemic stroke|11882102
streptokinase|isa|thrombolytic agents|11945105
pro-urokinase|isa|thrombolytic drugs|11945105
ancrod|treats|ischemic stroke|12074433
Ancrod|isa|biological agent|12365829
ancrod|treats|patients|12365829
ancrod|treats|stroke|12365829
fibrinogen|disrupts|blood viscosity|12917882
warfarin|isa|coumarin|15907979
warfarin|treats|HIT|15907979
coumarin|treats|HIT|15907979
warfarin|treats|HIT|15907979
danaparoid|treats|HIT|15907979
tissue plasminogen activator|isa|treatment|17126719
tissue plasminogen activator|treats|ischaemic stroke|17126719
snake venom|interacts_with|favourable|17126719
ancrod|administered_to|patients|17126719
ancrod|associated_with|ischaemic stroke|17126719
ancrod|treats|ischaemic stroke|17126719
ancrod|prevents|ICH|19110140
Ancrod|treats|ischemic stroke|19110140
ancrod|associated_with|ischemic stroke|19875736
ancrod|compared_with|placebo|19875736
Ancrod|associated_with|ischemic stroke|19875736
venom|converts_to|Ancrod|21868728
ancrod|treats|patients|21868728
fibrin|causes|cerebral microvascular occlusion|21868728
fibrinogen|disrupts|blood viscosity|22419274
Arwin|treats|patients|101819
Arwin|treats|peripheral arterial occlusive disease|101819
streptokinase|treats|myocardial infarction|716435
arwin|associated_with|unstable angina|716435
Arwin|affects|peripheral arterial occlusive disease|786664
Arwin|compared_with|conservative therapy|786664
Arwin|higher_than|conservative therapy|786664
Arwin|associated_with|circulatory disorders|786664
Arvin|treats|patients|831951
Arvin|treats|gangrene|831951
Arvin|affects|hemorheological|2078376
Arvin|treats|thromboses|2078376
streptokinase|associated_with|deep vein thrombosis|4886628
heparin|part_of|patients|4886628
Arvin|part_of|patients|4886628
streptokinase|part_of|patients|4886628
heparin|associated_with|deep vein thrombosis|4886628
Arvin|associated_with|deep vein thrombosis|4886628
Arvin|isa|treatment|4886628
Arvin|uses|Arvin|4886628
snake venom|inhibits|cholesterol|2282093
snake venom|affects|atherosclerosis|2282093
antivenomous|causes|acute renal failure|2651763
venomous|causes|acute renal failure|2651763
snake antivenom|treats|snake bite poisoning|5559044
snake venom|administered_to|patients|7362484
snake venom|associated_with|amyotrophic lateral sclerosis|7362484
anti snake venom|part_of|snake|7875785
Urokinase|interacts_with|thrombolytic|7956563
antivenin|isa|treatment|8202764
receptor|affects|platelet aggregation|8578476
receptor|affects|platelet thrombus|8578476
c7E3 Fab|prevents|complications|8578476
drugs|neg_disrupts|neurotoxic effects|8737971
NMDA receptors|neg_disrupts|neurotoxic effects|8737971
OS2|interacts_with|receptor sites|8737971
snake venom|part_of|mice|8872989
venom|causes|rhabdomyolysis|8872989
toxin|causes|rhabdomyolysis|8872989
snake venom|affects|tissue damaging|9237336
phospholipase A2|affects|tissue damaging|9237336
venom|causes|contractions|9237336
venom|causes|thrombi|9237336
venom|causes|emboli|9237336
venom|causes|Muscle necrosis|9237336
venom|affects|tissue damaging|9237336
snake venom|causes|tissue damage|9237336
VRCTC-310|treats|patients|9402309
VRCTC-310|treats|refractory cancer|9402309
venom|compared_with|venom|10403031
venom|higher_than|venom|10403031
DEX|isa|glucocorticoid|11152386
Hepatocyte growth factor|isa|growth factors|12845230
Hepatocyte growth factor|augments|growth|12845230
recombinant human HGF|part_of|human|12845230
HGF|augments|repair|12845230
Hepatocyte growth factor|augments|repair|12845230
Hepatocyte growth factor|augments|cell growth|12845230
snake venom|part_of|gastrocnemius|14677163
saline|isa|injection|14677163
saline|uses|saline|14677163
venom|causes|massive hemorrhage|14677163
snake venom|causes|myonecrosis|14677163
snake venom|causes|asthma|15945564
IgE binding proteins|part_of|patient|15945564
epitopes|coexists_with|venoms|15945564
venoms|disrupts|IgE binding|15945564
allergens|causes|anaphylaxis|15945564
jararhagin|isa|SVMP|16083850
metalloproteinases|affects|necrosis|16083850
jararhagin|part_of|muscle tissue|16083850
jararhagin|causes|host response|16083850
jararhagin|interacts_with|toxin|16083850
venom|causes|pathogenesis|16198390
antivenom|part_of|death adder|16498830
venom|part_of|lung|16911815
metalloproteinases|coexists_with|Viperid venoms|17543881
annexin V|affects|hemostasis|17543881
SVMPs|affects|hemostasis|17543881
neurotoxin|administered_to|humans|18197810
drug|treats|Multiple sclerosis|18197810
snake venom|administered_to|patient|18545005
ASV|part_of|ASV|18715131
hemotoxins|isa|toxins|19308897
toxins|causes|consumption coagulopathy|19308897
snake toxin|interacts_with|fibrinogen|19308897
venoms|interacts_with|toxin|19308897
fibrinogen|interacts_with|thrombin|19308897
factor VIII|interacts_with|thrombin|19308897
factor V|interacts_with|thrombin|19308897
venom|administered_to|rats|20223258
venom|coexists_with|antivenom|20223258
Crotalid venom|causes|tissue damage|22316194
Crotalid venom|causes|hematologic abnormalities|22316194
Crotalid venom|causes|neurological impairment|22316194
Crotalid venom|causes|hypotension|22316194
analgesic|isa|medications|22316194
venom|associated_with|growth arrest|23238991
CXCR3|isa|CKRs|23238991
toxins|coexists_with|venom|23594438
toxins|affects|hemorrhagic complications|23594438
antimicrobial|coexists_with|snake venoms|23657358
cytokines|interacts_with|BCV|23830987
immunomodulatory|affects|macrophages|23830987
BCV|interacts_with|immunomodulatory|23830987
snake venom|interacts_with|immunomodulatory|23830987
venom|associated_with|thrombus|8205048
thrombin|isa|injection|20367987
fibrinogen|interacts_with|fibrin|1209541
fibrinopeptide B|isa|Fibrinopeptide|1209541
fibrinopeptide|part_of|human|1209541
venom|inhibits|GPIIb/IIIa receptor|1900221
rt-PA|isa|injections|1900221
thrombolytic agents|treats|patients|1900221
thrombolytic agents|treats|acute myocardial infarction|1900221
recombinant tissue-type plasminogen activator|treats|canine|1900221
Kistrin|isa|platelet GPIIb/IIIa receptor antagonist|1900221
antivenom|part_of|equine|9237341
antithrombin III|treats|coagulopathy|9237341
antivenom|treats|coagulopathy|9237341
antivenom|treats|Coagulopathy|9237341
SQ 20858|disrupts|blood pressure|174133
SQ 20858|treats|lowering blood pressure|174133
synthetic peptide|inhibits|angiotensin converting enzyme|174133
angiotensin converting enzyme|associated_with|renal hypertension|174133
Norepinephrine|affects|cardiovascular functions|7913643
angiotensin II|treats|patients|7913643
renin|part_of|renal venous|234677
aldosterone|interacts_with|venom|1588674
renin|interacts_with|venom|1588674
vasopressin|administered_to|rat|3051054
tachykinins|neg_disrupts|brain|3051054
angiotensin II|interacts_with|eledoisin|3051054
renin|associated_with|renal dysfunction|8296375
diuretic|stimulates|cGMP|11304508
DNP|associated_with|CHF|11304508
DNP|augments|glomerular filtration rate|11304508
dendroaspis natriuretic peptide|associated_with|congestive heart failure|11304508
Natriuretic peptides|isa|hormones|17440808
BNP|interacts_with|peptide receptor|17440808
BNP|part_of|heart|17440808
BNP|part_of|organs|17440808
ANP|interacts_with|peptide receptor|17440808
ANP|part_of|heart|17440808
ANP|part_of|organs|17440808
cyclic guanosine monophosphate|affects|natriuresis|17440808
aldosterone|stimulates|NPR-A|17440808
renin|stimulates|NPR-A|17440808
NPs|treats|heart failure|17440808
NPs|associated_with|syndromes|17440808
phospholipase|augments|blood pressure|17897713
melittin|interacts_with|pressor|17897713
melittin|stimulates|adrenaline|17897713
melittin|stimulates|vasopressin|17897713
melittin|stimulates|noradrenaline|17897713
melittin|coexists_with|adrenaline|17897713
melittin|coexists_with|vasopressin|17897713
melittin|coexists_with|noradrenaline|17897713
prazosin|treats|rats|17897713
angiotensin II receptor antagonist|treats|normotensive|17897713
melittin|augments|blood pressure|17897713
angiotensin|predisposes|muscle atrophy|22673782
neutral endopeptidase|stimulates|natriuretic peptides|22942338
angiotensin-converting enzyme inhibitors|inhibits|angiotensin receptor|22942338
cardiovascular agents|inhibits|angiotensin receptor|22942338
therapeutic agents|treats|hypertension|22942338
therapeutic agents|treats|HF|22942338
therapeutic agents|treats|cardiovascular disease|22942338
chemotactic factor|affects|myocardium|303050
cobra venom factor|part_of|Dogs|303050
cobra venom factor|treats|dogs|303050
Trasylol|treats|dogs|303050
cobra venom factor|treats|ischemia|303050
cobra venom factor|prevents|tissue damage|641147
cobra venom factor|prevents|myocardial necrosis|641147
methadone|prevents|pain|1136977
diphenylhydantoin|prevents|pain|1136977
amitriptyline|prevents|pain|1136977
analgesics|administered_to|patients|1136977
complement|compared_with|antibody|2170825
complement|higher_than|antibody|2170825
antibody|disrupts|NK cells|2170825
antibody|coexists_with|NK|2170825
carrageenan|interacts_with|NK|2170825
antibodies|compared_with|antibodies|2170825
antibodies|higher_than|antibodies|2170825
antibodies|disrupts|cytotoxic T lymphocytes|2170825
antibodies|disrupts|natural killer cells|2170825
antibodies|affects|lysis|2233757
complement component C3|part_of|human|2233757
monoclonal antibodies|affects|lysis|2233757
complement|stimulates|monoclonal antibody 3F8|2233757
F(ab|coexists_with|complement|2233757
F(ab|compared_with|3F8 antibody|2233757
complement|affects|bronchoconstriction|2312187
cobra venom factor|affects|bronchoconstriction|2312187
CVF|inhibits|lung compliance|2312187
cobra venom factor|augments|bronchoconstriction|2312187
cobra venom factor|part_of|cells|2314052
antibodies|part_of|animals|2314052
catalase|inhibits|lipoxygenase|2314052
catalase|inhibits|thromboxane synthetase|2314052
antivenom|treats|patients|2389328
Anticholinesterase|neg_treats|paralysis|2389328
antivenom|part_of|cobra|2389328
antivenom|part_of|Bungarus caeruleus|2389328
cobra venom factor|treats|baboon|3191598
ibuprofen|prevents|infiltration|3191598
CVF|prevents|infiltration|3191598
complement|affects|injury|3191598
Complement|causes|myocardial injury|3191598
cobra venom factor|affects|host's|3286521
complement component|affects|irradiation|3286521
anticholinesterase drugs|treats|adults|3537783
edrophonium|treats|patient|3537783
edrophonium|treats|signs|3537783
edrophonium|treats|patients|3537783
cobra venom factor|part_of|animals|3599107
complement|part_of|rats|3716753
cobra venom factor|stimulates|complement|3716753
cobra venom factor|treats|rats|3716753
cobra venom factor|stimulates|glucocorticoids|3716753
C3-C9|isa|complement components|4588307
cobra venom factor|prevents|generalized Shwartzman reaction|4588307
antivenin|part_of|cobra|6625268
Cobra venom factor|stimulates|complement|6696049
cobra venom factor|augments|complement activation|6696049
indomethacin|treats|rats|7234970
cobra venom factor|treats|rats|7234970
cobra venom factor|treats|parameters|7347767
type II collagen|causes|polyarthritis|7347767
cobra venom factor|treats|cancer model|7493340
cobra venom|stimulates|complement|7493340
mab|compared_with|CVF|7493340
CVF|interacts_with|CVF|7493340
venoms|neg_affects|coagulopathy|8036678
Mercuric chloride|causes|autoimmunity|8082302
HgCl2|stimulates|autoantibodies|8082302
cobra venom factor|affects|vasculitis|8082302
GPI 562|disrupts|platelet aggregation|8693522
GPI 562|affects|graft survival|8693522
GPI 562|affects|platelet aggregation|8693522
CVF|coexists_with|GPI 562|8693522
immune complexes|stimulates|cobra venom factor|8755663
myeloperoxidase|disrupts|permeability|8755663
myeloperoxidase|disrupts|lung|8755663
myeloperoxidase|part_of|lung|8755663
myeloperoxidase|augments|vascular permeability|8755663
sCR1|interacts_with|C4b|8779679
alpha neurotoxins|administered_to|rabbits|8896193
Naja haje venoms|administered_to|rabbits|8896193
venoms|interacts_with|venoms|8896193
antivenom|interacts_with|venom|8896193
antibody|causes|injury|9371665
monoclonal antibodies|associated_with|cytotoxicity|9413745
complement|part_of|human|9413745
CVF|coexists_with|complement|9413745
anti-tumor antibodies|part_of|tumor|9413745
CVF|treats|PHN|9430849
CVF|part_of|rats|9430849
antivenom|neg_associated_with|symptoms|9509180
peripheral nerve myelin|part_of|nerve|9522271
Cobra Venom Factor|part_of|rats|9522271
peripheral nerve myelin|part_of|rats|9522271
Cobra Venom Factor|compared_with|peripheral nerve myelin|9522271
CR1|affects|Experimental Allergic Neuritis|9522271
CVF|treats|rats|9522271
sCR1|part_of|rats|9522271
sCR1|inhibits|complement|9522271
cobra venom factor|treats|experimental allergic neuritis|9522271
CVF|treats|monkey|10029251
CVF|treats|monkeys|10029251
CVF|administered_to|monkeys|10029251
antigen|administered_to|monkeys|10029251
saline|administered_to|control animals|10600909
cobra venom factor|inhibits|complement|10606985
CVF|isa|treatment|10606985
CVF|treats|disease|10606985
DAF|augments|gastritis|10623859
DAF|part_of|guinea pig|10623859
DAF|part_of|epithelium|10623859
DAF|part_of|epithelial cells|10623859
complement|affects|injury|11136932
cobra venom factor|part_of|animals|11136932
saline|isa|injection|11136932
saline|uses|saline|11136932
CVF|treats|brain edema|11136932
epoprostenol|prevents|spasms|11208190
CVF|administered_to|animals|11208190
CVF|coexists_with|epoprostenol|11208190
cobra venom factor|prevents|reperfusion injury|11208190
cobra venom factor|prevents|proteinuria|11253115
CVF|treats|rats|11253115
epitope|stimulates|monoclonal antibody|11253115
albumin|associated_with|PHN|11253115
antigen|associated_with|PHN|11253115
cobra venom factor|neg_prevents|neuronal loss|11278106
cobra venom factor|neg_prevents|atrophy|11278106
cobra venom factor|neg_prevents|edema|11278106
cobra venom factor|administered_to|Rats|11344557
immune complexes|causes|type III Arthus reaction|11441099
complement|associated_with|immune complex-mediated corneal disease|11441099
cobra venom factor|part_of|mice|11441099
Fc gamma receptors|associated_with|corneal inflammation|11441099
Cobra venom factor|augments|polymorphonuclear leukocytes|11446502
CVF|interacts_with|complement|11446502
CVF|treats|Rats|11446502
Complement|associated_with|myocardial ischemia-reperfusion injury|11446502
neutrophil elastase|associated_with|injury|11525781
neutrophil elastase inhibitor|administered_to|hamsters|11525781
CVF|isa|injection|11525781
CVF|uses|CVF|11525781
sivelestat|disrupts|elastase activity|11525781
neutrophil elastase|associated_with|acute lung injury|11525781
Complement|causes|tissue damage|11764002
cobra venom factor|inhibits|EDTA|11764002
K-76|part_of|Rats|11764002
cobra venom|causes|multiple-organ failure|15619012
C|causes|hypocomplementemia|15802558
snake venom|inhibits|nucleic acid|15813633
venom|coexists_with|nucleic acid|15813633
Snake venom|inhibits|nucleic acids|15813633
nucleic acid|associated_with|breast cancer|15813633
glucocorticoids|isa|treatments|15830600
intravenous fluids|isa|treatments|15830600
antiserum|treats|dogs|15830600
complement|associated_with|cerebral injury|15854749
cobra venom factor|prevents|cerebral injury|15854749
NaCl|part_of|guinea-pigs|16251069
zinc protoporphyrin|inhibits|HO-1|16251069
cobra venom factor|part_of|donors|16251069
protein|part_of|transplanted livers|16251069
cobra venom factor|stimulates|complement|16782534
complement|produces|complement inhibitors|16782534
CVF|stimulates|TNFalpha|16782534
complement factors|stimulates|complement|16782534
cobra venom factor|administered_to|rats|16782534
Complement inhibitors|disrupts|injury|16782534
toxin|associated_with|symptoms|16817641
MCTX|compared_with|toxin|16817641
complement|affects|graft survival|17175243
Y-CVF|prevents|humoral allograft rejection|17175243
Y-CVF|disrupts|humoral allograft rejection|17175243
cyclosporin A|inhibits|graft rejection|17991145
CVF|inhibits|complement membrane attack complex|17991145
CVF|augments|hearts|17991145
CSA|administered_to|rats|17991145
anti-C6 IgG|administered_to|rats|17991145
CVF|administered_to|rats|17991145
CVF|administered_to|rats|17991145
anti-C6 antibodies|administered_to|rats|17991145
complement proteins|coexists_with|complement|17991145
antivenom|administered_to|patients|19439335
ChEs|affects|aryl acylamidase (AAA) activity|19695303
enzyme|affects|aryl acylamidase (AAA) activity|19695303
cobra venom|coexists_with|AAA|19695303
cholinesterases|associated_with|pathogenesis|19695303
cobra venom|interacts_with|drugs|19695303
cobra venom|interacts_with|AAA|19695303
AAA|associated_with|AChE|19695303
acetylcholinesterase|affects|aryl acylamidase activity|19695303
Cobra venom|causes|arthritis|19825384
snake venom|associated_with|arthritis|19825384
opiates|isa|analgesics|21614945
opiates|treats|abuse|21614945
opiates|treats|adverse effects|21614945
opiate|isa|analgesics|21614945
complements|administered_to|rats|22666742
serum|part_of|liver|22666742
serum|part_of|livers|22666742
cobra venom factor|part_of|livers|22666742
CVC|disrupts|cells|22888519
SSRP|disrupts|growth|22888519
cytotoxin|affects|tumor|22888519
ricin|affects|tumor|22888519
cobra venom factor|interacts_with|complement inhibitor|23588254
CVF|inhibits|hyperalgesia|23588254
CVF|administered_to|rats|23588254
complements|affects|hyperalgesia|23588254
complement C3|associated_with|neuropathic pain|23588254
cardiotoxins|isa|cobra venom|23711147
cardiotoxins|augments|necrotic|23711147
complete Freund's adjuvant|treats|rats|19169271
nicotinic receptor|interacts_with|cholinergic system|19169271
IL-1|produces|TNF-alpha|19169271
IL-2|stimulates|IL-10|19169271
MLA|inhibits|analgesic|19169271
cytokines|affects|arthritis|19169271
naloxone|neg_inhibits|analgesic effect|21841815
cholinergic system|affects|inflammatory pain|21841815
venom|causes|fall|2077181
antivenin|part_of|habu|2077181
norepinephrine|part_of|aorta|2077181
venom|affects|vasorelaxant|2077181
batroxobin|part_of|mice|6083965
aprotinin|causes|toxicity|6083965
batroxobin|causes|toxicity|6083965
aprotinin|part_of|rats|6083965
CSF|part_of|brain|6202636
Melittin|stimulates|kallikrein|6202636
kinins|affects|cardiovascular function|6202636
scorpion Tityus serrulatus venom|causes|lung oedema|9440240
scorpion venom|administered_to|rats|9440240
heparin|causes|arterial hypertension|9440240
heparin|causes|lung oedema|9440240
scorpion venom|causes|lung oedema|9440240
aprotinin|neg_prevents|arterial hypertension|9440240
scorpion venom|causes|arterial hypertension|9440240
venom|augments|lung oedema|9440240
scorpion venom|causes|Lung oedema|9440240
venom|interacts_with|kinins|9637372
aprotinin|inhibits|bradykinin|9637372
icatibant|inhibits|bradykinin|9637372
icatibant|part_of|animals|9637372
venom|part_of|animals|9637372
bradykinin|coexists_with|plasma kinin|9637372
kinins|interacts_with|venom|9637372
scorpion venom|interacts_with|plasma kinins|9637372
aprotinin|inhibits|protease|19236611
aprotinin|isa|plasmin inhibitor|19236611
aprotinin|compared_with|aprotinin|19236611
plasmin inhibitor|inhibits|protease|19236611
plasmin inhibitor|compared_with|aprotinin|19236611
aprotinin|inhibits|protease|19236611
aprotinin|disrupts|fibrinolysis|19236611
aprotinin|treats|blood loss|19236611
aprotinin|inhibits|plasmin|19236611
anti-bleeding agent|treats|blood loss|19236611
Bee venom|disrupts|edema|474306
complete Freund's adjuvant|disrupts|polyarthritis|474306
albumin|part_of|egg|474306
corticosteroids|affects|immune response|474306
bee venom|part_of|patients|546252
bee venom|associated_with|bee sting hypersensitivity|546252
BV-specific IgG|part_of|patients|546252
antibodies|coexists_with|antibodies|838994
blocking antibody|coexists_with|bee venom|1172815
bee venom|causes|collapse|1359383
anti-allergic|isa|medication|1551035
honey bee venom|prevents|side effects|1551035
hymenoptera venoms|treats|patients|1897686
albumin|part_of|human|2419385
allergens|inhibits|allergenicity|2419385
albumin|isa|polymer|2419385
WVAP|isa|WVAP|2419385
albumin polymer preparations|isa|polymer|2737470
albumin|isa|polymer|2737470
VAP|isa|VAP|2737470
WFHVAP|isa|WFHVAP|2737470
VAP preparations|isa|VAP|2737470
hymenoptera venoms|treats|anaphylaxis|2737470
albumin|part_of|human|2737470
bee-venom|isa|allergens|3349595
antigen-|interacts_with|antibodies|3349595
isotype|interacts_with|antibodies|3349595
bee-venom|isa|antigens|3349595
venom|administered_to|patients|3711549
yellow jacket venom|administered_to|patients|3711549
bee venom|part_of|patient|3711549
antibodies|coexists_with|antibodies|3770979
antibodies|affects|protection|3770979
bee venom|associated_with|anaphylaxis|4071339
bee venom|disrupts|oedema|4152780
melittin|compared_with|mepyramine|4152780
albumin|disrupts|increased vascular permeability|4152780
methysergide|inhibits|increased vascular permeability|4152780
mepyramine|inhibits|increased vascular permeability|4152780
medications|treats|patients|6146275
beta-blockers|treats|patients|6146275
venom|disrupts|arthritis|6177321
cytochrome P-450|isa|treatments|6177321
heme oxygenase|part_of|microsomal|6177321
bee venom|administered_to|rats|6177321
microsomal enzymes|part_of|hepatic|6177321
venom|augments|heme metabolism|6177321
bee venom|isa|antigens|6619452
melittin|coexists_with|antibody|6619452
antibody|interacts_with|antigen|6619452
bee venom|isa|antigen|6619452
antibody|interacts_with|bee venom|6619452
venom|part_of|patients|7313646
bee venom|part_of|Wistar rats|7472785
bee venom|associated_with|infarct|7472785
noradrenaline|part_of|cardiac tissue|8054829
noradrenaline|treats|Wistar rats|8054829
ABV|part_of|animals|8054829
allergen|associated_with|bee sting allergy|8833918
bee venom|part_of|patients|8833918
cytokines|part_of|T cell|8833918
bee venom|isa|allergens|8835130
Antibody|interacts_with|royal jelly|8835130
peptides|coexists_with|immunodominant region|9257793
allergen|affects|cytokine secretion|9257793
c-Fos|interacts_with|morphine|9739136
bee venom|causes|pain|9739136
c-Fos protein|part_of|spinal cord|9739136
PLA2|augments|cells|10442531
purinoceptor|inhibits|P2x receptor|10643796
purinoceptor|stimulates|bee venom|10643796
bee venom|causes|pain|10643796
drug|affects|heat hyperalgesia|10793237
PKC|augments|sensitization|10793237
bee venom|causes|heat hyperalgesia|10793237
fexofenadine|prevents|side-effects|10843430
phospholipase A2|part_of|CBA/J mice|10898500
PLA2-specific IgE|coexists_with|IgG2a|10898500
PLA2|part_of|mice|10898500
bee venom|stimulates|histamine|11039839
Bee venom|stimulates|histamine|11039839
Freund's adjuvant|isa|injection|11207399
Freund's adjuvant|uses|Freund's adjuvant|11207399
BV|compared_with|injection|11207399
BV|causes|analgesic effect|11207399
allergens|part_of|recombinant|11340327
venom-specific IgE antibodies|compared_with|venom allergens|11340327
mast-cell-specific enzyme tryptase|associated_with|allergy|11340327
venom allergens|part_of|recombinant|11340327
bee venom|compared_with|acupuncture|11527062
wasp venoms|isa|allergens|11815741
anti-IgE|part_of|Basophils|11815741
anti-IgE|isa|antibody|11815741
allergen|part_of|Basophils|11815741
antibody|part_of|Basophils|11815741
IgE receptor|causes|histamine release|11815741
IgE receptor|causes|upregulation|11815741
Freund's adjuvant|isa|injection|12031688
Freund's adjuvant|uses|Freund's adjuvant|12031688
interleukin-6|causes|RA|12031688
bee venom|coexists_with|bee venom|12109787
tryptase|coexists_with|bee venom|12109787
venom|part_of|patients|12464961
capsaicin|treats|human volunteers|12536045
melittin|causes|hyperalgesia|12536045
Melittin|predisposes|neurogenic inflammation|12536045
capsaicin|treats|humans|12536045
melittin|compared_with|capsaicin|12536045
melittin|causes|neurogenic inflammation|12536045
ibotenic acid|isa|neurotoxin|12717146
ibotenic acid|part_of|RMM|12717146
BV|causes|heat hyperalgesia|12717146
Hoe 140|disrupts|oedema|12755378
BV|causes|oedema|12755378
BV|causes|inflammatory response|12755378
nitric oxide|stimulates|histamine receptor|12755378
tachykinins|interacts_with|kinins|12755378
venom|causes|inflammatory response|12755378
bee venom|interacts_with|venom|12782086
bee venom|disrupts|tumor growth|12782086
bee venom|disrupts|cell proliferation|12782086
NMDA|compared_with|NMDA receptor|12885421
bee venom|stimulates|calcium|14644579
bee venom|stimulates|sodium alginate|14644579
bee venom|coexists_with|liposome|14644579
melittin|isa|bee venom|14722668
immunoconjugates|compared_with|MAb|14722668
immunoconjugates|disrupts|tumour growth|14722668
ABV|administered_to|experimental animals|15057338
bee crude venom|part_of|animals|15311679
Apis mellifera venom|administered_to|mice|15311679
idazoxan|disrupts|alpha2-adrenoceptor|15336634
opioid receptors|affects|spinal cord|15336634
opioid receptors|affects|thermal hyperalgesia|15336634
melittin|causes|inflammation|15882816
TGF-beta1|affects|aromatase activity|15894134
aromatase|part_of|human|15894134
bee venom|interacts_with|aromatase|15894134
NMDA|isa|aspartate|15950221
acetylcholine|affects|anti-inflammatory effect|15953592
cholinergic antagonist|isa|nicotinic cholinergic antagonist|15953592
acetylcholine|part_of|spinal cord|15953592
receptors|augments|SPNs|15953592
muscarinic type 2 receptors|affects|anti-inflammatory effect|15953592
bee venom|part_of|Beekeepers|15985817
bee venom|part_of|family members|15985817
bee venom|affects|adjuvant-induced arthritis|15999553
BV|disrupts|inflammation|15999553
SIL|disrupts|cells|16315243
type II collagen|part_of|bovine|16457792
type II collagen|part_of|Sprague-Dawley rats|16457792
adrenergic receptor|associated_with|inflammatory pain|16457792
bee venom|coexists_with|phosphate buffer|16599259
Bee venom|associated_with|block|16599259
copolymer|neg_interacts_with|bee venom|16599259
Bee venom|coexists_with|cortical|16774771
venom|augments|injury|16774771
bee venom|part_of|patient|16889280
Nitric oxide|associated_with|anaphylaxis|16937763
NO|interacts_with|NO|16937763
NO|associated_with|anaphylaxis|16937763
bee venom|affects|adjuvant induced arthritis|17213605
bee venom|part_of|rats|17213605
TNF-alpha|isa|cytokine|17213605
Bee venom|inhibits|TNF-alpha|17213605
Bee venom|inhibits|IL-1 beta|17213605
BV|interacts_with|melittin|17303203
MMPs|stimulates|tumor necrosis factor alpha|17303203
MMPs|stimulates|LPS|17303203
MMPs|stimulates|interleukin 1beta|17303203
melittin|neg_inhibits|MMPs 1|17303203
melittin|inhibits|MMP 3|17303203
MMPs 1|inhibits|MMP 3|17303203
MMP 3|affects|chondrocytes|17303203
matrix metalloproteinase 3|interacts_with|melittin|17303203
polypeptide|disrupts|cancer cells|17363137
LHR|causes|cell death|17363137
PKA and PKC|affects|inflammation|17544210
PKA inhibitor|inhibits|PKC|17544210
H-89|inhibits|hyperalgesia|17544210
PKA and PKC|affects|hyperalgesia|17544210
PKA and PKC|affects|nociception|17544210
BV|affects|arthritis|17555825
BV|interacts_with|BV|17555825
c-Fos|part_of|spinal cord|17555825
bee venom|affects|cancer|17555825
bee venom|interacts_with|melittin|18212480
Mellitin|neg_interacts_with|IL-1beta|18212480
MMP3|neg_inhibits|MMP1|18212480
melittin|affects|rheumatoid|18212480
matrix metalloproteinase-1|interacts_with|melittin|18212480
saline|isa|injection|18226968
saline|uses|saline|18226968
SIL|disrupts|cells|18300479
BV|interacts_with|cholecystokinin octapeptide|18376296
interleukin 1|produces|tumor necrosis factor-alpha|18376296
BV|associated_with|AP|18376296
bee venom|affects|pancreatitis|18376296
p38|part_of|neurons|18445299
p38|part_of|microglia|18445299
p-p38|part_of|neurons|18445299
vitamin D|isa|medicine|18631428
GM-CSF|part_of|bone marrow cells|18790041
costimulatory|inhibits|BV|18790041
BV|interacts_with|immune-modulatory|18790041
bee venom|isa|antigens|19001136
antigens|causes|bee stings|19001136
bee venom|causes|bee stings|19001136
cytotoxic T lymphocyte-associated antigen 4|disrupts|T cell|19001136
bee venom|causes|analgesic effect|19010737
sera|part_of|Sera|19538349
venom-specific IgE|interacts_with|FAB|19538349
Honey-Bee venom|treats|individuals|19853357
MMP-9|affects|MCF-7 cells|19969058
Bee venom|disrupts|cell invasion|19969058
Bee venom|disrupts|phosphorylation|19969058
melittin|inhibits|MMP-9|19969058
Bee venom|inhibits|MMP-9|19969058
Bee venom|inhibits|p38|19969058
Bee venom|inhibits|NF-kappaB|19969058
bee venom|part_of|Mice|20034453
BV|causes|arthritis|20379856
BV|associated_with|CIA|20379856
Bee pollen|treats|people|20447747
Bee pollen|treats|allergy|20447747
Bee pollen|treats|children|20447747
bee venom|interacts_with|glucocorticoids|20457243
saline|administered_to|control group|20457243
metyrapone|treats|rabbits|20457243
bee venom|causes|signs|20558236
bee venom|administered_to|people|20558236
saline|isa|injection|20696145
saline|uses|saline|20696145
formalin|disrupts|nociception|20696145
BV|disrupts|nociception|20696145
Bee venom|affects|pain|20821823
Bee venom|affects|inflammation|20821823
Carbon tetrachloride|causes|hepatotoxicity|20821823
CCl4|causes|hepatic fibrosis|20821823
BV|affects|inflammation|20821823
CCl4|part_of|mice|20821823
alpha-smooth muscle actin|part_of|smooth muscle|20821823
BV|inhibits|transforming growth factor (TGF)-beta1|20821823
BV|inhibits|fibronectin|20821823
BV|inhibits|alpha-smooth muscle actin|20821823
TNF-alpha|inhibits|IL-1beta|20821823
BV|part_of|ETH|20821823
BV|inhibits|cytokines|20821823
Bee venom|disrupts|hepatic fibrosis|20821823
Bee venom|associated_with|arthritis|20950451
BV|associated_with|inflammatory reactions|20950451
Bee venom|associated_with|inflammatory diseases|20950451
bee venom|disrupts|neuron loss|20950451
Bee venom|affects|anti-inflammatory effect|20950451
BV|disrupts|caspase-3 activity|20950451
methamphetamine|treats|mice|20950675
BV|interacts_with|BV|20950675
BV|stimulates|Fos|20950675
BV|affects|NA|20950675
BV|affects|LC|20950675
BV|affects|SN|20950675
BV|compared_with|supplementation|20952702
melittin|affects|arthritis|21061459
melittin|isa|bee venom|21061459
cellular adhesion molecules|neg_interacts_with|BV|21061462
BV|augments|gene regulation|21061462
BV|inhibits|intercellular adhesion molecule-1|21061462
bee venom|disrupts|cell proliferation|21682930
melittin|disrupts|neuron loss|21682930
p38|part_of|spinal cord|21682930
p38|part_of|brainstem|21682930
honey bee venom|treats|chronic inflammatory disease|21756243
PGF2|augments|basophil activation|21843104
bee venom|isa|allergens|21843104
glial fibrillary acidic protein|affects|nociception|21889580
DBV|inhibits|adrenoceptor|21889580
tumor necrosis factor (TNF)-alpha|causes|inflammatory reactions|21928088
bee venom|disrupts|inflammatory reactions|21928088
melittin|affects|liver cells|21928088
melittin|administered_to|Mice|21928088
Melittin|inhibits|caspase|21928088
melittin|inhibits|cytokines|21928088
melittin|affects|apoptosis|21928088
melittin|affects|inflammation|21928088
hyaluronic acid|treats|osteoarthritis|21963244
venom|disrupts|side effects|22104605
bee venom|isa|allergens|22104605
Bee venom|isa|toxin|22109081
melittin|isa|bee venom|22109081
melittin|stimulates|PLA2|22109081
matrix metalloproteinases|causes|cell death|22109081
melittin|stimulates|immunomodulatory|22109081
bee venom|affects|tumor cells|22109081
melittin|associated_with|cancers|22109081
DBV|causes|analgesic effects|22217441
DBV|inhibits|pNR1|22217441
DBV|affects|neuropathic pain|22217441
DBV|disrupts|neuropathic pain|22217441
DBV|causes|analgesic effect|22217441
bee venom|affects|phosphorylation|22217441
wasp venom|causes|anaphylaxis|22409877
Pharmalgen|treats|allergy|22409877
HDA|compared_with|HDA|22409877
chemotherapeutic agents|causes|nerve damage|22898064
Melittin|isa|bee venom|22995146
bee venom|coexists_with|prostaglandin|22995146
Melittin|coexists_with|prostaglandin|22995146
pressor|treats|rats|22995146
histamine|part_of|extracellular|22995146
melittin|stimulates|histamine|22995146
pressor|interacts_with|melittin|22995146
insect venom|administered_to|AUTHORS|23076950
cytokines|associated_with|asthma|23121887
BV|disrupts|asthma|23121887
IL2|produces|cytokines|23121887
IL4|produces|cytokines|23121887
IL2|produces|Th1|23121887
IL17|produces|Th1|23121887
IL17|produces|cytokines|23121887
IL4|produces|Th1|23121887
cytokine|produces|IL10|23121887
ovalbumin|augments|regulatory T cells|23121887
BV|associated_with|toxicity|23375112
Bee venom|affects|erythropoiesis|23375112
endogenous opioid|predisposes|inflammation|23574036
bee venom|causes|inflammatory response|23574036
Bee venom|coexists_with|normal saline|23642945
bee venom|associated_with|diseases|23936001
MEL|affects|cells|23936001
MEL|inhibits|VEGF|23936001
MEL|disrupts|cancer progression|23936001
Melittin|inhibits|VEGF|23936001
cancer drugs|causes|peripheral neuropathic pain|23985901
bee venom|associated_with|pain|23985901
opioid receptors|interacts_with|DBV|23985901
adrenoceptors|interacts_with|DBV|23985901
opioid receptor antagonist|neg_interacts_with|DBV|23985901
oxaliplatin|treats|mice|23985901
PBV|disrupts|acnes|24063779
PBV|part_of|microorganism|24063779
drug|treats|acne vulgaris|24063779
PBV|isa|drug|24063779
PBV|treats|acne vulgaris|24063779
bee venom|causes|bee stings|24134690
bee venom|causes|immune tolerance|24912908
honey-bee venom|treats|beekeepers|24912908
neurotoxins|coexists_with|taipan venom|7570884
toxins|inhibits|toxins|8896191
Val|coexists_with|BmK|8896191
Ile|coexists_with|BmK|8896191
Lys|interacts_with|neurotoxins|8896191
Lys|interacts_with|receptor|8896191
neurotoxins|coexists_with|venom|10628285
sodium channels|part_of|kidney|11826163
sodium|part_of|extracellular|11826163
antivenom|treats|spider envenomation|12165044
neurotoxin|causes|syndrome|12165044
Neurotoxins|causes|paralysis|12165047
neurotoxins|coexists_with|venoms|12165047
venoms|part_of|families|12165047
neurotoxins|inhibits|nicotinic receptor|12165047
neurotoxins|affects|nervous tissues|15519751
curare|interacts_with|neurotoxins|17265902
drugs|treats|pain|17399793
drugs|treats|neurological disorders|17399793
Drugs|augments|neural circuits|17499645
PNV|administered_to|rats|17499645
neurotoxins|affects|neuromuscular junction transmission|20096908
peptidic|isa|ingredients|20358687
discharges|associated_with|paralysis|20840850
toxin|causes|epileptic|20840850
alpha-conotoxin|coexists_with|amino acids|23414173
scorpion venom|converts_to|peptides|24252544
agonists|augments|protein-mediated activation|8613234
G protein alpha-subunit|stimulates|phospholipase C|8613234
phospholipase C|interacts_with|phospholipase C|8613234
G protein|affects|cell membrane|8613234
G proteins|associated_with|hypertension|8613234
venom|stimulates|protein C|1904199
hirudin|inhibits|thrombomodulin|1904199
antivenoms|treats|mice|1904199
Echistatin|disrupts|platelet aggregation|1946598
batroxobin|interacts_with|endotoxin|6359574
Russell's viper venom|affects|blood coagulation|6737775
fibrinogen degradation products|augments|fibrinolysis|6737775
Russell's viper venom|affects|fibrinolysis|6737775
antithrombin III|stimulates|tissue factor|7974711
thrombomodulin|stimulates|tissue factor|7974711
cytokines|associated_with|cellular infiltrate|7974711
antivenom|treats|patient|8730340
antivenom|part_of|Crotalus durissus|9655642
antivenom|part_of|pit vipers|10218750
protein complex|inhibits|factor VIIa|16707924
venom|causes|poisoning|17265904
venom|causes|necrosis|17265904
Dapsone|treats|dermal lesions|17265904
carrageenin|causes|inflammatory response|7537590
phospholipase A2|coexists_with|venom|7537590
toxic non-enzymatic chaperon protein|interacts_with|crotapotin|7537590
crotapotin|affects|platelet aggregation|7537590
crotapotin|affects|cell degranulation|7537590
crotapotin|disrupts|oedema|7537590
carrageenin|causes|oedema|7537590
Crotapotin|stimulates|compound 48/80|7537590
arachidonic acid|stimulates|compound 48/80|7537590
platelet activating factor|stimulates|compound 48/80|7537590
thrombin|causes|platelet aggregation|7537590
ovalbumin|stimulates|TXB2|7537590
crotapotin|inhibits|cyclo-oxygenase|7537590
PLA2|part_of|extracellular|7537590
crotapotin|interacts_with|PLA2|7537590
venom|part_of|horses|8675476
crotalid venom|part_of|rabbit|8736137
crotalid venom|causes|syndrome|8736137
venom|causes|mononeuropathy|8736137
thrombin|causes|defibrination syndrome|10219986
venom|associated_with|bites|10219986
plasminogen activator inhibitor-1|stimulates|antigen|10219986
rattlesnake venom|causes|thrombocytopenia|12676300
nitric oxide|affects|macrophage|12782091
glucose|affects|macrophage|12782091
Crotalid venom|causes|analgesia|12782091
crotalid venom|affects|macrophage|12782091
venom|part_of|peritoneal macrophages|12782091
venom|isa|toxins|12782091
antivenom|part_of|crotalid|12782091
crotalid venom|disrupts|macrophage|12782091
crotoxin|interacts_with|crotalid venom|12782091
crotoxin|interacts_with|snake venom|12782091
Venom|causes|thrombocytopenia|17265901
calm|part_of|victim|17265901
antivenin|isa|therapy|17265901
rattlesnake venom|causes|injury|18457854
snake venom|causes|injury|18457854
antivenoms|treats|bites|656831
Antivenom|treats|poisoning|656831
venom|causes|necrosis|656831
factor X activator|coexists_with|venom|1919428
antivenom|part_of|horse|2089742
Antivenom|administered_to|children|2733617
antivenom|administered_to|children|2733617
Factor IX|treats|patients|3103794
thrombin|part_of|patient|3103794
venom|affects|blood coagulation|3103794
venom|causes|acute renal failure|4060176
venom|causes|rhabdomyolysis|4060176
venom|causes|myonecrosis|4060176
serum|part_of|serum|4060176
serum|part_of|urine|4060176
antivenins|produces|antivenin|6381754
antivenin|treats|snakebite|6968356
venom|causes|tissue damage|8083405
antivenoms|part_of|snakes|8327649
antivenoms|part_of|Bothrops|8327649
antivenoms|isa|treatment|8327649
antivenoms|administered_to|Patients|8327649
antivenom|part_of|Lachesis|9133709
AV|administered_to|children|11781603
hydrocortisone|treats|patients|11781603
antivenoms|treats|mice|12102539
antivenin|administered_to|patients|12733849
venom|causes|hemorrhage|14719029
venoms|compared_with|venom|14719029
venoms|lower_than|venom|14719029
antibody|coexists_with|immune sera|14719029
venom|coexists_with|antibody|14719029
venom|affects|glands|15536056
snake antivenom|treats|patients|16434468
snake antivenom|part_of|black|16434468
antivenom|neg_treats|paralysis|16847503
venom|causes|nephrotoxicity|17014559
antivenom|administered_to|patients|17357384
antihistamines|treats|patient|17554446
venoms|associated_with|MS|17583756
toxin|interacts_with|venoms|17583756
venom|affects|infection|17674318
toxins|part_of|extracellular|17674318
fibrinogen|produces|toxins|17674318
fibrinogen|produces|enzymes|17674318
fibronectin|produces|toxins|17674318
fibronectin|produces|enzymes|17674318
integrins|coexists_with|integrins|17979730
integrins|affects|angiogenesis|17979730
viper venom|affects|interaction|17979730
angiogenic viper venom peptides|interacts_with|alpha 1 beta 1 integrin|17979730
adrenaline|treats|medical staff|18081448
Venoms|coexists_with|proteins|18420371
proteins|disrupts|haemostasis|18420371
haemorrhagins|causes|disorders|18420371
thrombin|stimulates|factor V|18420371
thrombin|stimulates|factor X|18420371
thrombin|stimulates|enzymes|18420371
factor IX|isa|proteases|18420371
factor IX|stimulates|protein C|18420371
snake venoms|causes|Haemostasis disorders|18420371
snake venoms|causes|nephrotoxicity|18620959
anti-snake venoms|treats|high-risk groups|18715121
CroFab|isa|antivenom|18846756
CroFab|compared_with|antivenoms|18846756
venom|affects|growth|19327376
CCV|disrupts|growth|19327376
Snake venom|disrupts|growth|19327376
secretion components|causes|bites|19393681
Crotalidae Polyvalent Immune Fab|treats|patients|19545426
antivenom|treats|snakebite|19545426
antivenom|treats|victims|19545426
factor VIIa|part_of|recombinant|19594209
factor VIIa|treats|massive gastrointestinal hemorrhage|19594209
hemoglobin|part_of|blood|19594209
factor VIIa|part_of|Recombinant|19594209
factor VIIa|treats|gastrointestinal hemorrhage|19594209
venoms|part_of|Animal|20455317
natural products|associated_with|cancer|20455317
venoms|part_of|animal|20455317
antigens|affects|snakebite|20591352
antivenom|part_of|patients|20643156
antivenom|part_of|Bothrops|20643156
synaptophysin|part_of|skeletal muscle|20855420
phospholipases A2|causes|necrosis|20855420
hydrocortisone|isa|hormones|21115460
thyroxine|isa|hormones|21115460
hydrocortisone|part_of|Physicians|21115460
hormones|part_of|Physicians|21115460
thyroxine|part_of|Physicians|21115460
cholesterol|interacts_with|venom|21827516
toxin|administered_to|victim|21981407
Antivenom|treats|coagulopathy|23586640
Antivenom|treats|patients|23586640
venom|part_of|patients|23586640
venom|interacts_with|Antivenom|23586640
antivenom|administered_to|patients|23586640
venom|associated_with|coagulopathy|23586640
venom|causes|disseminated intravascular coagulation|17320134
venom|causes|consumptive coagulopathy|17320134
venom|causes|hemorrhage|17320134
venom|causes|increased fibrinolysis|17320134
toxins|affects|endothelium|17320134
haemorrhagin|causes|thrombocytopenia|1631797
haemorrhagin|affects|bleeding|1631797
venom|affects|platelets aggregation|1796474
venom|part_of|rats|1796474
batroxobin|part_of|rats|1796474
haemorrhagin|causes|thrombocytopenia|1796474
haemorrhagin|affects|bleeding|1796474
von Willebrand factor|treats|patients|1949067
von Willebrand factor|treats|bleeding|1949067
venom|part_of|rats|2804475
venom|affects|blood coagulation|7549984
antivenom|inhibits|antivenom|7549984
venom|part_of|dogs|8520523
fibrinogen|affects|fall|8520523
antivenom|part_of|Bothrops|11144814
venom|causes|tubular|11193194
venom|causes|thrombocytopenia|11341509
botrocetin|isa|venom|11341509
botrocetin|causes|platelet aggregation|11341509
aspercetin|causes|myonecrosis|11341509
aspercetin|causes|edema|11341509
aspercetin|causes|hemorrhage|11341509
aspercetin|part_of|mice|11341509
BaP1|administered_to|mice|11341509
cytokines|disrupts|tumoral growth|12396470
BjV|inhibits|cytokines|12396470
venom|part_of|animals|12396470
venom|part_of|cells|12396470
IL-6|interacts_with|BjV|12396470
IL-6|isa|cytokines|12419508
BjV|stimulates|TNF-alpha|12419508
venom|causes|Local inflammatory reaction|12419508
antivenom|neg_treats|symptoms|12676437
venom|augments|symptoms|12676437
specific antibodies|coexists_with|antivenom|12676437
antivenom|treats|network|12676437
venom|causes|leakage|12676437
Venom|augments|twitches|12715081
Venom|augments|neuromuscular blockade|12715081
venom|causes|neuromuscular blockade|12715081
venom|stimulates|GL|16751793
GL|treats|rats|16751793
GL|inhibits|bleeding|16751793
snake venom|stimulates|glycyrrhizin|16751793
Jararhagin|isa|metalloproteinase|17046041
metalloproteinase|causes|hemorrhage|17046041
Jararhagin|causes|hemorrhage|17046041
metalloproteinase|causes|edema|17046041
metalloproteinase|causes|necrosis|17046041
metalloproteinase|causes|inflammation|17046041
Jararhagin|causes|edema|17046041
Jararhagin|causes|necrosis|17046041
Jararhagin|causes|inflammation|17046041
jararhagin|administered_to|animals|17046041
jararhagin|isa|toxin|17046041
jararhagin|predisposes|edema|17046041
jararhagin|isa|Toxin|17046041
jararhagin|causes|interstitial edema|17046041
antivenom|part_of|equine|18028735
adrenaline|treats|patient|18028735
hydrocortisone|treats|patient|18028735
antivenom|causes|adverse reactions|19305361
CX3CL1-CX3CR1|produces|cell-cell adhesion molecular|16720640
blocking antibodies|part_of|macrophages|16720640
nitroglycerine|treats|children|16891681
nitroglycerine|treats|pulmonary congestion|16891681
Nitroglycerine|treats|scorpion sting|16891681
oxygen|treats|patient|19082377
batrachotoxin|causes|swelling|626887
batrachotoxin|causes|myelopathy|626887
toxin|administered_to|rats|636935
tityustoxin|isa|toxin|636935
tityustoxin|administered_to|rats|636935
phenoxybenzamine|prevents|pulmonary edema|636935
guanethidine|prevents|pulmonary edema|636935
veratridine|treats|rats|3830286
tityustoxin|isa|toxin|3830286
veratridine|part_of|lv|3830286
veratridine|causes|hypotension|3830286
veratridine|treats|rat|3830286
channel blockers|causes|seizures|10210033
venom-specific IgE|isa|antibody|637904
antigenic|isa|complex antigenic mixture|637904
venoms|administered_to|patients|1607552
Antibody variations|stimulates|IgG4|2522473
IgG1|augments|T suppressive cell|2522473
IgG4|augments|T suppressive cell|2522473
venoms|causes|confusion|3310714
HBV-specific IgG|isa|antibody|3592146
HBV-specific IgE|isa|antibodies|3592146
venom|part_of|patients|3624680
HBV|part_of|patients|3624680
HBV|administered_to|patients|3624680
honey bee venom|treats|patients|4008075
honey bee venom|treats|bee sting allergy|4008075
HBV-specific IgG|isa|antibodies|4008075
venom-specific IgE|affects|anaphylaxis|4008803
venoms|part_of|patients|6638413
venoms|associated_with|hypersensitivity|6638413
venoms|part_of|patients|7400882
Tryptase|isa|protease|7929694
tryptase|part_of|human|7929694
venom|part_of|patients|9257781
venom|associated_with|urticaria pigmentosa|9257781
BBV|part_of|patients|10696863
adrenaline|treats|patients|11097308
plasmids|isa|DNA|11207323
DNA vaccine|neg_augments|immune modulation|11207323
venom|part_of|patients|11964714
complete Freund's adjuvant|part_of|Sprague-Dawley male rats|12067099
venom|disrupts|inflammation|12067099
bee venom|affects|arthritis|12067099
ITV|part_of|patients|12861850
ITV|associated_with|allergy|12861850
hymenoptera venom|interacts_with|Vespula spp|12861850
venom-specific IgE|isa|antibodies|14629126
venom|part_of|patients|14629126
aluminium hydroxide|treats|allergy|15147443
HBV|causes|local reactions|15147443
adjuvant|part_of|mucosal|15203921
tetanus toxoid|treats|mice|15203921
phospholipase A2|part_of|CBA/J mice|15650311
PLA2|stimulates|PLA2-specific IgE|15650311
allergens|coexists_with|venom|15984315
glycoproteins|coexists_with|venoms|16197464
epitopes|causes|positive test results|16197464
Melittin|isa|venom|16310715
venom|causes|hyperalgesia|16310715
Melittin|causes|hyperalgesia|16310715
melittin|causes|hyperalgesia|16310715
melittin|causes|heat hyperalgesia|16310715
melittin|causes|Secondary heat hyperalgesia|16310715
venom|causes|inflammation|16446039
venom|causes|hypersensitivity|16446039
venom|causes|positive skin tests|16689180
venom allergens|part_of|patients|16825872
vaccine|isa|injection|17163183
vaccine|uses|vaccine|17163183
histamine|part_of|cells|18005261
leukotrienes|associated_with|systemic anaphylaxis|18005261
allergen|coexists_with|honey bee venom|18005261
immunoglobulin E|augments|basophils|18005261
secretory phospholipase A2|causes|leukotriene production|18005261
secretory phospholipase A2|causes|histamine release|18005261
sPLA2|coexists_with|venom|18693540
Poneratoxin|isa|venom|18693540
neuropeptide|coexists_with|venom|18693540
neuropeptide|coexists_with|Poneratoxin|18693540
Poneratoxin|interacts_with|sodium channels|18693540
LC|prevents|side effects|18845330
allergen|associated_with|allergy|19910026
YJ-HYA|associated_with|allergy|19910026
hyaluronidase|part_of|patients|19910026
epitopes|part_of|patients|19910026
YJ-HYA|inhibits|Api m 2|19910026
hyaluronidase|associated_with|allergy|19910026
Pharmalgen|administered_to|patients|20094101
tryptase|predisposes|anaphylactic reaction|20121769
tryptase|part_of|patients|20121769
peptides|affects|edematogenic|20177946
peptides|causes|hyperalgesia|20177946
melittin|predisposes|inflammation|20177946
melittin|predisposes|pain|20177946
insect venoms|causes|pain|20177946
insect venoms|causes|inflammation|20177946
venom|augments|vascular permeability|20543672
hymenoptera venom|treats|individuals|21658068
Melittin|coexists_with|venom|21969711
melittin|associated_with|liver fibrosis|21969711
melittin|part_of|mice|21969711
tumor necrosis factor alpha|part_of|Hepatic stellate cells|21969711
Melittin|inhibits|cytokines|21969711
melittin|disrupts|HSCs|21969711
Melittin|disrupts|injury|21969711
melittin|disrupts|cleavage|22812191
allergens|part_of|recombinant|22812191
melittin|isa|toxin|22851351
lidocaine|affects|skin temperature increase|22851351
N-methyl-D-aspartate (NMDA) glutamate receptor|augments|skin temperature increase|22851351
glutamate|stimulates|NMDA receptors|22851351
NMDA receptor antagonists|treats|inflammatory pain|22851351
NMDA receptor|associated_with|flare|22851351
wasp venom|associated_with|eosinophilia|23095437
wasp venom|associated_with|concomitant atopic diseases|23095437
honey bee venom|treats|cohort|23889248
Hymenoptera venom|treats|cohort|23889248
immunoglobulin E|isa|antibodies|24210352
IgE|isa|antibodies|24210352
IgE|predisposes|allergic disorders|24210352
DF|compared_with|UK|3499037
DF|higher_than|UK|3499037
UK|treats|dogs|3499037
defibrase|compared_with|urokinase|3499037
coagulation factors|part_of|individual|12009098
snake venom|interacts_with|coagulation factors|12009098
Venoms|affects|blood coagulation|12404853
proteins|causes|disorders|12404853
venom|administered_to|rabbits|15553173
hemostatic|treats|rabbits|15553173
Snake venoms|isa|complex mixtures|17979733
peptides|affects|hemostasis|17979733
Venom|affects|platelet function|17979733
Russell's viper venom|stimulates|coagulation factors V|22416129
serine protease|affects|blood coagulation|22416129
RVV-X|causes|consumption|22416129
RVV-X|administered_to|ICR mice|22416129
APC inhibitor|associated_with|complications|22416129
protein C|augments|consumptive coagulopathy|22416129
IgG4|isa|antibodies|23896012
antivenom|causes|anaphylactic reaction|2291986
venom|stimulates|Factors II|2291986
venom|stimulates|Factor X|2291986
venom|stimulates|prothrombin|2291986
proteases|causes|clotting|2291986
fibrinolytic agent|treats|patients|2209234
fibrinolytic agent|treats|acute myocardial infarction|2209234
DF|part_of|patients|2209234
defibrase|associated_with|CGN|2805953
defibrase|part_of|patients|2805953
defibrase|associated_with|CRF|2805953
Defibrase|coexists_with|glucose|2805953
captopril|part_of|patients|2805953
defibrase|associated_with|chronic glomerulonephritis|2805953
batroxobin|interacts_with|urokinase|3163298
heparin|interacts_with|urokinase|3163298
heparin|prevents|reocclusion|3163298
batroxobin|affects|coronary thrombosis|3163298
Batroxobin|disrupts|lung metastases|3300562
anti-asialo GM1 antibody|inhibits|NK|3300562
batroxobin|part_of|NK cell|3300562
Batroxobin|neg_interacts_with|NK|3300562
batroxobin|stimulates|NK|3300562
batroxobin|part_of|natural killer cells|3300562
lysyl-plasminogen|coexists_with|batroxobin|6503980
batroxobin|inhibits|alpha 2-plasmin inhibitor|6503980
batroxobin|inhibits|plasminogen|6503980
hemocoagulase|disrupts|bleeding|7933697
Botropase|interacts_with|hemocoagulase|8145382
Botropase|treats|intraocular bleeding|8145382
medication|treats|gastric bleeding|8556923
drugs|treats|disease|8897062
drugs|treats|thrombotic|8897062
heparin|isa|drug|8897062
drugs|prevents|stenosis|8897062
batroxobin|associated_with|deep partial thickness burn|11876881
batroxobin|associated_with|wound|11876881
Batroxobin|augments|wound healing|11876881
calcium|stimulates|thrombin|11943932
calcium|stimulates|batroxobin|11943932
thrombin|part_of|patient|11943932
batroxobin|compared_with|thrombin|11943932
batroxobin|part_of|patient|11943932
thrombin|part_of|blood|11943932
thrombin|causes|weaker|11943932
carrageenan|part_of|guinea pigs|12622893
normal saline|treats|control group|12622893
D-dimer|augments|effusion|12622893
Batroxobin|associated_with|inflammation|12622893
Batroxobin|associated_with|pleural fibrosis|12622893
Batroxobin|associated_with|pleural effusion|12622893
batroxobin|administered_to|control group|12856578
batroxobin|affects|atherosclerosis|12856578
batroxobin|part_of|control group|15181847
urokinase|part_of|control group|15181847
urokinase|predisposes|intracranial hemorrhage|15181847
urokinase|neg_predisposes|intracranial hemorrhage|15181847
serine protease|interacts_with|c-fos gene|15198899
serine protease|interacts_with|growth factor|15198899
BX|part_of|VSMCs|15198899
calcium|part_of|Intracellular|15198899
Batroxobin|inhibits|calcium|15198899
batroxobin|augments|wound healing|15796836
TAFI|produces|plasma|16093731
potato carboxypeptidase inhibitor|coexists_with|potato carboxypeptidase inhibitor|16093731
defibrase|administered_to|patients|16261883
defibrase|affects|neurological function|16261883
drugs|treats|cerebral infarction|16635411
defibrase|compared_with|drugs|16635411
batroxobin|administered_to|patients|16972594
batroxobin|associated_with|movement disorders|16972594
fibrinogen|associated_with|middle ear effusion|17039794
fibrinogen|associated_with|MEE|17039794
fibrin|isa|polymer|17039794
batroxobin|isa|treatment|17039794
fibrinogen|interacts_with|surface active agents|17039794
batroxobin|part_of|Patients|17287638
batroxobin|part_of|patients|17287638
batroxobin|neg_associated_with|hemorrhagic stroke|17287638
batroxobin|part_of|CD34+/CD31+ cells|19825915
FBG|part_of|blood|20193529
Batroxobin|inhibits|FBG|20193529
batroxobin|compared_with|aspirin|20831989
batroxobin|higher_than|aspirin|20831989
batroxobin|administered_to|Patients|20831989
batroxobin|part_of|mice|21165693
batroxobin|affects|experimental autoimmune encephalomyelitis|21165693
hemostatic agent|treats|neonates|21210254
Hemocoagulase|isa|hemostatic agent|21210254
Hemocoagulase|treats|neonates|21210254
hemostatic agent|treats|PH|21210254
hemocoagulase|isa|therapy|21210254
hemocoagulase|associated_with|PH|21210254
hemocoagulase|associated_with|pulmonary hemorrhage|21210254
Batroxobin|inhibits|fibrinogen|21570870
batroxobin|administered_to|authors|21909815
TXA|inhibits|blood loss|21909815
hemocoagulase|complicates|hypercoagulability|22539379
batroxobin|associated_with|DVT|24043672
hemocoagulase|part_of|animals|24228100
batroxobin|affects|hemostatic|24360185
TAT|associated_with|thrombosis|12009099
factor V|inhibits|prothrombin|12009099
factor V|inhibits|AT3|12009099
fragments X|coexists_with|bitten|6537796
adenosine diphosphate|augments|serotonin secretion|6537796
venom|neg_interacts_with|arachidonate|6537796
plasminogen activator|part_of|vascular|6537796
plasminogen activator|stimulates|plasminogen|6537796
prekallikrein|neg_coexists_with|factors X|12574817
prekallikrein|neg_coexists_with|von Willebrand factor|12574817
antithrombin|treats|patients|12574817
analgesic|coexists_with|venom|21438646
exendin 4|treats|mice|22776193
venom|interacts_with|venom|1858314
Antivenin|interacts_with|antivenom|1858314
antivenom|treats|snake-bite|1858314
antivenom|treats|victims|1858314
antivenom|treats|herpetologists|1858314
atroxase|isa|protease|2646751
Atroxase|stimulates|plasminogen|2646751
hyperbaric oxygen|treats|muscle necrosis|2757285
Antivenin|neg_affects|venom poisoning|2757285
antivenom|compared_with|saline solution|12605206
CroFab|isa|Crotalidae Polyvalent Immune Fab|12605206
venom|part_of|swine|12605206
Crotalidae polyvalent immune Fab|isa|antivenom|12605206
antivenin|administered_to|pigs|19888893
antivenom|treats|coagulopathy|3689023
antivenom|treats|bleeding|3689023
antivenom|part_of|Echis|3689023
antivenom|treats|West Africa|3689023
snake venom|affects|necrosis|12457878
venom|administered_to|mice|12457878
ACh receptors|part_of|muscle|698793
ACh receptors|affects|axonal transport|698793
venom|disrupts|ps)|4367126
acetylcholine receptor|part_of|muscle|2345558
AChR|part_of|adult human|2345558
anti-alpha-BuTx site antibodies|associated_with|pathophysiology|2345558
chemotherapeutic agents|treats|mice|7381752
Cyclophosphamide|compared_with|bromoacetylcholine|7381752
Cyclophosphamide|same_as|bromoacetylcholine|7381752
Cyclophosphamide|disrupts|neuroblastoma|7381752
bromoacetylcholine|disrupts|neuroblastoma|7381752
acetylcholine receptor|part_of|Torpedo|8390605
AChR antibodies|associated_with|signs|8390605
alpha-bungarotoxin|affects|voiding|10840125
toxin|disrupts|voiding|10840125
drugs|affects|striated muscle|10840125
neuromuscular junction blocking agent|treats|rat|10840125
alpha-bungarotoxin|isa|toxins|10896874
alpha-conotoxin ImI|isa|toxins|10896874
U-46619|interacts_with|cholinergic system|16133489
acetylcholine|part_of|extracellular|16133489
U-46619|coexists_with|acetylcholine|16133489
U-46619|coexists_with|choline|16133489
U-46619|stimulates|acetylcholine|16133489
U-46619|stimulates|choline|16133489
nicotinic receptor antagonist|interacts_with|pressor|16133489
U-46619|affects|bradycardic|16133489
alpha-bungarotoxin|inhibits|nicotinic acetylcholine receptors|16133489
methyllycaconitine|interacts_with|U-46619|16133489
TxA2 receptors|affects|bradycardic|16133489
Beta-bungarotoxin|isa|venom|16195243
synaptophysin|augments|immunoreactivity|16195243
syntaxin|augments|immunoreactivity|16195243
beta-bungarotoxin|causes|bites|16195243
arginine|associated_with|diabetes mellitus|17870107
p38 MAPK|associated_with|cytotoxicity|18037462
NMDA receptor|associated_with|cytotoxicity|18037462
phospholipase|interacts_with|pressor|19910175
cholinergic system|interacts_with|melittin|19910175
pressor|interacts_with|melittin|19910175
atropine sulfate|treats|rats|19910175
alpha-bungarotoxin|inhibits|alpha7 subtype nicotinic acetylcholine receptors|19910175
methyllycaconitine|inhibits|alpha7 subtype nicotinic acetylcholine receptors|19910175
melittin|affects|tachycardic|19910175
pressor|treats|rats|19910175
drug|affects|tachycardic|19910175
nicotinic receptors|interacts_with|pressor|19910175
neurotrophic factors|associated_with|hearing impairment|21215730
horseradish peroxidase|part_of|nerve|21215730
PGE2|interacts_with|TPA|704929
venom|isa|toxin|704929
melittin|isa|toxin|704929
PGE2|interacts_with|melittin|704929
melittin|interacts_with|PGE2|704929
melittin|augments|prostaglandin production|704929
dendrotoxin|inhibits|dopamine|3394161
equinatoxin II|augments|splenocytes|9237338
concanavalin A|augments|splenocytes|9237338
conotoxin|disrupts|inactivation|14976206
potassium channels|part_of|lymphocyte|15578998
calcium|stimulates|IKCa1|15578998
potassium channels|stimulates|IKCa1|15578998
kaliotoxin|isa|toxin|15578998
biopharmaceuticals|treats|multiple sclerosis|15578998
plant lectins|affects|protection|16542451
gut hormone|isa|amide|17263764
gut hormone|augments|insulin secretion|17263764
glucose-dependent insulinotropic polypeptide|interacts_with|incretin|17263764
GLP-1|inhibits|glucagon|17263764
exenatide|treats|Type 2 diabetes|17263764
Incretins|isa|peptides|17263764
Incretins|treats|diabetes|17263764
peptides|isa|Incretins|17263764
peptides|treats|diabetes|17263764
incretin hormones|affects|glucose homeostasis|19182763
proteases|interacts_with|peptides|19182763
glucose|augments|hypoglycemia|19182763
venom|associated_with|cancer|19754129
Akt|interacts_with|Akt|19754129
Akt|interacts_with|EGFR|19754129
toxin|affects|voltage-gated sodium channels|19912232
glucagon|affects|cell function|20115929
Exenatide|treats|T2DM|20115929
Exenatide|treats|patients|20115929
Incretin hormones|interacts_with|insulin|20206729
Glucagonlike peptide-1|interacts_with|incretin|20206729
Exenatide|stimulates|GLP-1 receptor|20206729
agonist|treats|patients|20206729
agonist|treats|type 2 diabetes|20206729
venom|converts_to|polypeptide|20607799
annexin A2|disrupts|growth|20607799
vascular endothelial growth factor|causes|retinal NV|20607799
annexin A2|part_of|choroidal|20607799
tissue plasminogen activator|interacts_with|annexin A2|20607799
plasminogen|interacts_with|annexin A2|20607799
annexin A2|disrupts|neovascularization|20607799
antihyperglycemic|isa|drugs|21441754
drugs|predisposes|hypoglycemia|21441754
antihyperglycemic|predisposes|hypoglycemia|21441754
Incretins|augments|insulin secretion|21441754
peptidase-4 (DPP-4) inhibitors|predisposes|hypoglycemia|21441754
jellyfish venoms|isa|toxins|21824078
immunotoxins|treats|cancer|21824078
toxins|stimulates|potassium channels|21824078
immunomodulators|treats|autoimmune diseases|21824083
Analogs|treats|autoimmune diseases|21824083
glucose-dependent insulinotropic polypeptide|affects|glucose homeostasis|22104467
GIP|stimulates|Unlike GIP, the actions of GLP-1 are preserved in patients with type 2 diabetes mellitus, which has led to the development of injectable GLP-1 receptor (GLP-1R) agonists and oral dipep|22104467
DPP-4 inhibitors|stimulates|GLP-1|22104467
enzymatic|inhibits|GLP-1|22104467
agonists|compared_with|DPP-4 inhibitors|22104467
agonists|inhibits|fasting|22104467
DPP-4 inhibitors|stimulates|GLP-1R|22104467
agonists|augments|satiety|22104467
agonists|inhibits|glucagon|22104467
DPP-4 inhibitors|inhibits|glucagon|22104467
agonists|treats|patients|22104467
agonists|affects|adverse events|22104467
DPP-4 inhibitors|affects|AEs|22104467
ion channels|associated_with|pain|23034652
mamba venom|part_of|Black|23034652
mamba venom|interacts_with|ion|23034652
Gln|inhibits|glucose|23388064
exendin-4|inhibits|glucose|23388064
CCK-8|affects|glucose tolerance|23388064
exendin-4|coexists_with|CCK-8|23388064
incretin hormones|treats|type 2 diabetes|23388064
melittin|inhibits|CRF|1312788
melittin|inhibits|vasopressin|1312788
insulin|treats|rats|1312788
melittin|stimulates|phospholipase A2|1475278
12-O-Tetradecanoylphorbol-13-acetate|isa|phorbol ester|1475278
arachidonic acid|interacts_with|TPA|1475278
protein kinase C|disrupts|phospholipase A2 activity|1475278
bleomycin|interacts_with|bleomycin|2421873
melittin|augments|toxicity|2421873
bradykinin|treats|rat|2907541
bradykinin|administered_to|animals|2907541
Melittin|causes|lysis|12469190
avidin|part_of|tumors|12469190
ribosomal protein L1|part_of|Helicobacter pylori|15358153
MLT|coexists_with|MLT|16009513
MLT|compared_with|ISA1|16009513
melittin|interacts_with|polymers|16009513
plasmids|part_of|Recombinant|16246304
plasmids|interacts_with|genes|16246304
melittin|disrupts|hemolysis|16294747
melittin|causes|rheumatoid arthritis|16294747
peptide fragment|interacts_with|melittin|16294747
phospholipase A2|associated_with|pathogenesis|16498630
PLA2|affects|tissue damage|16498630
PLA2|affects|death|16498630
cytosolic PLA2|stimulates|cytosolic PLA2|16498630
melittin|stimulates|PLA2|16498630
PLA2|stimulates|PLA2|16498630
PLA2|causes|death|16498630
mepacrine|treats|demyelination|16498630
PLA2|augments|SCI|16498630
phospholipase A2|associated_with|spinal cord secondary injury|16498630
acetylcholine|isa|biogenic amines|17724887
epinephrine|isa|steroids|17724887
antimicrobial|treats|infectious diseases|18457054
antimicrobial|interacts_with|melittin|18457054
antimicrobial|interacts_with|plasmid vector|18457054
melittin|compared_with|melittin|19274512
melittin|associated_with|tumors|19726870
Herceptin|isa|Trastuzumab|19896266
trastuzumab|part_of|human breast cancer cells|19896266
melittin|part_of|human breast cancer cells|19896266
chemokines|causes|tumors|21196415
polyIC|causes|tumors|21196415
dsRNA|augments|immune response|21196415
melittin|interacts_with|phospholipids|23790040
melittin|disrupts|melanoma cells|23790040
melittin|compared_with|melittin|23816641
melittin|part_of|recombinant|23816641
melittin|disrupts|growth|23816641
melittin|same_as|melittin|23816641
melittin|interacts_with|melittin|24014474
melittin|affects|cells|24014474
Melittin|disrupts|membranes|24734522
Survivin|augments|tissues|24734522
Mel|affects|cell lines|24734522
survivin|augments|tumor cells|24734522
plasmid|interacts_with|Mel|24734522
Mel|disrupts|growth|24734522
Mel|causes|cell death|24734522
Melittin|affects|hepatocellular carcinoma|24734522
prothrombin|interacts_with|venom|866568
venom|causes|deaths|866568
Russell's viper venom|affects|blood coagulation|916351
GBG|augments|complement fixation|943796
antivenoms|interacts_with|venom|943796
kallikrein|coexists_with|venom|12815846
plasmin|coexists_with|venom|12815846
prothrombin activator|causes|DIC|12815846
spider's venom|causes|lesions|11449301
Loxosceles venoms|causes|injury|11449301
serine proteases|interacts_with|proteolytic|11449301
venom|interacts_with|metalloproteases|11449301
venom|isa|toxins|11449301
proteases|associated_with|necrosis|11574290
collagenases|causes|necrotic lesions|11574290
collagenases|associated_with|necrosis|11574290
proteases|affects|necrosis|11574290
venom|causes|clotting time|15763387
thrombin|causes|Clotting|15763387
venom|causes|edema|15763387
venoms|causes|able|15763387
PLA2s|causes|edema|15763387
snake venoms|stimulates|serine-proteases|15763387
Equinatoxin II|isa|toxin|15769091
proteases|part_of|tumor|15769091
proteases|stimulates|toxin conjugate|15769091
L-amino acid oxidase|coexists_with|venoms|19585481
snake venoms|causes|tissue damage|19585481
proteases|part_of|intracellular|22142367
calcium|part_of|intracellular|22142367
crotamine|stimulates|calcium|22142367
Glucagon-like peptide-1|part_of|gut|20363879
Glucagon-like peptide-1|part_of|brain|20363879
GLP-1|stimulates|ACTH|20363879
Exendin-4|treats|rodents|20363879
Exendin-4|treats|humans|20363879
venom|stimulates|lactic acid|1211500
glucocorticoids|isa|treatments|12051509
antivenin|isa|treatments|12051509
antivenin|treats|dogs|12051509
venom|causes|disseminated intravascular coagulation|1276079
Heparin|treats|poisoning|1276079
antivenom|treats|patients|1276079
antivenom|part_of|Echis|1276079
heparin|treats|poisoning|1276079
thrombin|interacts_with|heparin|1276079
venom|converts_to|protein|2084943
echistatin|inhibits|ADP|2084943
collagen|augments|platelet aggregation|2084943
Echistatin|disrupts|platelet aggregation|2084943
echistatin|affects|platelet aggregation|2084943
echistatin|prevents|coronary artery thrombosis|2084943
Refludan|isa|Lepirudin|15771978
Refludan|isa|recombinant hirudin|15771978
heparin|part_of|CEC|15771978
antivenom|treats|women|18631310
antivenom|treats|maternal|18631310
CD39|isa|Apyrase|15389120
CD39|part_of|family|15389120
procoagulant|part_of|New Zealand male rabbits|15389120
apyrase|administered_to|control animals|15389120
venoms|part_of|horses|9028011
creatine kinase|inhibits|aspartate aminotransferase|9028011
Creatinine|coexists_with|urea|9028011
snake venoms|part_of|horses|9028011
BJC|affects|thrombotic|16707920
BJC|treats|mice|16707920
Bothrojaracin|converts_to|thrombin inhibitor|16707920
immunomodulatory|isa|drugs|21537162
Russell's viper venom|associated_with|multiple myeloma|21537162
integrins|affects|cell-matrix interactions|8191932
integrins|affects|cell|8191932
integrins|part_of|Osteoclast|8191932
Arg-Gly-Asp|interacts_with|integrins|8191932
Arg-Gly-Asp|part_of|Osteoclasts|8191932
snake venom|interacts_with|kistrin|8191932
calcium|affects|osteoclast|8191932
kistrin|inhibits|bone resorption|8191932
kistrin|affects|bone resorption|8191932
Viper venom|causes|coagulation disorders|9080875
venom|causes|acute renal failure|9080875
venom|causes|toxicity|9080875
mAbs|disrupts|melanoma metastasis|9457071
mAb|disrupts|adhesion|9457071
GRGDSP|disrupts|adhesion|9457071
eristostatin|disrupts|adhesion|9457071
RGD-containing peptides|disrupts|melanoma cell metastasis|9457071
eristostatin|inhibits|integrins|9457071
antivenom|part_of|ovine|10188967
snake venom|causes|able|10188967
snake venom|isa|complex mixture|12974396
serine proteases|coexists_with|venoms|14722941
neuronal pentraxin receptor|part_of|SCLC|16115696
NPR|part_of|neurons|16115696
taipoxin|coexists_with|NPR|16115696
receptor|associated_with|SCLC|16115696
taipoxin|associated_with|SCLC|16115696
taipoxin|affects|cell lines|16115696
VEGF|affects|repair|17120027
VEGF|associated_with|glomerulonephritis|17120027
alpha1beta1 integrin|interacts_with|collagen receptor|18712720
disintegrin|inhibits|integrin|18712720
Angiostatic|inhibits|alpha1beta1 integrin|18712720
PDGF-BB|part_of|DFAT cells|18957871
TGF-beta1|augments|renal cortex|18957871
fibronectin|augments|renal cortex|18957871
allergens|augments|symptoms|19494529
anti-cancer agent|treats|neuroblastoma|20091267
Integrin alphavbeta3|affects|cell proliferation|22049183
Integrin alphavbeta3|affects|neoangiogenesis|22049183
integrin alphavbeta3|associated_with|glomerulonephritis|22049183
creatinine|compared_with|treatment|22049183
Complementary|associated_with|MCs|22049183
integrin alphavbeta3|affects|lesions|22049183
cell growth inhibitory|affects|snake venom toxin|22644854
venoms|part_of|animal|23270323
toxins|part_of|cell|23270323
venoms|part_of|cell|23270323
toxins|part_of|cellular fractions|23270323
venoms|part_of|cellular fractions|23270323
venom|administered_to|dogs|892607
scorpion venom|administered_to|dogs|5416814
heparin|treats|coagulation abnormality|5416814
antivenom|treats|victims|7725329
venom|affects|hearts|7725329
venom|affects|atria|7725329
scorpion venom|interacts_with|dopamine|7725331
scorpion venom|interacts_with|butyric acid|7725331
GAD|augments|striatum|7725331
dopamine|stimulates|venom|7725331
scorpion venom|neg_causes|arterial hypertension|8896200
venom|causes|arterial hypertension|8896200
venom|neg_causes|arterial hypertension|8896200
venom|interacts_with|venom|8896200
venom|administered_to|dogs|9536646
triiodothyronine|treats|dogs|9536646
thyroid hormones|causes|fall|9536646
triiodothyronine|associated_with|acute myocarditis|9536646
thyroxine|associated_with|acute myocarditis|9536646
CTX|interacts_with|protein|9809993
CTX|interacts_with|receptor|9809993
venom|causes|contracture|10075062
scorpion venom|part_of|dogs|10075062
scorpion venom|interacts_with|scorpion venom|10075062
scorpion venom|administered_to|dogs|10075062
venom|administered_to|dogs|12130983
venom|part_of|dogs|12130983
scorpion venom|administered_to|dogs|12130983
venom|causes|acidosis|12130983
scorpion venom|inhibits|bicarbonate|12893063
venom|administered_to|dogs|12893063
venom|stimulates|Antivenom|12893063
antivenom|compared_with|therapy|12893063
antivenom|higher_than|therapy|12893063
alpha blockers|administered_to|patients|16944610
17-beta estradiol|administered_to|rats|19185478
progesterone|administered_to|rats|19185478
glucose|administered_to|rats|19185478
sodium|administered_to|rats|19185478
urea|administered_to|rats|19185478
creatinine|administered_to|rats|19185478
saline|administered_to|animals|20060404
scorpion venom|part_of|dogs|20060404
amylase|neg_interacts_with|LDH|20060404
prazosin|treats|patients|20935398
prazosin|treats|scorpion-stung|20935398
toxin|coexists_with|scorpion venom|22108716
CTX|inhibits|matrix metalloproteinase-2|22108716
chlorotoxin|interacts_with|Iron oxide|22108716
LD|part_of|mice|22149216
cDNA|isa|nucleotides|22542475
scorpion venom|part_of|mice|24260823
Russell's viper venom|causes|coagulopathy|7778131
antivenom|part_of|equine|7778131
antithrombin III|treats|rat|7778131
antivenom|treats|rat|7778131
antivenom|isa|Treatment|7778131
AT-III|treats|rats|7778131
Antivenom|prevents|coagulopathy|7778131
Russell's viper venom|coexists_with|normal saline|7855655
urea|part_of|blood|9861409
Russell's viper venom|augments|hemodynamics|17078988
proteolytic enzyme|compared_with|PLA2|17078988
proteolytic enzyme|higher_than|PLA2|17078988
TRH|part_of|survivors|2385744
GnRH|part_of|survivors|2385744
procoagulants|causes|death|12427109
venom|isa|toxins|19328509
venom|neg_disrupts|phospholipase activity|21682684
antivenom|part_of|Russell's viper|23212048
natriuretic peptides|associated_with|pathophysiology|12843686
endopeptidase inhibitors|treats|congestive heart failure|12843686
endopeptidase inhibitors|treats|hypertension|12843686
endopeptidase inhibitors|treats|cardiovascular diseases|12843686
endothelin-1|interacts_with|natriuretic peptides|12843686
7-Chlorokynurenic acid|prevents|convulsions|12457877
sphingomyelin|causes|convulsions|12457877
NMDA receptors|neg_coexists_with|cytolysin|12457877
disintegrin|causes|neuropathic pain|15364408
triflavin|inhibits|hyperalgesia|15364408
TFV|disrupts|sympathetic nerves|15364408
drugs|treats|neuropathic pain|15364408
Disintegrin|causes|hyperalgesia|15364408
disintegrin|disrupts|neuropathic pain|15364408
Cilengitide|stimulates|integrin|21417900
Integrins|augments|malignancies|21417900
Cilengitide|treats|GBM|21417900
cilengitide|treats|non-small-cell lung cancer|21417900
cilengitide|treats|squamous cell carcinoma|21417900
Cilengitide|inhibits|integrin|21417900
Cilengitide|treats|glioblastoma|21417900
Cilengitide|treats|malignancies|21417900
venom|affects|eyes|6335538
venom|administered_to|patients|6224840
immune complex|neg_coexists_with|acute-phase reactants|6224840
immune complexes|affects|tissues|7499864
complement|part_of|humans|7499864
Croton oil|causes|inflammation|1218511
spider Latrodectus tredecimguttatus poison|associated_with|progressive muscular dystrophy|1242318
venom|isa|biologic toxins|6381753
antivenom|treats|rabbits|6503783
drugs|treats|carcinoma|6503783
spider venom|affects|gastric emptying|8731350
PNV|administered_to|rats|8731350
prazosin|treats|rats|8731350
domperidone|treats|rats|8731350
beta-adrenergic receptors|part_of|smooth muscle|8731350
neurotransmitters|inhibits|excitatory amino acid receptors|10695969
venom|augments|arachnidism|11282664
venom|administered_to|New Zealand white rabbits|11282664
antivenom|treats|Symptoms|12175614
venom|affects|nerve-muscle preparation|12175614
venom|causes|muscle contracture|12175614
RBSAV|associated_with|symptoms|12175614
Venoms|causes|necrotic arachnidism|12322871
venom|compared_with|venom|12368110
venom|higher_than|venom|12368110
venom|causes|cardiac arrest|12467658
venom|causes|bradycardia|12467658
antivenom|treats|cohort|12864719
antivenom|treats|patients|12864719
antivenom|isa|treatment|15054982
antivenom|treats|syndrome|15054982
venom|causes|generalized tonic-clonic seizures|15953769
venom|disrupts|membranes|15953769
GABA|interacts_with|anticonvulsant|15953769
glutamate receptors|interacts_with|anticonvulsant|15953769
Anticonvulsant|interacts_with|wasp Polybia ignobilis venom|15953769
spider venom|causes|extravasation|16914387
toxin|causes|symptoms|17300533
toxin|causes|skin ulcers|17300533
venom|part_of|Chilean|18359568
codons|part_of|yeast|18359568
venom|causes|analgesia|18359568
antivenom|treats|neurological symptoms|18689308
captopril|administered_to|patient|18788004
meperidine|administered_to|patient|18788004
local anesthetic|treats|patient|18788004
antivenom|treats|patient|18788004
venom|causes|inflammatory response|19041422
toxin|causes|edema|19041422
toxins|augments|vascular permeability|19041422
venom|isa|toxins|19041422
toxins|disrupts|edema|19041422
toxins|disrupts|vascular permeability|19041422
serotonin|part_of|mice|19041422
histamine|part_of|mice|19041422
toxins|causes|edema|19041422
venom|causes|inflammatory responses|19041422
HWTX-III|disrupts|VGSCs|20506577
beta-lactamase|interacts_with|ampicillin|20600224
beta-lactamase|interacts_with|penicillin|20600224
venom|administered_to|rabbits|20600224
corticosteroid|treats|patient|21534346
toxin|augments|penile erection|21684302
Antivenoms|isa|treatment|21762981
Antivenoms|treats|spider envenomation|21762981
omega-conotoxin GVIA|inhibits|N-type calcium channel|21975567
arginine methyl ester|inhibits|N-type calcium channel|21975567
nNOS|produces|cGMP|21975567
tumour necrosis factor alpha|stimulates|interleukin 4|22052031
interleukin 6|associated_with|rheumatoid arthritis|22052031
cytokines|associated_with|pathogenesis|22082464
cytokines|produces|interleukin-8|22082464
Sphingomyelinase|coexists_with|Loxosceles venom|22082464
calcium|administered_to|patients|22116992
antivenom|administered_to|patients|22116992
dapsone|treats|symptoms|22479977
spasmolytic|isa|drugs|23572268
venom|isa|toxin|23597507
ziconotide|stimulates|calcium channels|23597507
analgesic|treats|cancer patients|23718272
opioids|causes|adverse effects|23718272
omega-conotoxin MVIIA|isa|analgesic|23718272
omega-conotoxin MVIIA|treats|cancer patients|23718272
venoms|part_of|Animal|23718272
omega-conotoxin MVIIA|associated_with|analgesia|23718272
Spider venoms|interacts_with|ion channel|24561180
CaV|part_of|Xenopus oocytes|24561180
CaV|affects|neurons|24561180
sodium|interacts_with|HEK|24561180
ziconotide|causes|adverse effects|24836473
venom|compared_with|ziconotide|24836473
venom|higher_than|ziconotide|24836473
ziconotide|treats|rodents|24836473
drug|treats|pain|24836473
antivenom|administered_to|patient|10326114
antivenom|part_of|equine|10326114
antivenom|associated_with|snake envenomations|10326114
fibrinogen|part_of|blood|14676521
antivenoms|treats|snake bite|18190937
antivenoms|treats|patients|18190937
antivenom|administered_to|patients|18190937
antivenom|treats|coagulopathy|18190937
antivenom|treats|snake bite|18190937
snake venoms|part_of|horses|1297173
hemoglobin|coexists_with|total serum proteins|1297173
creatine kinase|coexists_with|transaminases|1297173
antivenom|administered_to|horses|9709794
venom|part_of|horses|9709794
phospholipase A2|part_of|snake|11902659
VRCTC-310-ONCO|treats|rabbits|11902659
venom|affects|renal|16427672
crotoxin|affects|renal|16427672
phospholipase A2|affects|renal|16427672
CTX|inhibits|GFR|16427672
venom|affects|kidney|16427672
okadaic acid|isa|shellfish toxin|15051408
venom|inhibits|dopaminergic receptors|2087694
venom|part_of|rabbits|2087694
angiotensin-converting enzyme (ACE) inhibitors|treats|patients|16569814
ACE inhibitors|inhibits|angiotensin II receptor|16569814
ACE inhibitors|inhibits|angiotensin II|16569814
insect venom|causes|allergic reactions|16569814
Angiotensin-converting enzyme inhibitors|treats|patients|16569814
Angiotensin-converting enzyme inhibitors|treats|allergies|16569814
prostaglandins|augments|nociceptors|20860671
bradykinin|augments|nociceptors|20860671
ATP|augments|nociceptors|20860671
interleukins|augments|nociceptors|20860671
saline|prevents|hypersensitivity|20860671
saline|associated_with|hypersensitivity|20860671
AST|isa|aminotransferase|23218888
bradykinin potentiating factor|part_of|hepatic|23218888
Vasopressin|causes|contraction|12809950
charybdotoxin|augments|contraction|12809950
superoxide dismutase|neg_affects|contraction|12809950
vasopressin|treats|rats|12809950
therapeutic agents|treats|type II diabetes|18311183
exendin-4|treats|rats|18311183
exendin-4|affects|vascular|18311183
adrenoceptors|interacts_with|exendin-4|18311183
exenatide|affects|free water clearance|23692186
agonist|treats|rat|12964040
exendin-4|stimulates|glucagon-like peptide-1 receptor|12964040
EX4|treats|type 2 diabetes|12964040
EX4|interacts_with|EX4|12964040
GLP-1R|interacts_with|ACTH|12964040
GLP-1R|interacts_with|aldosterone|12964040
antidiabetic|isa|medication|22009172
potassium channels|interacts_with|morphine|9100281
calcium-activated potassium channels|interacts_with|morphine|9100281
venoms|augments|vascular permeability|12782082
crotapotin|augments|vascular permeability|12782082
phospholipases|augments|vascular permeability|12782082
capsaicin|treats|rats|12782082
cyproheptadine|prevents|extravasation|12782082
serotonin|isa|amines|12782082
histamine|isa|amines|12782082
substance P|augments|mast cells|12782082
phospholipases A2|causes|Inflammatory oedema|12782082
substance P|isa|tachykinin|17101218
substance P|affects|pain|17101218
Ziconotide|disrupts|internalization|21577088
substance P|associated_with|joint inflammation|21749865
tachykinin receptor|associated_with|joint inflammation|21749865
arthritis-induced pain|treats|humans|21749865
therapeutic agents|treats|inflammatory arthritis|21749865
OSA|part_of|children|24356854
substance P|coexists_with|OSA|24356854
GR-82334|interacts_with|SP|24356854
OSA|augments|cell proliferation|24356854
IL-6|interacts_with|SP|24356854
TNF-alpha|interacts_with|SP|24356854
OSA|part_of|Children|24356854
eledoisin|causes|water intake|2207700
physalaemin|causes|water intake|2207700
tachykinins|causes|water intake|2207700
tachykinins|neg_causes|drinking|2207700
eledoisin|treats|pigs|2207700
physalaemin|neg_interacts_with|AII|2207700
angiotensin II|affects|drinking|2207700
tachykinins|affects|drinking|2207700
eledoisin|isa|tachykinin|2326504
ELE|affects|drinking|2326504
ELE|affects|dehydration|2326504
ELE|affects|water intake|2326504
eledoisin|treats|mammals|2345760
angiotensin II|causes|water intake|3963799
tachykinins|disrupts|water intake|3963799
eledoisin|disrupts|drinking|3963799
physalaemin|disrupts|drinking|3963799
venom|inhibits|tetrodotoxin|8783449
venom|disrupts|twitches|8783449
adrenoceptors|interacts_with|adrenoceptors|8783449
leukotriene receptors|interacts_with|venom|8783449
adrenoceptors|interacts_with|venom|8783449
adrenoceptors|interacts_with|leukotriene receptors|8783449
TAN-67|treats|mice|10594315
nociceptin|stimulates|TAN-67|10594315
amino acids|coexists_with|physalaemin|10822362
amino acids|compared_with|tachykinins|10822362
peptides|augments|secretory|10822362
amino acids|causes|secretory|10822362
physalaemin|isa|amides|10822362
physalaemin|affects|salivation|10822362
drug|treats|dogs|1897488
antiarrhythmic agents|treats|toxicity|7906165
Atropine|treats|toxicity|7906165
toad venom|converts_to|Bufadienolides|8914298
bufotenine|compared_with|bufadienolides|8914298
Fab fragment|part_of|physicians|12639891
toad venom|causes|ocular toxicity|18216586
toad venom|causes|corneal edema|18216586
toad venom|causes|IOP|18216586
toad venom|causes|Ocular toxicity|18216586
gemcitabine|treats|patients|22782343
gemcitabine|treats|metastatic pancreatic adenocarcinomas|22782343
gemcitabine|compared_with|gemcitabine|22782343
gemcitabine|treats|pancreatic adenocarcinomas|22782343
Cantor|treats|cancers|23692970
oleic acid|causes|mitochondrial myopathies|3001330
enzymatic|affects|mitochondria|3001330
VRCTC-310|treats|dogs|7762000
VRCTC-310|treats|Beagle|7762000
VRCTC-310|treats|beagle|7762000
VRCTC-310|treats|patients|9543697
VRCTC-310|part_of|authors|9543697
VRCTC-310|treats|advanced cancer|9543697
crotoxin|isa|snake venoms|9543697
VRCTC-310|coexists_with|crotoxin|9543697
VRCTC-310|coexists_with|cardiotoxin|9543697
VRCTC-310|part_of|woman|9543697
VRCTC-310|associated_with|advanced breast cancer|9543697
immunostimulants|interacts_with|crotoxin|11277856
phospholipids|part_of|Liposomes|11277856
immunostimulants|part_of|liposomes|11277856
Crotoxin|isa|neurotoxin|11545249
concanavalin A|part_of|animals|11545249
CTX|isa|injection|11545249
concanavalin A|augments|cells|11545249
concanavalin A|produces|IL-10|11545249
CdtV|stimulates|CTX|11545249
N-acetylcysteine|prevents|distention|12412621
N-acetylcysteine|prevents|edema|12412621
N-acetylcysteine|prevents|collapse|12412621
N-acetylcysteine|augments|polymorphonuclear cells|12412621
analgesic|prevents|consumption|16857228
Crotoxin|administered_to|cancer patients|16857228
Cro|causes|analgesia|16857228
Cro|interacts_with|atropine|16857228
Cro|interacts_with|naloxone|16857228
naloxone|inhibits|analgesic effects|16857228
Atropine|inhibits|analgesic effects|16857228
opioid receptors|interacts_with|Cro|16857228
neurotoxin|interacts_with|crotoxin|21946324
CrTX|part_of|cells|21946324
CrTX|stimulates|p53|21946324
CrTX|disrupts|tumor xenograft growth|21946324
Crotoxin|isa|neurotoxin|22322185
CrTX|stimulates|Iressa|22322185
CrTX|interacts_with|CrTX|22322185
tyrosine kinase inhibitors|affects|cells|22322185
crotoxin|isa|neurotoxin|23202800
Crotoxin|disrupts|growth|23202800
crotoxin|disrupts|growth|23202800
Crotoxin|isa|toxin|23471322
venom|inhibits|neurotransmitters|23471322
crotoxin|affects|muscle|23471322
Crotoxin|causes|paralysis|23471322
crotoxin|causes|paralysis|23471322
Crotoxin|isa|neurotoxin|23715138
crotoxin|causes|paralysis|23715138
crotoxin|isa|injections|23715138
crotoxin|affects|hemifacial spasm|23715138
crotoxin|isa|treatment|23715138
neurotoxin|isa|toxin|24196093
neurotoxin|causes|paralysis|24196093
neurotoxin|isa|crotoxin|24196093
crotoxin|affects|nerves|24196093
neurotoxin|affects|nerves|24196093
opioid receptors|interacts_with|venom|11384730
microsomal cytochrome P450|isa|cytochrome|11384730
kappa opioid receptors|interacts_with|venom|11384730
venom|part_of|Mice|11384730
DAMGO|stimulates|mu-opioid receptor|11384730
venom|neg_causes|symptoms|11384730
potassium|causes|contractures|15109884
antivenom|neg_prevents|neuromuscular blockade|15109884
inflammatory mediators|interacts_with|venom|18604304
Cdt|associated_with|signs|18604304
Cdt|part_of|mice|18604304
antivenom|treats|Wistar rats|20073325
meat tenderizer|isa|proteolytic|1351283
vinegar|treats|victims|1974028
phentolamine|treats|symptoms|1974028
Jellyfish venoms|isa|complex mixtures|2869072
therapeutic agents|treats|syndromes|2869072
toxins|causes|hypersensitivity|2869072
venom|disrupts|pathogenesis|2869072
venom|causes|eruption|2869597
lymphokine|associated_with|cutaneous eruption|2869597
Phentolamine|prevents|shaking|2879213
toxins|coexists_with|venom|2888425
toxins|causes|syndromes|2888425
venom|causes|hypotension|12676441
venom|interacts_with|protein|12676441
venom|stimulates|calcium|12676441
venom|stimulates|voltage-dependent calcium channels|12676441
toxin|associated_with|cardiomyopathy|14719425
venom|administered_to|victim|16012438
antihistamine|causes|symptomless|18089481
ziconotide|isa|analgesic|21777663
ziconotide|treats|rats|21777663
creatine phosphokinase|stimulates|alkaline phosphatase|21821138
medications|administered_to|patients|22162597
medications|treats|Stings|22162597
gabapentin|treats|neuropathy pain|22361521
metalloproteinases|associated_with|toxicity|23536767
Jellyfish venom|causes|dermal toxicity|23536767
catecholamine|associated_with|syndrome|8713006
tranquillizers|treats|patients|12174784
analgesics|treats|patients|12174784
verapamil|treats|rats|15109889
AV|part_of|rats|15109889
AV|prevents|cardiovascular collapse|15109889
antivenom|interacts_with|jellyfish Chironex fleckeri venom|15109889
venom|compared_with|venom|16165181
venom|higher_than|venom|16165181
AV|associated_with|cardiovascular collapse|19429250
venom|neg_interacts_with|venom|19429250
Ab|interacts_with|venom|19429250
venom|causes|cardiovascular collapse|19429250
antivenom|compared_with|antibodies|19429250
somatostatin|part_of|gastric|2905061
Pentagastrin|augments|gastric acid secretion|2905061
PYY|disrupts|gastric acid secretion|2905061
peptide YY|disrupts|gastric acid secretion|2905061
analogue|interacts_with|somatostatin|15486809
exendin-4|interacts_with|somatostatin|15486809
exendin-4|isa|analogue|15486809
somatostatin|stimulates|glucose|15486809
somatostatin|stimulates|carbachol|15486809
somatostatin|stimulates|arginine|15486809
exendin-4|interacts_with|exendin-4|15486809
somatostatin|part_of|gastric|15486809
exendin-4|stimulates|somatostatin|15486809
Exendin-4|stimulates|somatostatin|15486809
glucagon|isa|insulin|23351716
exendin-4|treats|rats|23351716
tumor promoter|coexists_with|12-O-tetradecanoylphorbol-13-acetate|2873626
tumor promoter|coexists_with|tumor promoter|2873626
insulin|coexists_with|12-O-tetradecanoylphorbol-13-acetate|2873626
insulin|coexists_with|tumor promoter|2873626
palytoxin|coexists_with|12-O-tetradecanoylphorbol-13-acetate|2873626
palytoxin|coexists_with|tumor promoter|2873626
recombinant human IGF-I|part_of|human|2873626
recombinant human IGF-I|coexists_with|palytoxin|2873626
recombinant human IGF-I|coexists_with|TPA|2873626
palytoxin|compared_with|TPA|2873626
palytoxin|higher_than|TPA|2873626
insulin|augments|prostaglandin production|2873626
recombinant human insulin growth factor|augments|prostaglandin production|2873626
exendin-4|augments|cell replication|15220193
exendin-4|augments|insulin secretion|15220193
growth factors|part_of|cell|15220193
anti-T-cell antibodies|part_of|cell|15220193
Glucagon|disrupts|arm|15331551
insulin|interacts_with|hormones|21293084
glucagon|interacts_with|hormones|21293084
incretins|interacts_with|hormones|21293084
amylin|interacts_with|hormones|21293084
incretins|isa|hormones|21293084
saxagliptin|affects|physiology|21293084
DPP-4 inhibitors|causes|weight loss|21293084
Amylin|isa|Pharmaceuticals|14725490
Pharmaceuticals|treats|type 2 diabetes|14725490
AC 2993|stimulates|glucagon-like peptide-1|14725490
Amylin|treats|type 2 diabetes|14725490
exenatide|treats|type 2 diabetes|14725490
Humatrope|isa|human growth hormone|14725490
sulfonylureas|treats|patients|14725490
sulfonylureas|treats|type 2 diabetes|14725490
exenatide|treats|patients|14725490
RC-3095|disrupts|capillary|10773722
GRP|affects|microcirculation|10773722
gastrin-releasing peptide|affects|microcirculation|10773722
RC-3095|treats|experimental arthritis|18590783
gastrin-releasing peptide receptor|affects|arthritis|18590783
alkylating agent|interacts_with|RC-3095|19129973
TMZ|treats|glioma|19129973
gastrin-releasing peptide|neg_interacts_with|GRP|19516017
GRP|associated_with|inflammatory disease|19516017
RC-3095|treats|uveitis|19516017
saline|isa|saline|19516017
GRP|associated_with|inflammatory response|19516017
carrageenan|stimulates|RC-3095|20364359
RC-3095|coexists_with|lipids|20364359
RC-3095|coexists_with|proteins|20364359
GRP|affects|acute inflammation|20364359
RC-3095|administered_to|mice|21953084
methylated bovine serum albumin|causes|disease|21953084
RC-3095|part_of|mice|21953084
IL-17|disrupts|concentrations|21953084
GRP|associated_with|chronic arthritis|21953084
gastrin-releasing peptide receptor|interacts_with|RC-3095|21953084
RC-3095|part_of|patients|22735756
RC-3095|inhibits|TLR-4|22735756
TNF-alpha|augments|macrophages|22735756
RC-3095|treats|rats|22735756
GRP|treats|patients|22735756
GRP|treats|sepsis|22735756
Gastrin-releasing peptide|isa|neuropeptide|23621446
receptor|part_of|cancer cells|23621446
RC-3095|inhibits|GRPR|23621446
GRP|associated_with|inflammation|23621446
GRP|associated_with|airway hyperreactivity|23621446
receptor|associated_with|inflammation|23621446
molecular target|treats|inflammatory diseases|23621446
gemcitabine|interacts_with|RC-3095|24326363
gemcitabine|coexists_with|RC-3095|24326363
gemcitabine|prevents|tumors|24326363
gemcitabine|disrupts|growth|24326363
RC-3095|inhibits|gastrin-releasing peptide receptor|24326363
peptide|coexists_with|polyacrylamide-disc-gel|2930463
octreotide|isa|somatostatin analogue|21694700
octreotide|treats|rats|21694700
octreotide|augments|food intake|21694700
Exendin-4|disrupts|food intake|21694700
gut hormones|treats|patients|21694700
fire ant venom|part_of|patients|1401645
fire ant venom|associated_with|stings|1401645
IgG4|isa|antibodies|2324412
fire ant venom-specific IgE|isa|antibodies|9662108
calamine|treats|stings|16538941
antigens|administered_to|patients|19492665
antigens|administered_to|physicians|19492665
antigen|stimulates|IgE|19852199
anti-fire ant venom IgE|isa|antibodies|19852199
anti-fire ant venom IgE|part_of|children|19852199
venom|associated_with|rheumatoid arthritis|6367751
ant venom|affects|rheumatoid arthritis|6367751
copper|treats|arthritis|10573766
zinc|treats|arthritis|10573766
ant venoms|coexists_with|medications|10573766
Royal jelly|treats|postmenopausal symptoms|20806997
Propolis|treats|aphthous stomatitis|20806997
Cantharidin|treats|warts|20806997
Cantharidin|treats|molluscum contagiosum|20806997
glutathione|stimulates|malondialdehyde|22824368
SAV|stimulates|glutathione|22824368
SAV|stimulates|AKT1|22824368
venom|causes|degeneration|1446167
venom|causes|proliferative glomerulonephritis|1446167
venom|administered_to|mice|12180804
venom|affects|fibres|12180804
prazosin|treats|cardiovascular manifestations|1467032
nifedipine|treats|cardiovascular manifestations|1467032
Prazosin|treats|cardiovascular manifestations|1467032
atropine|treats|victims|1740816
atropine|treats|myocardial injury|1740816
atropine|treats|cardiovascular manifestations|1740816
prazosin|treats|cardiovascular manifestations|7801338
Prazosin|treats|cardiovascular manifestations|7801338
prazosin|treats|victims|7801338
nifedipine|affects|instability|7801338
drugs|inhibits|social interaction|8744988
MTV|stimulates|monoamine oxidase (MAO) A|8744988
venom|augments|acetylcholinesterase (AChE) activity|10492617
scorpion venom|affects|right atria|10492617
carnitine|treats|patients|15736551
carnitine|treats|toxicity|15736551
prostaglandins|augments|nociceptors|16202438
venom|causes|oedema|16202438
venom|augments|reflexes|16202438
venom|causes|hypertensive|19703520
antimicrobial|coexists_with|venom|22792229
analogues|treats|type 2 diabetes|16504599
amylin|treats|type 2 diabetes|16504599
pramlintide|treats|type 2 diabetes|16504599
Exenatide|treats|type 2 diabetes|16504599
rimonabant|interacts_with|endocannabinoid|16504599
GLP|interacts_with|Ang II|22826029
GLP-1|inhibits|cRaf|22826029
GLP-1|affects|glomerular endothelium|22826029
venom|administered_to|rabbits|8138962
bitten|part_of|patient|22172144
GM2 ganglioside|associated_with|GBS|22172144
venom|part_of|second group|22172144
gangliosides|part_of|second group|22172144
venom-specific IgE|isa|antibody|8227855
anti-human IgE|part_of|human|8227855
venom|inhibits|venom|8227855
YJV|inhibits|PWV|8227855
PWV|isa|allergens|8227855
YJV|inhibits|anti-PWV|8227855
YJV|part_of|patients|8227855
YJV|associated_with|allergy|8227855
wasp venom|stimulates|venom-specific IgE|9515600
wasp venom|isa|antigen|9515600
cytokines|stimulates|IL-10|9949326
histamine|compared_with|histamine|9949326
IL-10|produces|IL-10|9949326
IL-10|inhibits|histamine|9949326
histamine|stimulates|IL-10|9949326
antibodies|associated_with|allergy|10843426
wasp-venom|isa|antigens|10843426
venom-specific serum IgE|isa|antibodies|11400609
phorbol-12-myristate-13-acetate|stimulates|venom specific IgE|11422133
cytokine|part_of|intracellular|11422133
cytokine|coexists_with|CD4|11422133
antibodies|part_of|placental|12069385
interleukin|augments|abortions|12069385
interleukin|augments|births|12069385
antihistamines|treats|adverse reactions|16045862
venom-specific IgE|isa|antibodies|16585893
allergens|coexists_with|wasp venom|16585893
Wasp venom|augments|allergic reaction|20112605
venoms|associated_with|allergy|21114197
Vespula venom|disrupts|IgE binding|21114197
sequences|interacts_with|venom|22705119
protein families|coexists_with|venom|22705119
venoms|administered_to|allergists|23363701
venoms|part_of|patients|23363701
yellow jacket (YJ) venom|treats|test results|23363701
venom|augments|wheal|4037258
ziconotide|affects|nerve transmission|16207099
ziconotide|affects|nociception|16207099
analgesics|treats|severe chronic pain|16207099
morphine|treats|severe chronic pain|16207099
Ziconotide|treats|chronic pain|16207099
Prialt|treats|humans|16580601
morphine|disrupts|voltage-sensitive calcium channels|17963128
analgesics|disrupts|voltage-sensitive calcium channels|17963128
ziconotide|treats|severe chronic pain|17963128
ziconotide|treats|rats|17963128
ziconotide|treats|monkeys|17963128
ziconotide|treats|dogs|17963128
target organ toxicity|neg_coexists_with|Ziconotide|17963128
ziconotide|treats|mice|17963128
ziconotide|treats|humans|17963128
cilnidipine|treats|mice|19801830
drug|treats|neuropathic pain|19801830
ziconotide|inhibits|VDCC|19801830
PGC|treats|diabetes|21830140
GLP-1|interacts_with|GLP-1|21830140
PGC|interacts_with|GLP-1|21830140
TPCK|isa|protease inhibitor|22079475
Akt|affects|transcriptional|22079475
Kaliotoxin|inhibits|voltage-gated potassium channels|11145670
KTX|administered_to|Lewis rats|11145670
immunosuppressive agent|affects|neurological symptoms|11145670
voltage-gated K+ channels|affects|experimental autoimmune encephalomyelitis|11145670
MBP|augments|T cells|11717451
hornet venom|associated_with|intraocular pressure|2565189
hornet venom|part_of|Oriental|6136175
antisera|part_of|rabbit|6801104
hornet venoms|compared_with|antisera|6801104
yellow jacket venom|compared_with|hornet venom|6801104
yellow jacket venom|higher_than|hornet venom|6801104
allergenicity|compared_with|antigenicity|6801104
hornet venom|part_of|oriental|7067070
hornet venom|isa|venoms|7067070
venoms|isa|hornet venom|7067070
venoms|part_of|oriental|7067070
allergen|part_of|blood cells|10219425
snake antivenom|treats|dog|19335471
avidin|isa|proteins|17627607
peptides|affects|cell viability|23958314
prostacyclin|inhibits|TXA2|1655375
Iloprost|treats|patients|7525794
water|treats|pain|16584366
tetrodotoxin|affects|food poisoning|12182541
lignocaine|neg_treats|allodynia|17077153
lignocaine|neg_treats|hyperalgesia|17077153
muO-conotoxin MrVIB|inhibits|sodium channels|17077153
tetrodotoxin|inhibits|sodium channel|17320922
sodium channels|part_of|nerve|17320922
sodium channels|associated_with|epileptic seizures|17320922
tetrodotoxin|predisposes|poisoning|19505494
ciguatoxins|predisposes|poisoning|19505494
toxins|predisposes|poisoning|19505494
mu-conotoxins|part_of|Xenopus laevis oocytes|23351163
mu-conotoxins|interacts_with|INa|23351163
toxins|inhibits|INa|23351163
flavor|compared_with|flavors|2992719
insulin|compared_with|saline|2992719
Bufotenin|causes|hallucinations|1746631
refecoxib|disrupts|cyclooxygenase 2 pathway|12532190
eledoisin|treats|dry eye|1765297
eledoisin|treats|patients|1765297
eledoisin|treats|humans|1765297
Eledoisin|treats|dry eye|2347204
eledoisin|augments|lacrimal|2347204
eledoisin|augments|accessory lacrimal gland|2347204
eledoisin|neg_augments|lacrimal|2347204
Eledoisin|treats|rabbit|2347204
artificial tears|treats|keratoconjunctivitis sicca|3283426
artificial tears|treats|Sjogren's syndrome|3283426
eledoisin|treats|keratoconjunctivitis sicca|3283426
eledoisin|interacts_with|thyrotrophin|3929520
eledoisin|interacts_with|thyrotrophin-releasing hormone|3929520
eledoisin|inhibits|TRH|3929520
eledoisin|neg_coexists_with|L-dopa|3929520
thyrotrophin|treats|rats|3929520
carnitine|treats|patients|23906760
carnitine|treats|primary open-angle glaucoma|23906760
eledoisin|isa|drugs|23906760
carnitine|treats|syndrome|23906760
eledoisin|treats|patients|23906760
carnitine|inhibits|pressure|23906760
eledoisin|inhibits|pressure|23906760
eledoisin|treats|syndrome|23906760
sodium hyaluronate|interacts_with|eye drops|23906760
taurine|interacts_with|eye drops|23906760
eledoisin|interacts_with|eye drops|23906760
heparin|treats|parameters|17964518
thrombin|disrupts|fibrin deposition|17964518
cytokine|affects|apoptosis|18492290
exendin-4|augments|neurogenesis|18492290
EX-4|administered_to|rats|18492290
EX-4|produces|L-DOPA|18492290
EX-4|treats|lesions|18492290
EX-4|treats|type-II diabetes|18492290
EX-4|treats|patients|18492290
Exenatide|treats|type 2 diabetes|23728174
Vasodilators|treats|AHF|19096932
vasodilators|administered_to|patients|19096932
vasodilators|treats|patients|19096932
vasodilators|treats|borderline BP|19096932
Vasodilators|treats|acute heart failure|19096932
AV|administered_to|children|12163905
hydrocortisone|treats|patients|12163905
antivenin|administered_to|children|2723986
antivenin|administered_to|children|8215129
antivenin|predisposes|anaphylactic reactions|10065242
Antimuscarinic|isa|drugs|17870108
drugs|augments|bladder capacity|17870108
Antimuscarinic|augments|bladder capacity|17870108
antimuscarinic|isa|drugs|17870108
Prostaglandin E|causes|overactivity|17870108
propiverine|treats|rats|17870108
prostaglandin E|administered_to|rats|17870108
prostaglandin E|causes|overactivity|17870108
Propiverine|treats|detrusor function|17870108
Antimuscarinic|isa|drug|17870108
prostaglandin E2|inhibits|urethral pressure|17870108
drug|inhibits|overactivity|17870108
Antimuscarinic|inhibits|overactivity|17870108
EXE|coexists_with|E+G|18334612
exenatide|inhibits|EGP|18334612
EXE|inhibits|Acetaminophen|18334612
exenatide|treats|hyperglycemia|18334612
exenatide|prevents|hyperglycemia|18334612
ziconotide|affects|voltage sensitive calcium channels|21539704
morphine|affects|hyperalgesia|21539704
harmaline|treats|rats|22222861
clorgyline|treats|rats|22222861
5-MeO-DMT|causes|hypoactivity|22222861
5-MeO-DMT|compared_with|monoamine oxidase inhibitor|22222861
Ziconotide|isa|nonopioid analgesic|23972874
ziconotide|treats|patients|23972874
Hymenoptera venom|treats|general population|24365141
hymenoptera venoms|causes|anaphylactic reactions|9011167
prednisone|treats|patient|11799266
Corticosteroids|treats|good health|11799266
venom|part_of|patients|12201901
allergens|causes|symptoms|12592316
drugs|treats|allergic symptoms|12592316
filaggrin|neg_coexists_with|allergen|20975288
filaggrin's|associated_with|disease|20975288
allergens|part_of|recombinant|21598724
Dextrans|treats|deep venous thrombosis|2481750
warfarin|prevents|hemorrhagic complications|2481750
Exenatide|treats|type 2 diabetes|16988207
drug|treats|men|16988207
warfarin|isa|drug|16988207
warfarin|affects|pharmacokinetics|16988207
warfarin|affects|pharmacodynamics|16988207
warfarin|treats|men|16988207
Exenatide|coexists_with|warfarin|16988207
warfarin|treats|men|16988207
warfarin|interacts_with|exenatide|16988207
antivenom|treats|patients|8491579
urea|part_of|blood|8491579
ethanol|treats|rodents|15902919
alpha-conotoxin MII|treats|mice|15902919
alpha-conotoxin MII|treats|rats|15902919
MU-sensitive receptors|interacts_with|ethanol|15902919
adjuvant|treats|dependence|15902919
nicotine|predisposes|lung cancer|19151195
nAChR alpha7 subunit|affects|lung cancer development|19151195
Nicotinic acetylcholine receptors|affects|cell growth regulation|19326440
agonist|inhibits|nAChR|19326440
Erabutoxin|isa|toxin|19326440
alpha-CbT|interacts_with|toxin|19326440
alpha-CbT|interacts_with|Erabutoxin|19326440
nicotinic receptor|disrupts|tumorigenicity|19326440
echistatin|inhibits|bone resorption|7817829
echistatin|augments|osteoclasts|7817829
vitronectin|compared_with|echistatin|7817829
RGD peptides|interacts_with|echistatin|7817829
RGD peptides|interacts_with|vitronectin|7817829
cyclic RGD peptides|interacts_with|echistatin|7817829
cyclic RGD peptides|interacts_with|vitronectin|7817829
RGD peptides|neg_affects|platelet aggregation|7817829
RGD peptides|neg_affects|cell attachment|7817829
RGD peptides|neg_affects|bone resorption|7817829
thrombin inhibitor|interacts_with|von Willebrand Factor|8236159
albolabrin|compared_with|albolabrin|8236159
albolabrin|higher_than|albolabrin|8236159
disintegrins|disrupts|thromboembolism|8236159
brown recluse spider venom|part_of|pigs|20666855
homeopathic medicines|treats|PMS|23290881
antivenom|part_of|ovine|16982358
phospholipases|causes|instability|22283655
venoms|coexists_with|buffer|22283655
venoms|coexists_with|liposomes|22283655
venoms|part_of|poisonous animal|22283655
antivenom|administered_to|patients|21225218
antivenom|part_of|Micrurus|21225218
antivenom|administered_to|patients|23962099
NACSAV|administered_to|patients|23962099
venom|causes|eye lesion|8115801
haemorrhagins|causes|death|14559086
IL-1|isa|cytokines|16198389
LTB4|isa|eicosanoids|16198389
IL-6|interacts_with|BaV|16198389
IL-1|interacts_with|BaV|16198389
TXA2|interacts_with|BaV|16198389
TNF-alpha|interacts_with|BaV|16198389
LTB4|interacts_with|BaV|16198389
IL-6|isa|cytokines|16198389
TXA2|isa|injection|16198389
TXA2|neg_coexists_with|IL-1|16198389
LTB4|neg_coexists_with|IL-1|16198389
adhesion molecules|associated_with|infiltration|16198389
venom|causes|Inflammation|16198389
venom|causes|degeneration|22415117
venom|interacts_with|creatine kinase|22415117
venom|causes|muscle damage|22415117
venom|part_of|mice|22958286
fibronectin|isa|binding protein|22958286
fibrinogen|isa|binding protein|22958286
recombinant S.aureus proteins|part_of|mice|22958286
recombinant S.aureus proteins|interacts_with|Escherichia coli|22958286
FnBP|isa|FnBP|22958286
peptides|compared_with|SRT|1988658
peptides|higher_than|SRT|1988658
ET-1|interacts_with|receptors|1988658
SRT|interacts_with|receptors|1988658
endothelin|affects|cardiovascular function|1988658
ET|associated_with|pathogenesis|17074116
TNFalpha|associated_with|pathogenesis|17074116
tumor necrosis factor-alpha|associated_with|poisoning|17074116
endothelin|associated_with|poisoning|17074116
endothelin|associated_with|bee sting|17074116
tumor necrosis factor-alpha|associated_with|bee sting|17074116
Endothelin|stimulates|ET|17664390
sodium|part_of|renal|17664390
sarafotoxin 6c|coexists_with|ET|17664390
ET|causes|tachycardia|2181224
ET|affects|negative chronotropic|2181224
SRT|coexists_with|pressor|2181224
ET|causes|toxic effects|2181224
Sx6c|interacts_with|ETB|7536862
ET-1|interacts_with|ETB|7536862
ET-1|associated_with|asthma|10619183
receptors|associated_with|bronchial hyperresponsiveness|10619183
agonist|treats|rabbit|10619183
BO|causes|CO|11030442
BO|stimulates|propranolol|11030442
BO|stimulates|norepinephrine|11030442
BO|stimulates|epinephrine|11030442
BO|stimulates|adrenoceptor|11030442
exenatide|stimulates|adiponectin|20424219
exenatide|stimulates|C-reactive protein|20424219
vascular receptors|affects|blood flow|21382493
endothelin receptors|affects|blood flow|21382493
sarafotoxin 6c|coexists_with|mRNA|15243294
S6c|causes|fall|15243294
receptors|coexists_with|zone|15243294
S6c|part_of|hearts|15243294
S6c|neg_coexists_with|zone|15243294
Chlorotoxin|isa|venom|17335414
antivenin|treats|patients|21748231
troponin|part_of|blood|23499925
N-terminal pro B-type natriuretic peptide|treats|patients|23499925
incretin|treats|type 2 diabetes mellitus|17379054
alanine aminotransferase|part_of|Patients|17379054
HbA|predisposes|hepatic injury|17379054
incretin|treats|type 2 diabetes|18053320
alanine aminotransferase|part_of|Patients|18053320
creatine kinase|affects|heart|20060851
lactate dehydrogenase|affects|heart|20060851
creatine kinase|affects|lungs|20060851
aspartate aminotransferase|affects|heart|20060851
lactate dehydrogenase|affects|lungs|20060851
aspartate aminotransferase|affects|lungs|20060851
exenatide|stimulates|adiponectin|21660077
exenatide|treats|mice|23444782
exenatide|treats|obese mice|23444782
drug|treats|metabolic disease|23444782
drug|administered_to|obese mice|23444782
AST|predisposes|hepatic injury|23444782
Glucagon-like peptide 1 receptors|part_of|tissues|24477544
exenatide|treats|mice|24477544
Exenatide|coexists_with|Glp1r|24477544
amylase|isa|lipase|24477544
Exenatide|neg_coexists_with|Glp1r|24477544
glucose|coexists_with|Glp1r|24477544
insulin|compared_with|HLC|24477544
insulin|coexists_with|Glp1r|24477544
toxin|compared_with|oral administration|12782078
okadaic acid|isa|toxin|12782078
okadaic acid|compared_with|oral administration|12782078
OA|causes|diarrhoea|12782078
transaminase|neg_affects|myocardium|12782078
YTX|affects|fibrillar|12782078
derivatives|compared_with|OA|12782078
derivatives|lower_than|OA|12782078
Exendin-4|stimulates|glucagon-like peptide (GLP) receptor|16374859
glucagon-like peptide (GLP) receptor|augments|insulin secretion|16374859
Exendin-4|treats|hepatic steatosis|16374859
Exendin-4|treats|mice|16374859
Exendin-4|part_of|mice|16374859
Exendin-4|associated_with|oxidative stress|16374859
fatty acid|coexists_with|genes|16374859
Na+/K+-ATPase|interacts_with|toxin|21333670
interleukin-8|predisposes|myocardial injury|12011799
IL-8|associated_with|pathogenesis|12011799
acetylcholinesterase (AChE) inhibitory|interacts_with|fasciculin-2|2087485
muscarinic receptor|interacts_with|quinuclidinyl benzilate|2087485
muscarinic receptor|interacts_with|oxotremorine|2087485
K+-ATPase|part_of|cell membranes|9792167
analgesics|treats|neuropathic pain|14529519
drug|treats|neuropathic pain|14529519
cytokines|affects|myocardial cells|15687982
serotonin|stimulates|calcium ion|2116797
mastoparan|stimulates|serotonin|2116797
mastoparan|stimulates|pertussis toxin|2116797
Mastoparan|isa|wasp venom|2116797
wasp venom|stimulates|GTP-binding proteins|2116797
Mastoparan|stimulates|GTP-binding proteins|2116797
opioid receptors|augments|transduction|19940980
omega-conotoxin GVIA|causes|analgesic effects|19940980
MOR|augments|transduction|19940980
heterotrimeric G proteins|affects|protein kinase (MAPK) activation|9835628
heterotrimeric G proteins|affects|cytokine production|9835628
signaling molecules|part_of|intracellular|9835628
insulin|augments|gene transcription|14529486
G protein-coupled receptors|part_of|pancreatic beta-cells|14529486
GLP-1|augments|pancreatic islets|14529486
GLP-1|augments|cell death|14529486
GLP-1|augments|apoptosis|14529486
dipeptidyl peptidase IV|inhibits|GLP-1|14529486
GLP-1|interacts_with|serum albumin|14529486
Exendin-4|isa|peptide|14529486
GPCR|part_of|cell|14529486
therapeutic agents|treats|diabetes mellitus|14529486
potassium|interacts_with|drugs|15028774
potassium|interacts_with|neurotransmitters|15028774
protein-gated K|part_of|spinal cord|15028774
G-protein|neg_part_of|dorsal horn|15028774
protein-gated K|affects|nociception|15028774
protein-gated K|predisposes|analgesia|15028774
GLP-1 receptor|affects|carbohydrate metabolism|16202636
GLP-1|inhibits|glucagon|16202636
GLP-1|associated_with|type 2 diabetes|16202636
GLP-1|associated_with|pathogenesis|16202636
GLP-1|stimulates|GLP-1 receptor|16202636
glucagon-like peptide-1|associated_with|pathogenesis|16202636
gabapentin|treats|hypersensitivity|17325515
G protein|interacts_with|gabapentin|17325515
gabapentin|augments|noradrenergic|17325515
gabapentin|prevents|postoperative pain|17325515
Gabapentin|augments|noradrenergic|17325515
Insulin Glargine|inhibits|glucose|20494360
Insulin Glargine|inhibits|MDA|20494360
Insulin Glargine|inhibits|FFA|20494360
Exenatide|coexists_with|MDA|20494360
GLP-1|affects|myocardium|22650224
GLP-1|augments|cardiac function|22650224
GLP-1|associated_with|ischemic/reperfusion injury|22650224
GLP-1|affects|cardiac function|22650224
metabolite|neg_interacts_with|GLP-1 receptor|22650224
GLP-1|affects|heart|22650224
NNAV|inhibits|malondialdehyde|23228832
NNAV|inhibits|transforming growth factor-beta1|23228832
NNAV|associated_with|DN|23228832
venom|causes|Anaphylactic shock|22890734
morphine|treats|mice|22960549
peptide|affects|splanchnic circulation|2927238
physalaemin|affects|blood flow|2927238
physalaemin|affects|splanchnic circulation|2927238
FIIa|interacts_with|fibrinogen|15916735
toxin|causes|severe pain|2231840
venom|isa|toxin|2231841
synthetic peptide|causes|antibody formation|19576255
exenatide|neg_causes|hypersensitivity reactions|19576255
anti-exenatide antibody|neg_augments|TEAEs|19576255
Antivenin|treats|coagulopathy|9452286
antivenin|part_of|Agkistrodon halys|17914147
antivenin|isa|treatment|17914147
antivenin|treats|bites|17914147
catecholamine|causes|myocardial ischemia|2260099
heparin|treats|rabbits|7555240
heparin|interacts_with|aspirin|7555240
heparin|interacts_with|heparin|7555240
VV|disrupts|platelet aggregation|7555240
heparin|interacts_with|VV|7555240
heparin|treats|acute coronary syndromes|7555240
venom|disrupts|tumor growth|10944460
salmosin|associated_with|tumor cell metastasis|10944460
RGD|disrupts|cell adhesion|10944460
salmosin|part_of|Recombinant|10944460
salmosin|part_of|E. coli|10944460
collagen|part_of|melanoma cells|10944460
disintegrin|associated_with|melanoma cell metastasis|10944460
fibrinogen|part_of|rats|15844712
thromboxane B2|part_of|rats|15844712
snake venom|associated_with|fibrotic rat liver|15844712
desmin|stimulates|vimentin|9314534
antivenom|interacts_with|venom|11525706
antivenom|treats|snakebite|11525706
CroFab|isa|antivenom|15800419
CroFab|treats|humans|15800419
antivenom|treats|children|15800419
antivenom|treats|adults|15800419
CroFab|treats|children|15800419
CroFab|treats|adults|15800419
Antivenom|treats|snakebites|15800419
CroFab|isa|Crotalidae polyvalent immune Fab|19606002
antivenoms|treats|snake bite|19606002
Crotalidae polyvalent immune Fab|treats|snake bite|19606002
Crotalidae polyvalent immune Fab|compared_with|antivenoms|19606002
CroFab|part_of|patients|19606002
antivenin|isa|treatment|21740134
histamine|coexists_with|favour|10931125
IL-1beta|stimulates|NF-kappaB|23587180
p38-MAPK|augments|phosphorylation|23710144
MMP-9 protein|interacts_with|JNK|23710144
venom|interacts_with|acetylcholine receptor|24087853
chitosan|treats|central nervous system (CNS) disorders|24087853
antivenin|isa|treatment|11990168
antivenin|isa|management|11990168
antivenin|treats|aspiration pneumonitis|11990168
antivenom|administered_to|patients|17710993
antivenom|treats|patients|20637219
venom|isa|toxins|20637219
d-tubocurarine|treats|rats|6822252
alpha-Naja naja toxin|part_of|Naja naja|6822252
calmodulin|augments|conformational changes|15180477
apamin|isa|toxins|15180477
scyllatoxin|isa|toxins|15180477
apamin|augments|excitability|15180477
Exendin-4|treats|humans|18829977
exendin-4|part_of|animals|18829977
Exendin-4|stimulates|glucagon-like peptide 1 receptor|18829977
sea anemone venom|part_of|dogs|21682750
FGF21|part_of|hepatic|21956711
FGF21|produces|FGF21|21956711
FGF21|produces|fibroblast growth factor (FGF)21|21956711
exenatide|interacts_with|FGF21|21956711
AMP-activated protein kinase|part_of|hepatic|21956711
exendin-4|inhibits|triacylglycerol|21956711
triacylglycerol|inhibits|FGF21|21956711
mRNA|interacts_with|AMP-activated protein kinase|21956711
FGF21|associated_with|type 2 diabetes mellitus|21956711
FGF21|part_of|Hepatic|21956711
FGF21|augments|AMPK phosphorylation|21956711
fibroblast growth factor 21|part_of|hepatic|21956711
fibroblast growth factor 21|associated_with|disease|21956711
fibroblast growth factor 21|associated_with|non-alcoholic fatty liver|21956711
Exenatide|inhibits|fibroblast growth factor 21|21956711
apamin|affects|neurons|9092604
channel blockers|augments|excitability|9092604
small-conductance calcium-activated potassium channel|associated_with|brain oedema|15379997
antidepressant|treats|mouse|17761162
agmatine|stimulates|antidepressant|17761162
tetraethylammonium|treats|mice|17761162
apamin|interacts_with|agmatine|17761162
agmatine|neg_affects|locomotion|17761162
antidepressant|interacts_with|agmatine|17761162
agmatine|affects|excitability|17761162
potassium channels|interacts_with|antidepressant|17761162
mAb|part_of|mouse|2522969
transferrin receptors|part_of|mouse|2522969
gastrin-releasing peptide|affects|gastric acid secretion|2623192
gastrin-releasing peptide|isa|neuropeptide|2623192
NaCl|part_of|rat|2623192
antiserum|affects|acid secretion|2623192
GRP|isa|neuropeptide|2623192
lead compounds|treats|neurological diseases|16979678
lead compounds|treats|multiple sclerosis|16979678
lead compounds|treats|diabetic neuropathy|16979678
lead compounds|treats|shingles|16979678
nicotinic acetylcholine receptors|augments|sensory nerves|16979678
conotoxins|interacts_with|nicotinic acetylcholine receptor|16979678
neuropeptides|isa|hormones|18377785
palytoxin|causes|rhabdomyolysis|9617874
palytoxin|causes|Rhabdomyolysis|9617874
corticosteroids|treats|patient|19545971
histamine antagonist|treats|patient|19545971
sodium-potassium ATPase|isa|adenosinetriphosphatase|19545971
marine toxin|interacts_with|sodium-potassium ATPase|19545971
PTX|associated_with|disease|23702624
enzymes|causes|cell damage|2800879
Adder venom|causes|pancreatitis|2800879
viper venom|affects|pathogenesis|3317538
adder venom|part_of|Armenian|16373073
viper venom|causes|symptoms|21959940
viper venom|interacts_with|fluorophores|22659142
venom|interacts_with|fluorophores|22659142
GRGDS|inhibits|Cerastes cerastes venom|15072239
integrins|part_of|cancerous cells|15072239
insect venom|predisposes|anaphylaxis|10909168
specific antigen|part_of|leukocytes|11878133
Epinephrine|treats|children|12618751
Epinephrine|treats|adults|12618751
insect venom|part_of|basophils|17335884
RNA|associated_with|allergy|20334904
Medications|causes|anaphylaxis|23529459
anaesthetic drugs|isa|Medications|23529459
opiates|isa|Medications|23529459
nonsteroidal anti-inflammatory drugs|isa|Medications|23529459
anaesthetic drugs|causes|anaphylaxis|23529459
nonsteroidal anti-inflammatory drugs|causes|anaphylaxis|23529459
opiates|causes|anaphylaxis|23529459
exendin-4|administered_to|rats|10027577
incretin mimetic agent|augments|insulin secretion|16484515
Exenatide|treats|type 2 diabetes mellitus|16484515
Exenatide|treats|patients|16484515
Exenatide|isa|protein|16529340
exenatide|treats|type 2 diabetes mellitus|16529340
exenatide|treats|patients|16529340
exenatide|compared_with|placebo|16529340
glucagon|augments|insulin secretion|16529340
glucagon|inhibits|gastric emptying|16529340
Exenatide|disrupts|food intake|16529340
Incretins|augments|insulin secretion|17109672
glucagon|inhibits|gastric emptying|17109672
glucagon-like peptide-1|neg_augments|insulin secretion|17109672
Exenatide|isa|peptide|17109672
GLP-1|stimulates|GLP-1 receptor|17109672
glucose|treats|diabetic|17109672
glucose|treats|patients|17109672
exenatide|treats|diabetic|17109672
exenatide|treats|patients|17109672
Exenatide|associated_with|type 2 diabetes|17109672
exendin-4|part_of|Gila monster|20979668
glucose|treats|diabetic|20979668
glucose|treats|patients|20979668
exenatide|inhibits|glucose|20979668
insulin|disrupts|hypoglycaemic episodes|20979668
analogues|treats|hyperglycaemia|20979668
analogues|treats|critically ill|20979668
drugs|treats|cancer|18516973
drugs|treats|cancer pain|18516973
gabapentin|treats|neuropathic pain|18516973
ziconotide|isa|drugs|18516973
ziconotide|treats|neuropathic pain|18516973
Ziconotide|isa|nonopioid intrathecal analgesic|20639730
ziconotide|coexists_with|drugs|20639730
ziconotide|neg_affects|respiratory depression|20639730
ziconotide|neg_affects|bradycardia|20639730
ziconotide|causes|analgesia|20639730
Applaggin|interacts_with|glycoprotein IIb/IIIa receptor|8246155
Applaggin|stimulates|binding sites|8246155
applaggin|prevents|carotid artery thrombosis|8246155
regular human insulin|part_of|human|19193822
lispro|compared_with|regular human insulin|19193822
lispro|higher_than|regular human insulin|19193822
insulin|causes|hypoglycemia|19193822
glargine|compared_with|neutral protamine Hagedorn insulin|19193822
glargine|higher_than|neutral protamine Hagedorn insulin|19193822
glycated hemoglobin|part_of|patients|19193822
human insulins|prevents|hypoglycemia|19193822
Opioids|stimulates|adrenoceptor|12172710
voltage-gated calcium channels|affects|parameters|12172710
drugs|treats|rats|12172710
clonidine|inhibits|MAP|12172710
verapamil|inhibits|MAP|12172710
PYY|disrupts|food intake|20559304
exendin-4|disrupts|food intake|20559304
gut hormones|interacts_with|exenatide|21632815
Exenatide|treats|type 2 diabetes|21632815
exenatide|treats|PWS|21632815
C-peptide|isa|insulin|21632815
PYY|treats|patients|21632815
Exenatide|inhibits|PYY|21632815
exenatide|treats|patients|21632815
hormones|affects|PWS|21632815
fusion proteins|interacts_with|E. coli|21793303
analgesic|treats|mice|21793303
venom|causes|lung edema|14727383
venom|causes|cardiac failure|14727383
venom|compared_with|injection|14727383
glutamate|neg_coexists_with|valine|14727383
amino acids|treats|people|14992323
amino acids|treats|diabetes|14992323
amylin|part_of|human|14992323
agonist|administered_to|rats|15879053
Exendin-4|causes|hyperglycemia|15879053
glucagon|isa|insulin|15879053
Ex-4|interacts_with|glucose|15879053
Ex-4|interacts_with|fatty acid|15879053
snake venom|disrupts|platelet aggregation|8788436
Triflavin|interacts_with|fibrinogen|8788436
triflavin|treats|rats|8788436
triflavin|treats|arterial thrombosis|8788436
disintegrin|disrupts|tumor growth|12076080
salmosin|associated_with|PCO|12076080
salmosin|disrupts|LECs|12076080
salmosin|treats|PCO|12076080
disintegrin|interacts_with|salmosin|12076080
cilengitide|part_of|Rats|21512659
cilengitide|treats|bone metastases|21512659
tumor necrosis factor-alpha|interacts_with|MMP-9|23435195
RGD|part_of|recombinant|23435195
venom|part_of|Animals|6129332
scorpion venom|causes|acute myocarditis|6129332
scorpion Buthus martensi Karch (BmK) venom|causes|edema|18619501
venom|causes|edema|18619501
venom|causes|hyperalgesia|19782067
angiotensin II receptor antagonist|isa|drugs|20686848
exenatide|causes|contraction|20686848
exenatide|inhibits|angiotensin II|20686848
exenatide|inhibits|diuretics|20686848
incretin hormones|affects|glucose homeostasis|19073224
exendin-4|interacts_with|incretins|19073224
analogues|treats|glucose intolerance|19073224
Antidiabetic|interacts_with|GIP receptor|19073224
pathogenic factors|augments|diabetes|19074620
GIP|neg_affects|insulin secretion|19074620
GLP-1|associated_with|T2DM|19074620
GLP-1|stimulates|GLP-1 receptor|19074620
exenatide|stimulates|GLP-1 receptor|19074620
Exenatide|inhibits|blood glucose|19074620
DPP4 inhibitors|stimulates|incretins|19074620
incretins|affects|glucose homeostasis|19074620
incretins|affects|diabetes|19074620
Epinephrine|isa|treatment|16266376
Epinephrine|treats|acute anaphylaxis|16266376
epinephrine|treats|anaphylaxis|16266376
venom specific IgE|coexists_with|OPN|17130676
OPN|affects|immune response|17130676
apamin|affects|lungs|8560501
apamin|disrupts|paradoxical sleep|8930341
apamin|disrupts|slow sleep|8930341
apamin|causes|Sleep cycle disturbances|8930341
apamin|inhibits|calcium-activated potassium channels|11165532
calcium-activated potassium channels|disrupts|myotonia|11165532
drugs|augments|atrial effective refractory period|21394037
small conductance calcium-activated potassium) channel|affects|long term potentiation|22983217
Nf1|compared_with|Nf1|22983217
calcium|stimulates|potassium|22983217
calcium|interacts_with|apamin|22983217
Venom|administered_to|rats|3257850
venom|administered_to|mice|16446169
venom|part_of|mice|16446169
mouse rat monoclonal antibody|part_of|rat|16446169
mRNA|part_of|cells|16446169
venom|part_of|Neutrophils|16446169
antivenom|treats|poisonings|12841560
antivenom|administered_to|patients|23289356
antivenom|treats|snake-bite envenomation|3367819
antivenom|isa|treatment|3367819
anticholinesterase|treats|bites|3367819
transcriptional factor|stimulates|genes|15775723
angiotensin II|affects|protection|15775723
AII|treats|rats|15775723
AII|treats|GN|15775723
dendrotoxin|part_of|rats|3629616
dendrotoxin|causes|signs|3629616
Dendrotoxin|isa|toxin|3629616
venom|converts_to|KV1.6 potassium channels|12733854
venom|converts_to|Dendrotoxin|12733854
F(ab|part_of|equine|8283161
antivenom|treats|Patients|8283161
antivenom|neg_treats|patients|8283161
antivenom|administered_to|patients|8283161
antivenom|administered_to|patient|15521621
antivenom|part_of|equine|15521621
antivenom|part_of|sheep|15521621
antivenom|treats|patients|16496490
F(ab|part_of|equine|16496490
antivenom|treats|toxic effects|19681776
antivenin|treats|dogs|24102941
F(ab|part_of|dogs|24102941
corticosteroids|treats|dogs|24102941
exenatide|part_of|patient|19703814
exenatide|associated_with|pancreatitis|19703814
liraglutide|associated_with|pancreatitis|21487080
liraglutide|causes|pancreatitis|21487080
Liraglutide|treats|patients|21487080
exenatide|treats|diabetes mellitus|22068258
exenatide|affects|acute necrotizing pancreatitis|22068258
amylase|treats|patients|22440997
amylase|treats|type 2 diabetes|22440997
lipase|treats|patients|22440997
agonists|administered_to|patients|22440997
peptidase-4 inhibitors|administered_to|patients|22440997
pancreatic amylase|isa|amylase|22589391
pancreatic amylase|predisposes|pancreatitis|22589391
amylase|predisposes|pancreatitis|22589391
liraglutide|part_of|ZDF rats|22589391
exenatide|augments|amylase activity|22589391
liraglutide|augments|amylase activity|22589391
agonists|neg_affects|exocrine pancreas|22589391
myeloperoxidase|part_of|rats|22836857
exenatide|part_of|rats|22836857
myeloperoxidase|compared_with|exenatide|22836857
exenatide|treats|rats|22836857
venom|augments|excitability|3627455
toxins|coexists_with|venom|9209224
antivenom|treats|victims|9209224
antivenin|part_of|Crotalid|11348818
Dendroaspis natriuretic peptide|affects|renal function|11906482
DNP|affects|excretion|11906482
DNP|augments|renal water excretion|11906482
Dendroaspis natriuretic peptide|augments|renal water excretion|11906482
CNP|isa|NP|19395584
NP|associated_with|heart failure|19395584
natriuretic peptides|affects|renal|20178049
peptide receptors|stimulates|cyclic guanosine monophosphate|20178049
natriuretic peptide|treats|heart failure|20178049
cyclooxygenase inhibitor|inhibits|hypotension|7846692
prostacyclin|affects|hypotensive|7846692
prostaglandins|affects|hypotensive|7846692
cyclooxygenase inhibitor|neg_affects|leukopenia|7846692
cyclooxygenase inhibitor|neg_affects|thrombocytopenia|7846692
5-lipoxygenase inhibitor|neg_affects|leukopenia|7846692
5-lipoxygenase inhibitor|neg_affects|thrombocytopenia|7846692
nitric oxide synthase|causes|allodynia|18440503
ziconotide|treats|sensitivity|18440503
antivenom|isa|antibody|3833008
Hymenoptera venom|causes|complications|3833008
Epinephrine|isa|treatment|12825843
Epinephrine|treats|acute anaphylaxis|12825843
venom-specific IgE|isa|antibodies|12825843
epinephrine|treats|hypersensitivity (SIH) reactions|20642208
epinephrine|treats|patients|20642208
epinephrine|uses|epinephrine|20642208
epinephrine|isa|treatments|20642208
antihistamines|administered_to|patients|20642208
epinephrine|administered_to|patients|20642208
injectable epinephrine|treats|patients|20642208
epinephrine|treats|hypersensitivity reactions|20642208
spider venom|part_of|wolf|22441089
spider venom|affects|necrotic arachnidism|22441089
muscle relaxants|coexists_with|Opioid analgesics|22352727
Antivenom|treats|symptom|22352727
snake antivenom|administered_to|patients|7573709
snake antivenom|administered_to|victims|15911942
SAV|treats|patients|15911942
snake antivenom|treats|patients|15911942
SAV|prevents|complications|18356348
antigenic|part_of|nematocyst|6144703
Ziconotide|isa|calcium channel blocker|11060815
ziconotide|treats|chronic pain|11060815
ziconotide|causes|analgesia|11060815
ziconotide|treats|pain|11060815
nonopioid|treats|chronic pain|16845440
ziconotide|coexists_with|ziconotide|16845440
ziconotide|interacts_with|morphine|16845440
Ziconotide|treats|refractory pain|16845440
glucagon|augments|insulin secretion|17566392
enzyme|interacts_with|GLP-1|17566392
liraglutide|isa|GLP-1|17566392
glucagon|inhibits|gastric emptying|17662202
GLP-1 receptors|stimulates|insulin|17662202
drug|treats|type 2 DM|17662202
exenatide|affects|weight loss|18500914
Pramlintide|causes|hypoglycemia|18500914
insulin|compared_with|agents|18500914
exenatide|compared_with|agents|19719703
exenatide|compared_with|placebo|19719703
exenatide|inhibits|HbA|19719703
gastrointestinal hormones|affects|glucose homeostasis|20465123
GLP-1|interacts_with|incretin|20465123
GLP-1|affects|insulin secretion|20465123
GLP-1 receptors|interacts_with|incretin|20465123
agonists|coexists_with|GLP-1 receptor|20465123
Analogues|treats|type 2 diabetes|22158422
glucagon-like peptide-1|affects|appetite|22158422
Liraglutide|stimulates|GLP-1 receptor|22725703
drugs|compared_with|drugs|22853443
liraglutide|isa|drugs|22853443
liraglutide|compared_with|drugs|22853443
drugs|isa|liraglutide|22853443
liraglutide|compared_with|liraglutide|22853443
insulin glargine|associated_with|type 2 diabetes|22853443
exenatide|associated_with|type 2 diabetes|22853443
insulin glargine|compared_with|exenatide|22853443
insulin glargine|part_of|People|22853443
liraglutide|compared_with|rosiglitazone|22853443
exenatide|part_of|People|22853443
exenatide|isa|drugs|22853443
liraglutide|compared_with|exenatide|22853443
liraglutide|isa|drug|22853443
liraglutide|interacts_with|liraglutide|22853443
drug|interacts_with|liraglutide|22853443
liraglutide|compared_with|treatments|22853443
liraglutide|higher_than|treatments|22853443
medication|administered_to|cohorts|23697475
medication|administered_to|control groups|23697475
medication|treats|T2DM|23697475
medication|administered_to|members|23697475
insulin|treats|T2DM|23697475
medication|administered_to|individuals|23697475
medication|administered_to|member|23697475
exenatide|stimulates|Glucagon-Like Peptide-1 (GLP-1) receptors|24923102
HbA|compared_with|exenatide|24923102
glargine|isa|basal insulin|24923102
antihistamines|isa|medications|11235817
medications|treats|symptoms|11235817
histamine H1 receptor antagonists|isa|antihistamines|11235817
antihistamines|treats|symptoms|11235817
histamine H1 receptor antagonists|treats|children|11235817
histamine H1 receptor antagonists|treats|adults|11235817
drugs|causes|sedation|11235817
drugs|causes|cardiotoxicity|11235817
antidote|neg_treats|overdose|11235817
cetirizine|treats|sedation|11235817
antihistamines|treats|children|11235817
strychnine|isa|drug|16457861
neurotransmitter|part_of|brain|16457861
venom|part_of|cell|6301872
venom|interacts_with|sodium channels|6301872
antivenom|treats|children|14705838
Antivenom|administered_to|patients|14705838
antivenom|administered_to|toddlers|14705838
antivenom|administered_to|patients|14705838
antivenom|isa|therapies|23283277
antivenom|uses|antivenom|23283277
antivenom|treats|patients|23283277
C-reactive protein|isa|acute phase serum protein|6363539
C-reactive protein|interacts_with|polysaccharide|6363539
acute phase serum protein|interacts_with|polysaccharide|6363539
CRP|part_of|mice|6363539
CRP|augments|splenic|6363539
CRP|interacts_with|particulate PnC antigens|6363539
PC|treats|mice|6363539
T-independent antigen|neg_affects|antibody response|6363539
PC|interacts_with|particulate antigen|6363539
CRP|disrupts|antibody response|6363539
C-reactive protein|disrupts|antibody responses|6363539
Loxosceles deserta venom|part_of|hindlimb|7975131
antivenom|administered_to|patients|9861376
enzymes|affects|hydrolysis|19689415
enzymes|coexists_with|glycerophospholipids|19689415
leukotrienes|interacts_with|lipid mediators|19689415
prostaglandin|interacts_with|lipid mediators|19689415
enzymes|associated_with|tumor|19689415
silk|coexists_with|medicine|21658450
medication|treats|hyperglycemia|18266113
Exenatide|isa|medication|18266113
Exenatide|associated_with|type 2 diabetes|18266113
Exenatide|treats|hyperglycemia|18266113
anti-hyperglycemic agent|treats|patients|18266113
exenatide|treats|patients|18266113
exenatide|treats|type 2 diabetes|18266113
exenatide|treats|Asian|18266113
Exenatide|inhibits|blood glucose|18093209
Exenatide|prevents|insulin resistance|18093209
Hymenoptera Venom|treats|insect sting allergy|11720652
Vespula venom|causes|adverse effects|16892788
venom|inhibits|IgE|17441797
tryptase|associated_with|anaphylaxis|20485157
venom|affects|platelet aggregation|7080054
venom|affects|fibrinolysis|7080054
tGLP-1|inhibits|blood glucose|15240633
exendin-4|treats|volunteers|15240633
exendin-4|treats|type 1 diabetes|15240633
insulin|inhibits|glucagon|15240633
insulin|associated_with|type 1 diabetes|15240633
opioid|treats|severe chronic pain|15578997
ziconotide|isa|analgesics|15578997
ziconotide|treats|patients|15578997
ziconotide|isa|drugs|15578997
calcium channel blocker|treats|severe chronic pain|15578997
oral morphine|neg_treats|severe pain|19530373
morphine|treats|patients|19530373
morphine|treats|pain|19530373
tricyclic|treats|patients|19530373
antiepileptic drugs|treats|patients|19530373
ziconotide|treats|pain|19530373
ziconotide|treats|patients|19530373
ziconotide|compared_with|morphine|19530373
antiepileptic drugs|treats|neurogenic pain|19530373
tricyclic|treats|neurogenic pain|19530373
ziconotide|compared_with|placebo|19530373
ziconotide|augments|pain|19530373
ziconotide|associated_with|neurogenic pain|19530373
incretin|treats|patients|17292977
incretin|treats|type 2 diabetes|17292977
Exenatide|stimulates|GLP-1 receptor|17292977
GLP-1|stimulates|adenylate cyclase|17292977
glucose|treats|diabetic|17292977
glucose|treats|mice|17292977
insulin|treats|mice|17292977
exenatide|interacts_with|GLP-1 receptor|17292977
Ziconotide|inhibits|N-type voltage-sensitive calcium channels|14709577
ziconotide|treats|pain|14709577
ziconotide|treats|patients|14709577
ziconotide|administered_to|Patients|14709577
ziconotide|administered_to|patients|14709577
ziconotide|treats|refractory pain|14709577
anatoxin|administered_to|patient|16225115
acetylcholine antagonists|treats|rodent pain models|16539838
opioid|associated_with|analgesia|16539838
cholinergic system|associated_with|analgesia|16539838
naloxone|inhibits|analgesic effects|16539838
Atropine|inhibits|analgesic effects|16539838
cobra venom|causes|analgesia|16539838
analgesic|treats|chronic intractable pain|16599651
ziconotide|compared_with|placebo|16599651
ziconotide|higher_than|placebo|16599651
Ziconotide|treats|withdrawal symptoms|16703976
non-opioid analgesic|treats|chronic pain|18050098
drug|treats|patients|18050098
Ziconotide|treats|neuropathic pain|18050098
opioid|isa|drug|18227325
drug|treats|severe chronic pain|18227325
opioid|treats|severe chronic pain|18227325
Ziconotide|treats|severe chronic pain|18227325
Ziconotide|isa|drug|18227325
ziconotide|administered_to|patients|18227325
ziconotide|treats|patients|18227325
ziconotide|treats|refractory chronic pain|18227325
ziconotide|treats|severe chronic pain|18227325
morphine|treats|patients|18366507
morphine|treats|pain|18366507
morphine|treats|severe chronic pain|18366507
ziconotide|treats|patients|18366507
ziconotide|treats|patients|18366508
ziconotide|administered_to|Patients|18366508
ziconotide|coexists_with|morphine|18366508
morphine|treats|patients|18366508
ziconotide|administered_to|patients|18366508
ziconotide|treats|severe chronic pain|18366508
conotoxins|associated_with|cancer|18781995
conotoxins|associated_with|psychiatric disorders|18781995
Ziconotide|isa|conotoxin|19034250
calcium channels|disrupts|perception|19034250
drug|treats|severe chronic pain|19034250
drug|treats|chronic pain|19034250
ziconotide|treats|severe chronic pain|19668287
ziconotide|treats|intractable pain|19668287
opioid|treats|patients|19668287
opioid|treats|refractory chronic pain|19668287
ziconotide|treats|patients|19668287
ziconotide|treats|refractory chronic pain|19668287
ziconotide|treats|pain|19668287
ziconotide|isa|analgesics|19740270
opioid|isa|drugs|19740270
drug|treats|chronic pain|19740270
drug combinations|treats|chronic pain|19740270
nonopioid intrathecal analgesic|isa|drug|22082570
Ziconotide|isa|drug|22082570
morphine|treats|pain|22082570
opioids|coexists_with|morphine|22082570
ziconotide|treats|pain|22082570
opioids|coexists_with|ziconotide|22082570
morphine|treats|refractory cancer pain|22082570
ziconotide|treats|refractory cancer pain|22082570
Ziconotide|isa|analgesic agent|22996851
ziconotide|affects|adverse events|22996851
ziconotide|inhibits|adverse events|22996851
drug|affects|adverse events|22996851
ziconotide|treats|refractory cancer pain|22996851
magnesium|inhibits|analgesic|23039299
magnesium|administered_to|Patients|23039299
magnesium|compared_with|placebo|23039299
Ziconotide|treats|chronic pain|23537340
ziconotide|isa|drugs|23537340
non-opioid intrathecal analgesic|treats|patients|23999971
non-opioid intrathecal analgesic|treats|chronic pain|23999971
ziconotide|isa|non-opioid intrathecal analgesic|23999971
ziconotide|treats|patients|23999971
ziconotide|treats|patients|23999971
ziconotide|treats|refractory noncancer-related pain|23999971
ziconotide|treats|cancer|23999971
ziconotide|administered_to|patients|23999971
ziconotide|treats|severe, unremitting pain|23999971
ziconotide|treats|chronic pain|23999971
yessotoxin|interacts_with|toxins|11602282
Yessotoxin|compared_with|intraperitoneal injections|11602282
venom|causes|acute myocardial infarction|8752202
antivenin|treats|patient|9663693
antivenin|part_of|Vipera palaestinae|9663693
antivenin|treats|patients|9663693
venom|part_of|sciatic nerve|16328169
venom|part_of|animals|16328169
venom|affects|nerve damage|16328169
integrins|affects|cell adhesion|19502781
collagen receptors|affects|adhesion|19502781
integrin|affects|cells|19502781
alpha1beta1 integrin|affects|cells|19502781
edrophonium|treats|patients|7570895
drugs|treats|patients|7570895
antivenom|treats|bleeding|7611559
hemostatic|interacts_with|antivenom|7611559
antivenom|treats|patients|7660450
antivenom|administered_to|patients|7660450
antivenom|treats|bites|7660450
taipan venom|causes|HUS|9423222
venom|causes|cardiovascular collapse|22771951
taipan venom|part_of|Papuan|22771951
taipan venom|causes|hypotension|22771951
Venom|causes|cardiovascular collapse|22771951
heparin|prevents|collapse|22771951
venom|causes|collapse|22771951
indomethacin|prevents|collapse|22771951
Venom|neg_affects|hearts|22771951
Venom|stimulates|indomethacin|22771951
Venom|stimulates|Rp-8-CPT-cAMPs|22771951
Venom|stimulates|IbTx|22771951
autacoids|affects|protein kinase A cascade|22771951
F(ab|part_of|equine|11450339
antivenom|part_of|king cobra|17156231
antivenom|causes|anaphylaxis|17156231
Exenatide|disrupts|food intake|16985091
metformin|treats|unable|16985091
exenatide|compared_with|placebo|16985091
insulin glargine|treats|patients|16985091
Exenatide|treats|type 2 diabetes|16985091
toxin|causes|lesion|15313850
venom|administered_to|Wistar rats|18845177
Tsv|causes|oedema|18845177
Tsv|causes|dependent paw oedema|18845177
Tsv|causes|inflammatory response|18845177
COX-2|associated_with|inflammatory response|18845177
Tsv|causes|pain|18845177
COX-2|interacts_with|Tsv|18845177
scorpion venom|stimulates|Inflammatory mediators|18845177
scorpion venom|affects|mechanics|19470319
scorpion venom|affects|inflammation|19470319
venom|causes|acute lung injury|19470319
EXE|prevents|hyperglucagonemia|21216851
EXE|prevents|glucose intolerance|21216851
exenatide|produces|exenatide|23425609
exenatide|coexists_with|antidiabetic agents|23425609
basal insulin|treats|patients|23425609
Exenatide|treats|patients|23425609
Exenatide|compared_with|basal insulin|23425609
Exenatide|higher_than|basal insulin|23425609
exenatide|treats|patients|23425609
GRP|affects|gastrointestinal motility|11159876
GRP|affects|gallbladder contraction|11159876
GRP|affects|gastric emptying|11159876
saline|isa|buffer|11856115
omega-agatoxin IVA|isa|calcium channel blocker|12499053
voltage-gated calcium channels|affects|disorders|12499053
bicuculline|treats|rat|12499053
analgesic|isa|medications|19477168
nicotinic acetylcholine receptors|inhibits|alpha-Conotoxins|19477168
peptides|augments|recovery|19477168
GABA-B receptors|part_of|Xenopus oocytes|19477168
GABA-B receptors|part_of|cells|19477168
alpha-Conotoxins|inhibits|nicotinic acetylcholine receptors|20889259
GABA|associated_with|pain|20889259
nAChRs|associated_with|pain|20889259
alpha-Conotoxin AuIB|inhibits|nAChR|20889259
alpha-conotoxins|inhibits|nAChR|20889259
peptides|interacts_with|alpha-conotoxins|22306793
alpha-conotoxins|administered_to|rats|22306793
allergen|interacts_with|bovine serum albumin|23285945
Conantokin-G|inhibits|aspartate|10871336
Con-G|disrupts|brain infarction|10871336
BmK|interacts_with|PTZ|14687481
glutamate|isa|neurotransmitter|14687481
BmK|inhibits|glutamate|14687481
BmK|inhibits|INa|14687481
BmK|stimulates|INa|14687481
drug|treats|epilepsy|14687481
pentylenetetrazol|treats|Rats|14687481
excitatory neurotransmitter|affects|synaptic transmission|15857299
NMDA receptor antagonists|treats|neurological diseases|15857299
glutamate|associated_with|ischemic brain injury|15857299
exendin-4|affects|diabetic retinopathy|20688733
E4a|treats|Rats|20688733
E4a|inhibits|glutamate|20688733
GLP-1R|disrupts|retina|20688733
glutamate|part_of|retina|20688733
glutamate|part_of|retinal|20688733
exendin-4|treats|rats|20688733
Conantokin-G|inhibits|NMDA receptors|19010337
omega-conotoxin MVIIA|causes|side effects|19010337
analgesic|coexists_with|peptides|19010337
nitric oxide donor|compared_with|amlodipine|19166832
aspartate|interacts_with|cilnidipine|19166832
NMDA|causes|retinal damage|19166832
drug|causes|glaucoma|19166832
drug|causes|occlusion|19166832
drug|causes|cell death|19166832
disintegrin|disrupts|platelet aggregation|10446992
basic fibroblast growth factor|stimulates|Salmosin|10446992
vitronectin|interacts_with|salmosin|10446992
salmosin|disrupts|tumor growth|10446992
salmosin|disrupts|tumor angiogenesis|10446992
Integrins|affects|cellular adhesion|23378223
alphavbeta8 integrins|part_of|blood vessels|23378223
transforming growth factor-beta|part_of|cell lines|23378223
cilengitide|interacts_with|Smad2|23378223
transforming growth factor-beta|augments|inactive|23378223
antiangiogenic agent|associated_with|glioblastoma|23378223
cilengitide|disrupts|phosphorylation|23378223
transforming growth factor-beta|associated_with|glioblastoma|23378223
Integrin|interacts_with|transforming growth factor-beta|23378223
gut hormone|affects|glucose metabolism|18633100
gut hormone|affects|cardiovascular function|18633100
exendin-4|part_of|mice|18633100
Ex4|affects|vascular|18633100
GLP|inhibits|reactive oxygen species|18633100
GLP-1|affects|peripheral blood flow|18633100
glucagon-like peptide-1|affects|blood flow|18633100
glucagon-like peptide-1|affects|insulin sensitivity|18633100
Advanced glycation end products|associated_with|diabetic nephropathy|23159951
receptor|associated_with|diabetic nephropathy|23159951
Asymmetric dimethylarginine|inhibits|nitric oxide synthase|23159951
glucagon-like peptide-1|disrupts|inflammatory reactions|23159951
GLP-1|interacts_with|reactive oxygen species|23159951
ADMA|treats|rats|23159951
small-interfering RNAs|inhibits|GLP-1|23159951
GLP-1|inhibits|RAGE|23159951
GLP-1|inhibits|ADMA|23159951
GLP-1|inhibits|ROS|23159951
GLP-1|inhibits|PRMT-1|23159951
agonist|inhibits|ADMA|23159951
agonist|inhibits|asymmetric dimethylarginine|23159951
capsaicin|augments|voltage sensitive calcium channels|9211477
calcium channel blockers|affects|normal sensory|9211477
capsaicin|treats|rats|9211477
omega-conotoxin MVIIA|treats|rats|17717191
calcium channel blocker|administered_to|patients|10834782
ziconotide|isa|calcium channel blocker|10834782
ziconotide|administered_to|patients|10834782
drug|administered_to|patients|10834782
ziconotide|administered_to|patients|10834782
ziconotide|treats|patients|10834782
Ziconotide|isa|calcium channel blocker|10834782
calcium channel blocker|treats|acute postoperative pain|10834782
Ziconotide|treats|acute postoperative pain|10834782
tryptase|part_of|patients|16889279
medications|treats|cardiac disease|17620826
beta-blockers|interacts_with|drugs|17620826
beta-blockers|augments|anaphylaxis|17620826
BTC|part_of|patients|20100187
mAb|part_of|murine|20109740
omalizumab|treats|chronic urticaria|20109740
tryptase|associated_with|stings|21554093
medications|causes|anaphylaxis|21659864
Cilengitide|isa|antiangiogenic agent|17693653
cilengitide|treats|patients|17693653
cilengitide|treats|solid tumors|17693653
venom|part_of|mice|11405281
antivenoms|interacts_with|venom|20890557
peptides|interacts_with|sodium|22450487
antivenom|treats|paralysis|20701896
antivenom|associated_with|neuroparalysis|20701896
Neostigmine|treats|patients|20701896
alpha-smooth muscle actin|part_of|smooth muscle|24363240
autoantibodies|disrupts|spleen|24363240
alpha-smooth muscle actin|disrupts|spleen|24363240
Lachesis muta venom|affects|scleroderma|24363240
Zn|affects|scleroderma|24363240
Se|affects|scleroderma|24363240
Integrins|isa|cell adhesion molecules|17017851
integrin|associated_with|tumor angiogenesis|17017851
integrin alphavbeta3|isa|integrins|17017851
Integrins|associated_with|pathological angiogenesis|17979731
venoms|interacts_with|integrins|17979731
contortrostatin|isa|disintegrin|17979731
chemotherapeutic agents|treats|cancer|17979731
disintegrins|disrupts|angiogenesis|17979731
exenatide|compared_with|glibenclamide|20151774
exenatide|stimulates|glibenclamide|20151774
FPG|stimulates|glibenclamide|20151774
exenatide|inhibits|PPG|20151774
exenatide|inhibits|Resistin|20151774
glibenclamide|treats|insulin resistance|20151774
exenatide|treats|insulin resistance|20151774
glibenclamide|treats|diabetes|20151774
glibenclamide|treats|patients|20151774
Exenatide|treats|diabetes|20151774
Exenatide|treats|patients|20151774
Exenatide|compared_with|glibenclamide|20151774
FPPr|coexists_with|metformin|23984793
FPPr|coexists_with|exenatide|23984793
beta hCG|isa|hCG|11925119
hCG receptor|part_of|culture cells|11925119
hCG receptor|part_of|tumor|11925119
beta hCG|affects|cell line|11925119
hCG receptor|part_of|cells|11925119
hCG receptor|part_of|tissues|11925119
Hecate-betaCG|augments|cell types|12784188
inhibin alpha-subunit|part_of|Transgenic (TG) mice|15967102
Hecate-CGbeta|neg_augments|apoptosis|15967102
exendin-4|isa|incretin|19120286
Ex-4|affects|cell proliferation|19120286
drugs|treats|pain|17168706
Venoms|isa|complex mixtures|17168706
Venoms|interacts_with|ion channel|17168706
complex mixtures|interacts_with|ion channel|17168706
omega-conotoxin|affects|voltage sensitive calcium channels|20002322
ziconotide|compared_with|flupirtine|20002322
supernatants|part_of|whole-blood|16776670
medication|treats|diseases|18286468
IL-4|coexists_with|genes|18286468
medication|treats|mice|18286468
immunomodulator|isa|medication|18286468
immunomodulator|treats|mice|18286468
omega-conotoxin MVIIA|treats|injury|11430886
dexmedetomidine|inhibits|slope|12542459
drugs|treats|chronic pain|12542459
dexmedetomidine|treats|rabbit|12542459
dexmedetomidine|inhibits|allodynia|15627431
dexmedetomidine|treats|hypersensitivity|15627431
nonopioid|treats|chronic pain|16225359
ziconotide|compared_with|placebo|16225359
Ziconotide|treats|patients|16225359
Ziconotide|treats|refractory pain|16225359
Ziconotide|isa|calcium channel blocker|18518786
calcium channel blocker|treats|chronic pain|18518786
Ziconotide|treats|chronic pain|18518786
ziconotide|administered_to|Patients|18518786
amlodipine|prevents|cerebral edema|20048438
omega-conotoxin|disrupts|cell death|20048438
Prialt|treats|chronic pain|22608964
calcium channel blockers|treats|chronic pain|22608964
voltage-gated calcium channels|interacts_with|analgesic|22725651
voltage-gated calcium channels|coexists_with|peptide|22725651
complete Freund's adjuvant|causes|neuropathic pain|22869352
omega-conotoxins|coexists_with|Ca2|23470283
omega-conotoxin|associated_with|adverse effects|23470283
conotoxins|disrupts|neurotransmission|23713957
omega-conotoxin MVIIA|inhibits|hyperalgesia|24148893
omega-conotoxin MVIIA|treats|pain|24148893
VGCC|coexists_with|paclitaxel|24148893
analogue|interacts_with|cytokines|20410202
Exendin-4|treats|Wistar rats|20410202
anti-interferon-gamma antibody|causes|total recovery|20410202
Glucagon-like peptide-1|augments|insulin secretion|21253697
GLP-1|affects|diabetic nephropathy|21253697
exendin-4|affects|macrophages|21253697
exendin-4|affects|glomerular endothelial cells|21253697
type IV collagen|affects|kidney tissue|21253697
agonists|prevents|disease progression|21253697
agonist|treats|renal injury|21253697
exendin-4|treats|type 2 diabetes mellitus|23709595
Ex-4|treats|dysfunction|23709595
Ex-4|affects|diabetic cardiomyopathy|23709595
Ex-4|interacts_with|Ex-4|23709595
Ex-4|associated_with|left ventricular dysfunctions|23709595
antioxidants|inhibits|NADPH oxidase 4|23709595
glutathione peroxidase|inhibits|NADPH oxidase 4|23709595
agonism|treats|imbalance|23709595
ammodytin L|causes|necrosis|8835336
toxin|neg_causes|morphological change|8835336
ammodytin L|affects|muscular cells|8835336
chloride channels|part_of|epithelial cells|16183882
adenosine triphosphate|part_of|cytosolic|16183882
adenylyl-imidodiphosphate|interacts_with|venom|16183882
BmK|interacts_with|sodium channels|16229835
BmK|stimulates|Fos|16229835
BmK|affects|neurons|16229835
BmK|affects|epileptic seizures|16229835
BmK|causes|epileptic seizures|16229835
Exenatide|treats|type 2 diabetes|17323791
Exenatide|inhibits|gastric emptying|17323791
exenatide|treats|patients|17323791
exenatide|coexists_with|statin|17323791
Exenatide|interacts_with|statin|17323791
venoms|part_of|animal|18620956
chemicals|causes|poisonings|18620956
utrophin|augments|skeletal muscle|10757347
utrophin|augments|skeletal muscles|10757347
dystrophin|part_of|C57BL/10 mice|10757347
adenovirus-delivered antigens|stimulates|utrophin|10757347
snake venom|causes|glomerulonephritis|18551312
beta-galactosidase|part_of|transgenic mice|18551312
vascular endothelial cell growth factor|part_of|cell|18551312
IL-12|augments|monocyte production|11529902
cytokines|disrupts|Th2 cells|11529902
Cytotoxic T lymphocyte associated antigen-4|affects|T lymphocytes|22723841
F(ab|part_of|Patients|9861375
F(ab|part_of|equine|9861375
antivenom|causes|recovery|9861375
collagenase|part_of|liver|11405280
Exenatide|isa|incretin|16278786
metformin|treats|type 2 diabetes|16278786
glucose|compared_with|placebo|16278786
Exenatide|affects|cell|16278786
exenatide|treats|type 2 diabetes|16278786
exenatide|treats|patients|16278786
drug combinations|administered_to|patients|17619527
insulin|associated_with|atherogenesis|17619527
exenatide|treats|diabetes|17619527
pramlintide|treats|diabetes|17619527
insulin|affects|gastric emptying|17619527
amylin|part_of|human|17619527
Pramlintide|treats|patients|17619527
Pramlintide|treats|diabetes|17619527
Exenatide|treats|type 2 diabetes|17619527
Exenatide|treats|patients|17619527
Amylin|isa|Pharmaceuticals|18622276
C-peptide|inhibits|glucagon|18622276
exenatide|treats|transplant recipients|18622276
glucagon|treats|patients|19092720
insulin|affects|gastric emptying|19092720
amylin|part_of|human|19092720
glucagon|treats|type 2 diabetes|19092720
Pramlintide|part_of|human|19092720
Pramlintide|isa|amylin|19092720
glucagon-like peptide 1|interacts_with|receptor|19092720
receptor|associated_with|type 1 diabetes|19092720
GLP-1|affects|gastric emptying|19092720
insulin|associated_with|T1DM|19092720
agonists|treats|children|19092720
amylin analogs|treats|children|19092720
sCT|disrupts|food intake|20554932
Ex-4|stimulates|amylin|20554932
metformin|treats|patients|20580422
exenatide|stimulates|glucagon-like peptide 1 receptor|20580422
pioglitazone|treats|patients|20580422
metformin|treats|type 2 diabetes|20580422
drug|administered_to|patients|20580422
exenatide|inhibits|HbA|20580422
HbA|compared_with|pioglitazone|20580422
HbA|higher_than|pioglitazone|20580422
exenatide|inhibits|pioglitazone|20580422
exenatide|compared_with|pioglitazone|20580422
exenatide|higher_than|pioglitazone|20580422
Amylin|isa|Pharmaceuticals|20580422
insulin glargine|administered_to|people|21138825
HbA1|part_of|participants|21138825
exenatide|stimulates|insulin|21138825
Amylin|isa|Pharmaceuticals|21138825
exenatide|treats|type 2 diabetes|21138825
exenatide|treats|patients|21138825
exenatide|treats|diabetic|22017240
exenatide|treats|patients|22017240
hormones|treats|obesity|22017240
Exenatide|augments|satiety|22017240
exenatide|treats|obesity|22017240
leptin|treats|obesity|22565812
amylin|interacts_with|leptin|22565812
leptin|augments|weight loss|22565812
hormones|treats|obese (DIO) mice|22565812
exendin-4|treats|DIO mice|22565812
exendin-4|compared_with|leptin|22565812
leptin|administered_to|obese mice|22565812
exenatide|treats|type 2 diabetes mellitus|22669803
Amylin|isa|Pharmaceuticals|22669803
sulfonylureas|treats|patients|22669803
metformin|treats|patients|22669803
metformin|treats|type 2 diabetes|22669803
sulfonylureas|treats|type 2 diabetes|22669803
thiazolidinediones|treats|patients|22669803
thiazolidinediones|treats|type 2 diabetes|22669803
exenatide|part_of|patients|22669803
Exenatide|treats|type 2 diabetes|22669803
metformin|treats|type 2 diabetes|22683137
glimepiride|treats|patients|22683137
glimepiride|treats|type 2 diabetes|22683137
exenatide|treats|type 2 diabetes|22683137
exenatide|treats|patients|22683137
exenatide|compared_with|glimepiride|22683137
exenatide|administered_to|patients|22683137
metformin|treats|type-2 diabetes|22683137
glimepiride|treats|type-2 diabetes|22683137
exenatide|treats|type-2 diabetes|22683137
Amylin|isa|Pharmaceuticals|22683137
Exenatide|treats|type 2 diabetes|22683137
Exenatide|treats|patients|22683137
Exenatide|compared_with|glimepiride|22683137
exenatide|treats|type 2 diabetes|23141817
exenatide|treats|patients|23141817
liraglutide|treats|type 2 diabetes|23141817
liraglutide|treats|patients|23141817
exenatide|compared_with|liraglutide|23141817
antihyperglycaemic|isa|drugs|23141817
Exenatide|treats|type 2 diabetes|23141817
Exenatide|treats|patients|23141817
Exenatide|compared_with|liraglutide|23141817
Exenatide|treats|type 2 diabetes mellitus|24039406
Amylin|isa|Pharmaceuticals|24039406
exenatide|treats|T2DM|19459763
exenatide|treats|patients|19459763
exenatide|administered_to|patients|19459763
exenatide|inhibits|HbA(1c|19459763
exenatide|treats|type 2 diabetes|19459763
exenatide|treats|metabolic syndrome|19459763
exenatide|treats|type 2 diabetes|19930004
exenatide|treats|type 2 diabetes|20557887
exenatide|inhibits|lipid|20557887
exenatide|inhibits|lipoprotein|20557887
exenatide|interacts_with|lipids|20557887
exenatide|interacts_with|apolipoproteins|20557887
exenatide|interacts_with|lipoproteins|20557887
exenatide|compared_with|placebo|20557887
Exenatide|coexists_with|lipids|20557887
Exenatide|coexists_with|lipoproteins|20557887
agonist|treats|humans|22492091
exenatide|treats|humans|22492091
exenatide|compared_with|placebo|22492091
apolipoprotein B-100|produces|apolipoprotein B-48|22492091
exenatide|interacts_with|particle|22492091
exenatide|affects|glucose homeostasis|22492091
lipoprotein|part_of|intestinal|22492091
Exenatide|stimulates|glucagon-like peptide-1 receptor|22492091
agonist|inhibits|lipoprotein|22492091
exenatide|stimulates|GLP-1 receptor|23078638
Exenatide|stimulates|glucagon-like peptide 1 receptor|23166441
exenatide|treats|type 2 diabetes|23166441
exenatide|treats|patients|23166441
Exenatide|stimulates|high-density lipoprotein-2 cholesterol|23166441
exenatide|coexists_with|lipid|23166441
exenatide|stimulates|glucagon-like peptide-1 (GLP-1) receptor|23522121
agonist|compared_with|oral glucose-lowering medication|23522121
metformin|treats|patients|23522121
exenatide|treats|type 2 diabetes|23522121
exenatide|treats|patients|23522121
exenatide|compared_with|oral glucose-lowering medications|23522121
toxin|affects|toxin hemolytic activity|11005650
toxin|part_of|erythrocytes|11005650
toxin|coexists_with|toxin|11005650
BQ123|treats|Sprague-Dawley rats|9285935
BQ123|inhibits|pressor|9285935
antivenin|part_of|crotalid|15634863
metformin|treats|obesity|22681705
metformin|treats|patients|22681705
metformin|treats|pre-diabetes|22681705
exenatide|compared_with|metformin|22681705
exenatide|inhibits|Triglycerides|22681705
metformin|treats|obese|22681705
alpha1-syntrophin|affects|muscle regeneration|12221071
alpha1-syntrophin|causes|muscle hypertrophy|12221071
cytokines|affects|muscle regeneration|12819025
chemokine receptors|affects|macrophages|12819025
chemokines|affects|macrophages|12819025
osteopontin|affects|inflammation|12819025
osteopontin|affects|tissue repair|12819025
cardiotoxin|isa|injection|12819025
cardiotoxin|precedes|expression|12819025
exendin-4|disrupts|adhesion|20068138
apoE|disrupts|adhesion|20068138
exendin-4|inhibits|CD11b|20068138
exendin-4|treats|lesion|20068138
agonist|disrupts|adhesion|20068138
metformin|treats|patients|21284481
metformin|treats|type 2 diabetes mellitus|21284481
exenatide|treats|type 2 diabetes mellitus|21284481
exenatide|treats|patients|21284481
exenatide|interacts_with|prostaglandin F2alpha|21284481
exenatide|interacts_with|C-reactive protein|21284481
glucose|compared_with|placebo|21284481
PGF2alpha|part_of|maker|21284481
exenatide|inhibits|free fatty acids|22013105
venom|converts_to|peptide|15690125
Chlorotoxin|associated_with|tumor|15690125
Chlorotoxin|administered_to|patients|15690125
iodine-131|treats|glioma|16877732
131I-TM-601|administered_to|patients|16877732
receptor|part_of|glioma|21185076
Chlorotoxin|interacts_with|receptor|21185076
Exendin-4|stimulates|glucagon-like peptide 1 (GLP-1) receptor|11404233
saline|treats|volunteers|11404233
exendin-4|part_of|Volunteers|11404233
glucose|treats|type 2 diabetes|11404233
glucose|treats|volunteers|11404233
Exendin-4|inhibits|fasting|11404233
EX4|treats|normoglycemic|12736719
EX4|treats|rats|12736719
EX4|administered_to|Rats|12736719
EX4|neg_interacts_with|insulin|12736719
EX4|neg_interacts_with|leptin|12736719
EX4|neg_interacts_with|glucagon|12736719
EX4|stimulates|GLP-1 receptors|12736719
EX4|affects|glucose metabolism|12736719
Exenatide|treats|diabetes|14700743
Exenatide|treats|patients|14700743
glucagon|augments|insulin secretion|14700743
exendin-4|treats|disease progression|14700743
exendin-4|disrupts|apoptosis|14700743
GLP-1|stimulates|cell mass via stimulation|14700743
cell mass via stimulation|augments|cell proliferation|14700743
exendin-4|treats|type 2 diabetes|14700743
peptide hormone|augments|insulin secretion|15155141
peptide hormone|inhibits|glucagon|15155141
peptide hormone|disrupts|appetite|15155141
peptide hormone|disrupts|food intake|15155141
dipeptidyl peptidase IV|interacts_with|hormone|15155141
GLP-1 receptor|inhibits|DPP-IV|15155141
antidiabetic agents|treats|patients|15155141
antidiabetic agents|treats|indicated|15155141
agonists|treats|type 2 diabetes mellitus|15155141
Exenatide|causes|nausea|15343588
Exenatide|causes|vomiting|15343588
insulin|treats|patients|15346979
insulin|treats|type 2 diabetes|15346979
metformin|treats|type 2 diabetes|15346979
Exenatide|isa|therapeutic agents|15386269
exenatide|inhibits|blood glucose|15386269
9-27|coexists_with|DMSO|15386269
exenatide|treats|type 2 diabetes|15504997
exenatide|treats|patients|15504997
glucose|compared_with|placebo|15504997
liraglutide|treats|type 2 diabetes|15562141
liraglutide|treats|patients|15562141
exenatide|treats|type 2 diabetes|15562141
exendin-4|treats|human|15562141
exenatide|treats|patients|15562141
NN2211|isa|liraglutide|15562141
liraglutide|treats|human|15562141
NN2211|treats|human|15562141
insulin|inhibits|glucagon|15562141
glucagon|affects|gastric emptying|15562141
glucagon|affects|early satiety|15562141
GLP-1|affects|cell function|15562141
glucagon|augments|insulin secretion|15811484
glucagon|inhibits|gastric emptying|15811484
exenatide|treats|type 2 diabetes mellitus|15811484
exenatide|treats|patients|15811484
exenatide|compared_with|injection|15811484
incretin|associated_with|type 2 diabetes|15831781
Exenatide|isa|incretin|15831781
Exenatide|associated_with|type 2 diabetes|15831781
exenatide's|interacts_with|acetaminophen|15831781
incretin|interacts_with|exenatide|15855571
metformin|treats|type 2 diabetes|15855571
exenatide|treats|type 2 diabetes|15855571
exenatide|treats|patients|15855571
exenatide|treats|patients|15855572
exenatide|treats|type 2 diabetes|15855572
Incretin hormones|augments|cell function|15860408
Incretin hormones|augments|growth|15860408
Incretin hormones|treats|diabetes|15860408
Incretin hormones|augments|satiety|15860408
Exenatide|treats|type 2 diabetes|15929678
glucose|treats|patients|15929678
glucose|treats|type 2 diabetes|15929678
Exenatide|inhibits|fasting|15929678
exenatide|coexists_with|glucose|15929678
exenatide|administered_to|patients|15929678
exenatide|compared_with|placebo|15929678
metformin|treats|type 2 diabetes|15929678
Exenatide|treats|patients|15929678
Exenatide|isa|incretin|16060703
exenatide|interacts_with|HbA|16060703
metformin|treats|type 2 diabetes|16060703
insulin glargine|treats|patients|16060703
insulin glargine|treats|type 2 diabetes|16060703
exenatide|treats|type 2 diabetes|16060703
exenatide|treats|patients|16060703
exenatide|part_of|patients|16060703
drugs|treats|type 2 diabetes|16137221
incretin|treats|patients|16137221
exenatide|augments|insulin secretion|16144950
exenatide|treats|patients|16144950
GLP-1|stimulates|c-Fos|16154233
insulin|treats|patients|16230722
insulin|treats|type 2 diabetes mellitus|16230722
insulin|administered_to|Physicians|16230722
metformin|treats|patients|16230722
metformin|treats|type 2 diabetes mellitus|16230722
insulin glargine|treats|patients|16230722
insulin glargine|treats|type 2 diabetes mellitus|16230722
insulin glargine|compared_with|metformin|16230722
exenatide|administered_to|patients|16230722
Exenatide|inhibits|insulin glargine|16230722
insulin glargine|inhibits|exenatide|16230722
exenatide|associated_with|nocturnal hypoglycemia|16230722
Exenatide|treats|type 2 diabetes|16230722
insulin glargine|treats|type 2 diabetes|16230722
Exenatide|treats|patients|16230722
Exenatide|compared_with|insulin glargine|16230722
glucagon|inhibits|gastric emptying|16341288
exenatide|disrupts|insulin secretion|16341288
glucose|inhibits|glycated hemoglobin|16341288
peptide hormone|part_of|intestinal|16370928
exendin-4|treats|patients|16370928
medicines|treats|Type 2 diabetes|16370928
exendin-4|treats|type 2 diabetes mellitus|16447056
exendin-4|treats|pigs|16447056
Exenatide|treats|Type 2 diabetes|16492205
Exenatide|treats|patients|16492205
exenatide|administered_to|patients|16492205
glucose|treats|patients|16492205
glucose|treats|Type 2 diabetes|16492205
antidiabetic agent|treats|patients|16534527
antidiabetic agent|treats|type 2 diabetes|16534527
Exenatide|isa|incretin|16534527
leptin|interacts_with|exenatide|16534527
agonism|treats|rodents|16534527
exenatide|affects|consumption|16534527
exenatide|treats|Sprague-Dawley rats|16534527
exenatide|treats|C57BL/6 mice|16534527
Exenatide|treats|mice|16534527
exenatide|inhibits|weight gain|16534527
exenatide|treats|rodents|16534527
exenatide|inhibits|HbA|16634116
exenatide|treats|participants|16634116
HbA|part_of|patients|16634116
metformin|treats|type 2 diabetes|16634116
sulphonylureas|treats|type 2 diabetes|16634116
Exenatide|treats|type 2 diabetes|16634116
Exenatide|treats|patients|16634116
exendin-4|augments|cell proliferation|16643856
agonist|treats|Type 2 diabetes|16722815
Exenatide|stimulates|glucagon-like peptide 1 receptor|16722815
glucagon|augments|insulin secretion|16722815
incretin|treats|patients|16722815
Exenatide|disrupts|food intake|16722815
incretin|treats|diabetes|16722815
Exenatide|isa|incretin|16722815
Exenatide|treats|patients|16722815
agonist|treats|Type 2 diabetes mellitus|16722815
exenatide|isa|antidiabetic drug|16772206
incretin|augments|insulin secretion|16772206
GLP-1|inhibits|glucagon|16772206
Exenatide|isa|analogue|16772206
Exenatide|coexists_with|sulfonylureas|16772206
Exenatide|isa|antidiabetic agent|16772206
drug|treats|patients|16772206
drug|treats|diabetes|16772206
drug|treats|obese|16772206
exenatide|treats|diabetes|16772206
exenatide|treats|patients|16776749
exenatide|inhibits|haemoglobin A1c|16776749
Exenatide|inhibits|HbA1c|16776749
incretin|treats|type 2 diabetes|16776751
exenatide|treats|patients|16776751
exenatide|treats|unable|16776751
exenatide|administered_to|patients|16776751
drug|augments|insulin secretion|16782054
Exenatide|isa|drug|16782054
Exenatide|augments|insulin secretion|16782054
Exenatide|disrupts|apoptosis|16782054
Exenatide|isa|drug|16788334
exenatide|treats|type 2 diabetes|16788334
exenatide|treats|patients|16788334
incretin mimetic agent|treats|type 2 diabetes mellitus|16788334
glucagon|affects|gastric emptying|16859392
incretins|treats|Type 2 diabetes mellitus|16859392
exenatide|treats|hepatic steatosis|16953843
exenatide|treats|type 2 diabetes|16953843
alanine aminotransferase|predisposes|liver steatosis|16953843
HbA|coexists_with|HbA|17020425
exenatide|treats|Type 2 diabetes|17020425
exenatide|associated_with|Type 2 diabetes|17020425
incretin hormone|stimulates|insulin|17098089
incretin hormone|inhibits|glucagon|17098089
incretin hormone|inhibits|gastric emptying|17098089
incretin hormone|disrupts|appetite|17098089
incretin hormone|disrupts|food intake|17098089
agonists|disrupts|dipeptidyl peptidase-4 (DPP-4) activity|17098089
haemoglobin A1c|disrupts|fasting|17098089
agonists|affects|adverse event|17098089
DPP-4 inhibitors|inhibits|HbA1c|17098089
peptidase-4 inhibitors|associated_with|type 2 diabetes|17098089
GLP-1|interacts_with|GLP-1|17125767
agonism|affects|axonal structure|17125767
Ex4|affects|secretion pathways|17125767
peptides|associated_with|type II diabetes mellitus|17125767
Leptin|disrupts|food intake|17130484
GLP-1|affects|anorexic|17130484
leptin|disrupts|food intake|17130484
Leptin|stimulates|glucagon-like peptide-1 receptor|17130484
biphasic insulin aspart|treats|patients|17160407
biphasic insulin aspart|treats|type 2 diabetes|17160407
exenatide|treats|type 2 diabetes|17160407
exenatide|treats|patients|17160407
exenatide|compared_with|biphasic insulin aspart|17160407
Exenatide|isa|analog|17195423
glucagon|affects|gastric emptying|17195423
GLP-1|stimulates|insulin|17195423
Exenatide|treats|type 2 diabetes|17195423
Exenatide|stimulates|GLP-1|17201111
Exenatide|treats|humans|17201111
insulin|treats|patients|17220786
insulin|treats|type 1 diabetes|17220786
glucose|causes|insulin secretion|17220786
Glucagon-like peptide-1|stimulates|glucose|17220786
exenatide|affects|insulin secretion|17220786
exenatide|treats|elevated glucose|17220786
exenatide|coexists_with|glucose|17220786
Exenatide|augments|insulin secretion|17220786
exenatide|affects|cell function|17220786
exenatide|isa|drug|17292559
exenatide|treats|fasting|17292559
biotin|treats|fasting|17292559
Exenatide|treats|diabetics|17292559
biotin|treats|diabetics|17292559
metformin|treats|type 2 diabetes|17342635
exenatide|treats|type 2 diabetes|17342635
incretin-mimetic agent|treats|type 2 diabetes mellitus|17342635
metformin|treats|type 2 diabetes|17353504
insulin glargine|treats|type 2 diabetes|17355742
insulin glargine|treats|individuals|17355742
exenatide|compared_with|insulin glargine|17355742
exenatide|treats|type 2 diabetes|17355742
exenatide|treats|individuals|17355742
Exenatide|treats|type 2 diabetes|17355742
insulin glargine|treats|patients|17355742
insulin glargine|treats|type 2 diabetes|17355742
Exenatide|treats|patients|17355742
Exenatide|compared_with|insulin glargine|17355742
incretin hormone|part_of|gut|17360951
exendin-4|affects|diabetes|17360951
exendin-4|treats|mice|17360951
exendin-4|compared_with|exendin-4|17360951
exendin-4|treats|hypertrophy|17360951
peroxisome proliferator-activated receptor alpha|augments|immunoreactivity|17360951
exendin-4|associated_with|diabetic nephropathy|17360951
metformin|treats|type 2 diabetes|17404349
sulfonylureas|treats|type 2 diabetes|17404349
exenatide|compared_with|placebo|17404349
exenatide|associated_with|type 2 diabetes|17404349
Exenatide|treats|type 2 diabetes mellitus|17428109
Exenatide|treats|patients|17428109
drug|compared_with|pioglitazone|17428109
exenatide|treats|type 2 diabetes|17541529
exendin-4|disrupts|food intake|17581835
agonist|disrupts|food intake|17581835
Exendin-4|stimulates|glucagon-like peptide-1 (GLP-1) receptor|17581835
Ex4|affects|food intake|17581835
Ex4|disrupts|food intake|17581835
GLP-1|affects|glucose tolerance|17584962
GLP-1r|part_of|portal vein|17584962
exendin-4|neg_affects|glucose tolerance|17584962
des|inhibits|GLP-1r|17584962
insulin|treats|patients|17595353
insulin|treats|type 2 diabetes|17595353
Immune modulators|treats|type 1 diabetes mellitus|17673522
anti-CD3 monoclonal antibody|treats|NOD mice|17673522
exendin-4|stimulates|glucagon-like peptide-1 receptor|17673522
anti-CD3 monoclonal antibody|treats|T1DM|17673522
anti-CD3 mAb|treats|mice|17673522
anti-CD3 mAb|treats|NOD mice|17673522
glucose|associated_with|diabetes|17673522
glucose|part_of|mice|17673522
antigenicity|part_of|islet cells|17673522
Exendin-4|prevents|diabetogenic|17673522
insulin|associated_with|T1DM|17673522
insulin|treats|mice|17673522
anti-CD3 mAb|treats|T1DM|17673522
anti-CD3 monoclonal antibody|treats|diabetes|17673522
Exenatide|treats|type 2 diabetes|17705687
metformin|treats|type 2 diabetes|17705687
glucose|compared_with|placebo|17705687
metformin|treats|patients|17705687
exenatide|treats|type 2 diabetes|17705687
exenatide|treats|patients|17705687
exenatide|isa|therapeutic agents|17713050
drugs|augments|insulin secretion|17713050
glucagon|inhibits|gastric motility|17713050
drugs|treats|fasting|17713050
insulin|interacts_with|exenatide|17872344
hypoglycemic agents|interacts_with|exenatide|17872344
exenatide|treats|type 2 diabetes|17872344
exenatide|administered_to|patients|17872344
Exenatide|treats|type 2 diabetes|17872344
Exenatide|treats|obese|17872344
Exenatide|treats|patients|17872344
insulin|treats|type 2 diabetes mellitus|17872344
thiazolidinedione|treats|type 2 diabetes mellitus|17896900
glucagon|inhibits|gastric emptying|17896900
Exenatide|inhibits|blood glucose|17896900
drug|treats|patients|17896900
drug|treats|obese|17896900
exenatide|treats|patient|17896900
exenatide|treats|type 1 diabetes mellitus|17896900
exenatide|treats|human immunodeficiency virus infection|17896900
exenatide|treats|patients|17896900
exenatide|treats|type 1 diabetes|17896900
insulin|isa|drugs|17909374
exenatide|isa|drug|17909374
exenatide|compared_with|drugs|17909374
exenatide|compared_with|insulin|17909374
metformin|treats|type 2 diabetes mellitus|17919559
exenatide|isa|medication|17919559
exenatide|associated_with|diabetes mellitus|17919559
glucagon|inhibits|gastric emptying|17931093
glucose|compared_with|metformin|17931093
insulin|treats|patients|17931093
exenatide|treats|patients|17931093
Exenatide|predisposes|hypoglycaemia|17931093
antidiabetic|isa|medication|17940451
glucagon|augments|insulin secretion|17940451
glucagon|inhibits|gastric emptying|17940451
incretin|inhibits|hemoglobin A1c|17940451
Incretins|treats|diabetes|17940451
Exenatide|treats|type 2 diabetes|18087791
Exenatide|treats|adults|18087791
insulin glargine|compared_with|insulin aspart|18087791
exenatide|compared_with|insulins|18087791
exenatide|same_as|insulins|18087791
exenatide|administered_to|patients|18087791
exenatide|treats|patients|18087791
insulin|treats|patients|18087791
insulin|treats|type 2 diabetes|18087791
exenatide|treats|type 2 diabetes|18087791
exenatide|treats|type 2 diabetes|18158075
exenatide|treats|patients|18158075
insulin glargine|treats|patients|18158075
insulin glargine|treats|type 2 diabetes|18158075
glucose|treats|type 2 diabetes|18158075
antidiabetic agent|treats|type 2 diabetes|18158075
glucose|compared_with|antidiabetic agent|18158075
exenatide|coexists_with|HbA|18158075
insulin glargine|compared_with|exenatide|18158075
insulin glargine|coexists_with|HbA|18158075
insulin glargine|treats|patients|18158075
insulin glargine|treats|type 2 diabetes|18158075
medications|treats|diabetes|18173970
metformin|treats|patients|18218179
insulin|inhibits|glycosylated hemoglobin A|18218179
insulin|compared_with|exenatide|18218179
glargine|isa|insulin|18218179
biphasic insulin aspart|isa|insulin|18218179
metformin|treats|overweight|18218179
exenatide|compared_with|insulin|18218179
exenatide|associated_with|type 2 diabetes mellitus|18237357
metformin|treats|type 2 diabetes|18237357
Exenatide|treats|type 2 diabetes|18291606
micronutrients|isa|protein|18347527
hemoglobin A|part_of|patient's|18363534
glucagon-like peptide-1|interacts_with|incretin hormone|18366986
exenatide|treats|type 2 diabetes|18366986
exenatide|treats|patients|18366986
Exenatide|treats|obesity|18366986
Exenatide|treats|diabetes|18366986
Ex4|neg_prevents|diabetes|18374122
Ex4|inhibits|BG|18374122
Ex4|affects|uptake|18374122
Exendin-4|treats|rats|18374122
insulin glargine|inhibits|glucose|18394265
exenatide|affects|hyperglycemia|18394265
exenatide|treats|type 2 diabetes|18394265
insulin glargine|treats|patients|18394265
insulin glargine|treats|type 2 diabetes|18394265
exenatide|treats|patients|18394265
exenatide|affects|graft|18444920
etanercept|affects|graft|18444920
insulin|part_of|patients|18463034
insulin|treats|patients|18463034
insulin|treats|T2DM|18463034
insulin|treats|type 2 diabetes mellitus|18463034
peptide hormone|part_of|intestinal|18473991
GLP-1|augments|insulin secretion|18473991
exendin-4|inhibits|glucose|18473991
exenatide|coexists_with|metformin|18473991
Exenatide|compared_with|insulin glargine|18473991
Exenatide|same_as|insulin glargine|18473991
medicines|treats|type 2 diabetes|18473991
Exenatide|isa|incretin|18491986
vildagliptin|treats|patients|18491986
vildagliptin|treats|type 2 diabetes|18491986
Exenatide|treats|type 2 diabetes|18491986
metformin|treats|renal insufficiency|18491986
peptidase 4 inhibitors|treats|type 2 diabetes|18491986
Incretin hormones|interacts_with|blood glucose|18512528
drugs|affects|insulin secretion|18512528
hormones|treats|type 2 diabetes|18525067
antihyperglycemic|isa|medication|18525067
Incretin hormones|augments|insulin secretion|18525067
incretin|isa|peptide incretin hormone|18525067
dipeptidyl peptidase IV|inhibits|GLP-1|18525067
glucagon|affects|gastric emptying|18525067
exenatide|interacts_with|GLP-1|18525067
agonist|inhibits|DPP-IV|18525067
thiazolidinedione|treats|patients|18525067
exenatide|treats|cardiovascular risk factors|18525067
incretin hormones|affects|type 2 diabetes|18525067
Exenatide|interacts_with|GLP-1|18533126
glucagon|inhibits|gastric emptying|18533126
exenatide|treats|patients|18533126
exenatide|treats|weight loss|18533126
Exenatide|treats|type 2 diabetes|18533126
exenatide|part_of|patients|18555933
antidiabetic|isa|medications|18555933
exenatide|treats|patients|18555933
exenatide|compared_with|placebo|18555933
exenatide|associated_with|hyperglycemic|18555933
exenatide|associated_with|hyperglycemia|18555933
exenatide|treats|type 2 diabetes|18555933
Exenatide|stimulates|receptors|18561773
Exenatide|inhibits|glycated haemoglobin|18561773
metformin|treats|type 2 diabetes|18561773
Exenatide|associated_with|overweight|18561773
Exenatide|treats|type 2 diabetes|18561773
metformin|treats|cardiovascular risk factors|18603639
drugs|treats|type 2 diabetes|18603639
antidiabetic drugs|affects|hyperglycaemia|18630617
hormones|part_of|human|18630617
exenatide|augments|insulin secretion|18630617
antidiabetic drug|treats|type 2 diabetes mellitus|18630617
exenatide|treats|type 2 diabetes mellitus|18662495
exenatide|treats|patients|18662495
Exenatide|treats|diabetes|18694484
exenatide|compared_with|insulin glargine|18694484
exenatide|same_as|insulin glargine|18694484
insulin glargine|coexists_with|insulin glargine|18694484
exenatide|coexists_with|insulin glargine|18694484
exenatide|treats|type 2 diabetes|18694484
insulin glargine|treats|type 2 diabetes|18694484
insulin glargine|compared_with|exenatide|18694484
exenatide|treats|patients|18694484
insulin glargine|treats|patients|18694484
insulin glargine|treats|patients|18694484
insulin glargine|treats|type 2 diabetes|18694484
incretin|treats|patients|18782641
incretin|treats|type 2 diabetes|18782641
Exenatide|isa|incretin|18782641
Exenatide|treats|patients|18782641
exenatide|treats|type 2 diabetes|18782641
exenatide|treats|patients|18782641
exenatide|administered_to|patients|18782641
exenatide|neg_predisposes|hypoglycaemia|18782641
Exenatide|treats|type 2 diabetes|18782641
agonist|interacts_with|exenatide|18786299
exenatide|administered_to|Patients|18786299
exenatide|stimulates|PPG|18786299
exenatide|inhibits|PPG|18786299
exenatide|inhibits|glucagon|18786299
glucagon|treats|patients|18786299
exenatide|inhibits|gastric emptying|18786299
insulin|interacts_with|exenatide|18786299
glucose|interacts_with|exenatide|18786299
glucagon|interacts_with|exenatide|18786299
Exenatide|treats|Type 2 diabetes|18793576
HbA|part_of|patients|18803987
HbA|associated_with|type 2 diabetes|18803987
insulin|treats|type 2 diabetes|18822227
exenatide|causes|weight-loss|18822227
exenatide|treats|patients|18822227
Exenatide|treats|patient|18822227
Exenatide|treats|overweight|18822227
pioglitazone|treats|T2DM|18828960
exenatide|treats|T2DM|18828960
exenatide|coexists_with|pioglitazone|18828960
exenatide|treats|patients|18828960
therapeutic agents|treats|type 2 diabetes mellitus|18957626
exenatide|treats|type 2 diabetes mellitus|18957626
exenatide|compared_with|agents|18957626
exenatide|isa|drugs|18957626
exenatide|compared_with|exenatide|18957626
exenatide|associated_with|type 2 diabetes|18957626
analogues|interacts_with|hypoglycemic|18977255
exendin-4|compared_with|exendin-4|18977255
exendin-4|same_as|exendin-4|18977255
antidiabetic agent|treats|type 2 diabetes|18977255
exendin-4|treats|type 2 diabetes|18977255
exendin-4|isa|antidiabetic agent|18977255
exendin-4|interacts_with|hypoglycemic|18977255
human huntingtin protein|part_of|mice|18984744
agonist|treats|mice|18984744
agonist|treats|Huntington's disease|18984744
exenatide|treats|type 2 diabetes|19019476
exenatide|treats|patients|19019476
exenatide|compared_with|placebo|19019476
exenatide|higher_than|placebo|19019476
metformin|treats|type 2 diabetes|19019476
anti-diabetic agents|treats|type 2 diabetes|19022515
exenatide|inhibits|DPP-4|19022515
Exenatide|neg_causes|hypoglycemia|19048830
Exendin-4|stimulates|glucagon-like peptide-1 (GLP-1) receptor|19084986
GLP-1|interacts_with|blood glucose|19084986
exendin-4|affects|DR|19084986
E4a|treats|rats|19084986
normal saline|treats|rats|19084986
E4a|inhibits|blood glucose|19084986
exendin-4|associated_with|diabetic retinopathy|19084986
exenatide|treats|patients|19095598
exenatide|treats|metabolic syndrome|19095598
medication|treats|endocrine disorders|19095598
exenatide|causes|parameters|19095598
EXN|stimulates|daclizumab|19104401
|treats||19164583
|isa||19164583
|treats||19164583
Ex-4|treats|stroke|19164583
exenatide|treats|type 2 diabetes|19194050
exenatide|treats|patients|19194050
Exenatide|treats|type 2 diabetes|19194050
Exenatide|treats|patients|19194050
insulin glargine|compared_with|metformin|19203299
exenatide|compared_with|metformin|19210140
exenatide|associated_with|T2DM|19210140
exenatide|part_of|patients|19210140
exendin-4|isa|incretin|19217320
Ex-4|associated_with|hyperglycemia|19217320
Ex-4|administered_to|NOD mice|19217320
Exendin-4|treats|nonobese diabetic mice|19217320
Exenatide|isa|incretin|19236187
Exenatide|coexists_with|Exenatide|19236187
Exenatide|coexists_with|incretin|19236187
glucose|treats|diabetic|19236187
glucose|treats|patients|19236187
glucagon|inhibits|gastric emptying|19236187
Exenatide|neg_interacts_with|antidiabetic drugs|19236187
antidiabetic drugs|disrupts|food intake|19236187
Exenatide|treats|type 2 diabetes mellitus|19236187
agonist|treats|type 2 diabetes mellitus|19243286
Exenatide|stimulates|glucagon-like peptide-1 (GLP-1) receptor|19243286
Exenatide|inhibits|blood glucose|19243286
Exenatide|treats|type 2 diabetes|19243286
long-acting insulin|treats|patients|19277932
long-acting insulin|treats|diabetes mellitus|19277932
insulin glargine|compared_with|glimepiride|19277932
insulin glargine|compared_with|rosiglitazone|19277932
insulin glargine|higher_than|rosiglitazone|19277932
exenatide|predisposes|pancreatitis|19278373
exenatide|isa|incretin|19278373
exenatide|compared_with|agents|19278373
exenatide|treats|patients|19278373
exenatide|associated_with|pancreatitis|19278373
Exendin-4|administered_to|Neonatal|19287346
Ex-4|part_of|neonatal|19287346
Ex-4|affects|vascular|19287346
Ex-4|part_of|Neonatal|19287346
Ex-4|administered_to|rats|19287346
Ex-4|prevents|diabetes|19287346
Exendin-4|affects|vascularity|19287346
Exenatide|stimulates|glucagon-like-peptide-1 receptors|19383034
Exenatide|isa|incretin|19383034
incretin|stimulates|glucagon-like-peptide-1 receptors|19383034
glucose|inhibits|glucagon|19383034
exenatide|stimulates|insulin preparations|19383034
Exenatide|treats|diabetic|19383034
Exenatide|treats|patients|19383034
incretins|treats|type 2 diabetes mellitus|19421968
drugs|treats|type 2 diabetes|19421968
glucagon-like peptide 1|inhibits|dipeptidyl peptidase IV|19421968
exenatide|isa|incretins|19421968
drugs|compared_with|agents|19421968
incretin|associated_with|type 2 diabetes mellitus|19421968
exenatide|neg_treats|patients|19446153
exenatide|compared_with|placebo|19446153
exenatide|stimulates|exenatide|19446153
exenatide|treats|type 2 diabetes mellitus|19446153
exenatide|treats|patients|19446153
glucose|treats|participants|19454385
exenatide|treats|participants|19454385
hemoglobin A1c|neg_coexists_with|glucose|19454385
antihyperglycaemic|isa|drugs|19515413
agonists|augments|weight loss|19515413
drugs|stimulates|glucagon-like peptide-1 (GLP-1) receptor|19515413
antihyperglycaemic|stimulates|glucagon-like peptide-1 (GLP-1) receptor|19515413
exenatide|stimulates|GLP-1 receptor|19515413
GLP-1|stimulates|GLP-1 receptor|19515413
liraglutide|isa|GLP-1|19515413
GLP-1|compared_with|exenatide|19515413
liraglutide|compared_with|exenatide|19515413
liraglutide|stimulates|GLP-1 receptor|19515413
Liraglutide|inhibits|HbA|19515413
HbA|compared_with|exenatide|19515413
HbA|higher_than|exenatide|19515413
Liraglutide|inhibits|exenatide|19515413
Liraglutide|inhibits|glucose|19515413
drugs|augments|weight losses|19515413
liraglutide|lower_than|exenatide|19515413
liraglutide|treats|type 2 diabetes|19515413
exenatide|treats|type 2 diabetes|19515413
Liraglutide|compared_with|exenatide|19515413
Liraglutide|treats|type 2 diabetes|19515413
GLP-1|augments|insulin secretion|19545590
Exenatide|isa|analogue|19545590
incretins|inhibits|DPP-4|19545590
glucagon-like peptide|stimulates|exendin-4|19558363
exendin-4|augments|cells|19558363
exenatide|treats|Type 2 diabetes|19573122
agonists|affects|glucose homeostasis|19624785
agonists|affects|cardiovascular risk factors|19624785
Exenatide|treats|type 2 diabetes|19624785
agonists|treats|type 2 diabetes|19624785
exenatide|compared_with|insulin glargine|19640359
Exenatide|compared_with|insulin glargine|19640359
insulin glargine|treats|patients|19640359
insulin glargine|treats|Type 2 diabetes|19640359
Exenatide|treats|Type 2 diabetes|19640359
Exenatide|treats|patients|19640359
Exenatide|treats|type 2 diabetes mellitus|19695400
insulin|treats|T2DM|19695400
insulin|treats|patients|19695400
insulin|interacts_with|exenatide|19695400
insulin|part_of|Patients|19695400
exenatide|inhibits|HbA|19695400
incretin|treats|Type 2 diabetes|19719716
Exenatide|isa|incretin|19719716
Exenatide|treats|Type 2 diabetes|19719716
insulin|treats|woman|19719716
insulin|coexists_with|exenatide|19719716
HbA|inhibits|insulin|19719716
exenatide|treats|Type 2 diabetes|19719716
exenatide|treats|patient|19719716
insulin|inhibits|glucagon|19719716
insulin glargine|treats|patients|19732121
exenatide|compared_with|insulin glargine|19732121
Exenatide|compared_with|insulin glargine|19732121
insulin glargine|associated_with|type 2 diabetes|19732121
GLP-1|augments|insulin secretion|19748064
liraglutide|augments|insulin secretion|19748064
glucose|causes|weight loss|19748064
glimepiride|treats|patients|19758357
glimepiride|treats|type 2 diabetes|19758357
antidiabetic drugs|treats|patients|19770100
antidiabetic drugs|treats|type 2 diabetes|19770100
Exenatide|treats|patients|19770100
Exenatide|isa|antidiabetic drugs|19770100
Exenatide|interacts_with|incretin|19770100
drug|treats|type 2 diabetes|19770100
Exenatide|affects|gastric emptying|19808924
incretin|neg_stimulates|C-peptide|19808924
daclizumab|neg_augments|cells|19808924
exenatide|neg_augments|cells|19808924
daclizumab|interacts_with|exenatide|19808924
glucagon-like peptide-1 receptor|disrupts|apoptosis|19836346
exendin-4|affects|glucose tolerance|19836346
exendin-4|affects|cell proliferation|19836346
exendin-4|treats|mice|19836346
GLP-1|augments|cell growth|19836346
exendin-4|prevents|diabetes|19846744
HGP|treats|rats|19846744
HGP|treats|IUGR|19846744
exendin-4|administered_to|neonatal|19846744
exendin-4|administered_to|rats|19846744
insulin|inhibits|HGP|19846744
exendin-4|prevents|insulin resistance|19846744
Lantus|isa|insulin glargine|19905038
Lantus|isa|antidiabetic agents|19905038
medications|coexists_with|medications|19905038
exenatide|treats|type 2 diabetes mellitus|19905038
insulin glargine|treats|type 2 diabetes mellitus|19905038
drug|coexists_with|exenatide|19905038
drug|compared_with|drug|19905038
exenatide|associated_with|type 2 diabetes mellitus|19905038
exenatide|part_of|patients|19905038
HbA|part_of|patients|19911661
drug combination|treats|patients|19911661
drug combination|treats|type 2 diabetes|19911661
Exenatide|treats|diabetes|19930005
Exenatide|treats|patients|19930005
exenatide|compared_with|insulin glargine|19930005
Exenatide|compared_with|Long-Acting insulin|19930005
Long-Acting insulin|treats|patients|19930005
Long-Acting insulin|treats|diabetes|19930005
Exenatide|treats|overweight|19930005
Long-Acting insulin|treats|overweight|19930005
exenatide|causes|overweight|19930005
insulin glargine|causes|overweight|19930005
Exenatide|compared_with|long-acting insulin|19930005
Exendin-4|stimulates|glucagon-like peptide-1-receptor|20019445
agonist|augments|cell function|20019445
Exendin-4|augments|cell proliferation|20019445
Exendin-4|augments|apoptosis|20019445
hemoglobin A|disrupts|BP|20019672
exenatide|treats|type 2 diabetes|20019672
exenatide|treats|patients|20019672
exenatide|treats|hypertension|20019672
exenatide|affects|systolic blood pressure|20019672
exendin-4|compared_with|penetratin|20060451
penetratin|augments|nasal|20060451
incretin|treats|type 2 diabetes mellitus|20082536
Exenatide|isa|incretin|20082536
Exenatide|treats|type 2 diabetes mellitus|20082536
exenatide|treats|type 2 diabetes mellitus|20082536
incretin|stimulates|GLP-1 receptors|20152707
exendin-4|stimulates|GLP-1 receptor|20152707
lizard venom|stimulates|GLP-1 receptor|20152707
exenatide|augments|energy expenditure|20152707
exenatide|causes|weight loss|20152707
Exenatide|isa|antidiabetic agent|20184107
insulin|treats|patients|20184107
Exenatide|treats|obese|20184107
Exenatide|treats|patients|20184107
GLP-1|affects|food intake|20197503
Exendin-4|stimulates|glucagon-like peptide-1 receptor|20197503
GLP-1|affects|glucose homeostasis|20197503
drug|treats|patients|20197503
drug|treats|type 2 diabetes mellitus|20197503
Ex-4|treats|rats|20197503
Ex-4|inhibits|GLP-1R|20197503
GLP-1|neg_causes|hyperglycemia|20197503
Ex-4|causes|Acute hyperglycemia|20197503
Ex-4|affects|glucose tolerance|20197503
Ex-4|treats|humans|20197503
Exendin-4|stimulates|blood glucose|20197503
exenatide|inhibits|glucose|20200309
exenatide|inhibits|lipid|20200309
exenatide|compared_with|placebo|20200309
triglyceride|interacts_with|exenatide's|20200309
Exenatide|treats|endothelial dysfunction|20200309
exenatide|treats|type 2 diabetes|20200309
exenatide|treats|individuals|20200309
exenatide|treats|impaired glucose tolerance|20200309
insulin|stimulates|blood glucose|20206728
drugs|predisposes|hypoglycemia|20206728
liraglutide|affects|cell function|20206728
vildagliptin|treats|type 2 diabetes mellitus|20298625
DPP-4 inhibitors|compared_with|analogues|20298625
analogues|interacts_with|blood glucose|20298625
DPP-4 inhibitors|causes|weight gain|20298625
drugs|treats|type 2 diabetes|20298625
glucose|interacts_with|Liraglutide|20332351
exenatide|treats|type 2 diabetes|20332351
exenatide|treats|patients|20332351
Exenatide|associated_with|type 2 diabetes|20332358
exenatide|treats|type 1 diabetes|20332358
exenatide|treats|adolescents|20332358
exenatide|associated_with|type 1 diabetes|20332358
EXE|stimulates|MET|20357372
drug|treats|type 2 diabetes|20382777
exenatide|interacts_with|agonist|20382777
drug|affects|food intake|20382777
eNOS|part_of|aortic|20382777
exenatide|treats|hyperplasia|20382777
exenatide|associated_with|obese|20382777
exenatide|prevents|hyperplasia|20382777
metformin|treats|type 2 diabetes|20399326
exenatide|associated_with|overweight|20399326
exenatide|treats|type 2 diabetes|20399326
exenatide|treats|patients|20399326
glucose|interacts_with|blood glucose|20425675
metformin|treats|patient|20425675
metformin|treats|type-2 diabetes|20425675
exenatide|treats|type-2 diabetes|20425675
exenatide|treats|patient|20425675
insulin glargine|treats|patient|20425675
insulin glargine|treats|type-2 diabetes|20425675
exenatide|treats|diabetic|20447851
exenatide|treats|patients|20447851
insulin|part_of|patients|20460445
exenatide|part_of|patients|20460445
exenatide|administered_to|patients|20460445
exenatide|compared_with|insulin|20463421
exenatide|lower_than|insulin|20463421
insulin|treats|weight loss|20463421
exenatide|affects|blood pressure|20463421
Exenatide|compared_with|insulin|20463421
Exenatide|lower_than|insulin|20463421
agonist|treats|type 2 diabetes|20464538
exenatide|stimulates|glucagon-like peptide-1 receptor|20464538
exenatide|isa|incretin|20464538
exenatide|administered_to|participants|20484613
insulin|treats|type 2 diabetes mellitus|20530705
agonist|treats|adults|20530705
agonist|treats|T2DM|20530705
Exenatide|stimulates|GLP-1 receptor|20530705
insulin|treats|weight gain|20530705
exenatide|treats|weight gain|20530705
exenatide|treats|T2DM|20530705
exenatide|treats|type 2 diabetes|20598606
exenatide|treats|patients|20598606
Exenatide|treats|patients|20598606
HbA|inhibits|HbA|20598608
NPH insulin|treats|patients|20615102
NPH insulin|treats|type 2 diabetes mellitus|20615102
exenatide|compared_with|insulin glargine|20615102
hypoglycemic agents|neg_treats|Patients|20615102
hypoglycemic agents|neg_treats|type 2 diabetes mellitus|20615102
insulin glargine|administered_to|patients|20615102
exenatide|treats|Asian Indians|20615102
HbA|compared_with|placebo|20616619
liraglutide|administered_to|Patients|20616619
Exenatide|isa|analogue|20624837
Exenatide|associated_with|type 2 diabetes|20624837
insulin|associated_with|obesity|20624837
insulin|associated_with|type 2 diabetes|20624837
exenatide|associated_with|type 2 diabetes|20624837
Exenatide|treats|type 2 diabetes|20624837
Exenatide|treats|people|20624837
hormones|stimulates|insulin|20644202
Incretins|isa|hormones|20644202
Incretins|stimulates|insulin|20644202
glycated haemoglobin|coexists_with|long-acting insulin|20646668
glycated haemoglobin|coexists_with|DPP-4 inhibitors|20646668
glitazones|treats|hyperglycaemia|20646668
exenatide|treats|patient|20646668
Exenatide|compared_with|glargine|20646668
drugs|causes|fluctuations|20646668
insulins|treats|type 2 diabetes|20646668
long-acting insulin|compared_with|insulins|20646668
long-acting insulin|neg_higher_than|insulins|20646668
long-acting insulin|treats|type 2 diabetes|20646668
insulin|treats|type 2 diabetes|20646668
exenatide|predisposes|pancreatitis|20682680
exenatide|treats|type 2 diabetes|20682680
exenatide|inhibits|insulin|20701787
insulin|treats|control group|20701787
exenatide|administered_to|Patients|20701787
Exenatide|treats|hyperglycemia|20701787
incretin hormone|treats|type 2 diabetes|20736238
GLP-1|augments|blood pressure|20736238
GLP-1|augments|vagus nerve|20736238
Exenatide|isa|incretin|20738033
Liraglutide|isa|incretin|20738033
insulin glargine|treats|patients|20738033
exenatide|treats|patients|20738033
insulin glargine|compared_with|exenatide|20738033
liraglutide|compared_with|glimepiride|20738033
liraglutide|neg_lower_than|glimepiride|20738033
liraglutide|causes|pancreatitis|20738033
liraglutide|compared_with|exenatide|20738033
liraglutide|predisposes|thyroid cancer|20738033
exenatide|treats|adverse effects|20738033
triacylglycerol|part_of|liver|20795946
alpha-glucosidase inhibitors|treats|type 2 diabetes|20809667
sulfonylureas|treats|pathophysiology|20809667
glucose|associated_with|type 2 diabetes|20809667
glucagon|disrupts|appetite|20809667
agonists|augments|insulin secretion|20809667
peptidase-4 (DPP-4) inhibitors|augments|insulin secretion|20809667
triglyceride|inhibits|C-reactive protein|20841306
exenatide|treats|type 2 diabetes mellitus|20841306
CRP|neg_affects|weight loss|20841306
Exenatide|treats|type 2 diabetes|20841306
Exenatide|treats|patients|20841306
exenatide|interacts_with|anti-emetics|20854385
exenatide|disrupts|nausea|20854385
exenatide|disrupts|vomiting|20854385
anti-emetic|isa|medications|20854385
medications|prevents|nausea|20854385
anti-emetic|prevents|nausea|20854385
exenatide|affects|fat deposition|20874425
exenatide|administered_to|Patients|20874425
exenatide|inhibits|systolic blood pressure|20874425
exenatide|inhibits|waist circumference|20874425
exenatide|treats|patients|20874425
exenatide|treats|metabolic syndrome|20874425
exenatide|treats|diabetes|20878660
liraglutide|treats|Individuals|20887303
liraglutide|treats|nausea symptoms|20887303
HbA|disrupts|systolic blood pressure|20887303
exenatide|compared_with|agent|20929995
exenatide|treats|type 2 diabetes|20929995
exenatide|treats|patients|20929995
HbA|compared_with|placebo|20977576
Exenatide|inhibits|HbA|20977576
HbA|higher_than|placebo|20977576
exenatide|compared_with|placebo|20977576
exenatide|inhibits|HbA|20977576
exenatide|treats|hypoglycaemia|20977576
liraglutide|compared_with|exenatide|21034377
exenatide|treats|type 2 diabetes|21034377
liraglutide|treats|type 2 diabetes|21034377
PLGA|treats|type 2 diabetes mellitus|21048339
exenatide|treats|type 2 diabetes mellitus|21048339
hypoglycemic|treats|mice|21126761
exendin-4|treats|diabetes|21126761
agonist|augments|insulin secretion|21142268
glucagon|inhibits|gastric emptying|21142268
Exenatide|stimulates|glucagon-like peptide-1 receptor|21142268
exenatide|treats|type 2 diabetes|21142268
exenatide|treats|patients|21142268
exenatide|compared_with|placebo|21142268
HbA|compared_with|placebo|21142268
exenatide|stimulates|exenatide|21142268
agonists|affects|cells|21144822
exendin-4|affects|cells|21144822
exendin-4|affects|macrophages|21144822
tumor necrosis factor alpha|part_of|macrophages|21144822
inducible nitric oxide synthase|part_of|macrophages|21144822
Exendin-4|stimulates|glucagon-like peptide-1 receptor|21144822
exenatide|treats|type 2 diabetes|21158486
glargine|treats|patients|21158486
glargine|treats|type 2 diabetes|21158486
exenatide|treats|patients|21158486
exenatide|compared_with|glargine|21158486
glargine|part_of|patients|21158486
exenatide|part_of|patients|21158486
glimepiride|treats|T2DM|21194600
liraglutide|compared_with|exenatide|21194600
liraglutide|higher_than|exenatide|21194600
HbA|part_of|patient|21194600
glimepiride|treats|type 2 diabetes|21194600
agonists|inhibits|glucose|21208359
agonist|affects|hyperglycaemia|21208359
agonists|inhibits|haemoglobin A1c|21208359
antidiabetic drugs|inhibits|HbA1c|21208359
HbA1c|compared_with|antidiabetic drugs|21208359
insulin glargine|inhibits|HbA1c|21208359
insulin glargine|inhibits|antidiabetic drugs|21208359
antidiabetic drugs|inhibits|antidiabetic drugs|21208359
exendin-4|associated_with|type 2 diabetes|21215253
agonists|affects|cardiovascular diseases|21215253
exendin-4|affects|thickening|21215253
platelet-derived growth factor|stimulates|exendin-4|21215253
agonist|inhibits|thickening|21215253
Exendin-4|stimulates|glucagon-like peptide-1 receptor|21215253
HbA|part_of|white|21219119
antihyperglycemic|isa|drug|21219119
cholesterol-lowering drug|isa|medication|21219119
exenatide|treats|Patients|21219119
agonist|treats|diabetes mellitus|21227526
Exenatide|stimulates|GLP-1|21227526
Exenatide|affects|weight reduction|21227526
Exenatide|affects|appetite suppression|21227526
Exenatide|treats|age groups|21255526
exenatide|isa|drugs|21266202
drugs|predisposes|type 2 diabetes|21266202
pioglitazone|treats|type 2 diabetes|21270189
exenatide|treats|type 2 diabetes|21270189
metformin|treats|patients|21270189
exenatide|associated_with|hypoglycemia|21285388
Exenatide|treats|type 2 diabetes|21285388
Exenatide|treats|patients|21285388
agonism|treats|patients|21307137
agonism|treats|type 2 diabetes|21307137
exenatide|compared_with|exenatide|21307137
exenatide|treats|type 2 diabetes|21307137
exenatide|treats|patients|21307137
antihyperglycaemic|isa|drugs|21320263
exenatide|isa|drugs|21320263
drugs|isa|exenatide|21320263
drugs|compared_with|drugs|21320263
exenatide|compared_with|drugs|21320263
exenatide|compared_with|exenatide|21320263
exenatide|compared_with|antihyperglycaemic|21320263
exenatide|treats|obesity|21320263
Glucagon-like peptide-1 (GLP-1) receptors|part_of|neural tissues|21323903
agonist|treats|rats|21323903
agonist|treats|Diabetic|21323903
exendin-4|prevents|peripheral nerve degeneration|21323903
GLP-1|associated_with|peripheral neuropathy|21323903
exendin-4|treats|rats|21323903
peptidase-4 inhibitors|causes|cancer|21334333
exenatide|compared_with|therapies|21334333
drugs|predisposes|pancreatic cancer|21334333
exendin-4|treats|type 2 diabetes|21334413
exendin-4|part_of|human|21334413
drug|treats|type 2 diabetes mellitus|21334413
ritonavir|treats|mice|21359201
Exenatide|affects|glucose homeostasis|21359201
insulin|part_of|patients|21410858
exenatide|part_of|patients|21410858
exenatide|inhibits|insulin|21410858
agonist|treats|hyperglycemia|21410975
exenatide|treats|patients|21410975
exendin-4|treats|type II diabetes mellitus|21415845
exendin-4|treats|rats|21415845
liraglutide|treats|rats|21415845
exendin-4|treats|high fat/sucrose diet|21415845
Liraglutide|treats|high fat/sucrose diet|21415845
liraglutide|affects|weight loss|21415845
drugs|treats|obesity|21415845
liraglutide|disrupts|food intake|21415845
exenatide|coexists_with|HbA|21434995
exenatide|administered_to|patients|21434995
glucagon-like peptide-1|interacts_with|Exendin-4|21461562
Exendin-4|administered_to|mice|21461562
exendin-4|associated_with|transient cerebral ischemia|21472764
incretin hormone|augments|insulin secretion|21487412
exendin-4|treats|type 2 diabetes mellitus|21487412
cyclic AMP|part_of|intracellular|21487412
cAMP|part_of|intracellular|21487412
exendin-4|interacts_with|cAMP|21487412
Exendin-4|treats|ischemic stroke|21487412
Exendin-4|stimulates|glucagon-like peptide-1 receptor|21487412
agonist|treats|transient focal cerebral ischemia|21487412
drugs|treats|type 2 diabetes mellitus|21515323
exenatide|affects|fasting|21557790
Exenatide|treats|SBS|21557790
exenatide|treats|short bowel syndrome|21557790
exenatide|treats|type 2 diabetes|21563878
insulin glargine|treats|patients|21563878
insulin glargine|treats|type 2 diabetes|21563878
exenatide|treats|patients|21563878
exenatide|compared_with|insulin glargine|21563878
insulin glargine|associated_with|type 2 diabetes|21563878
exenatide|inhibits|DPP-4|21574000
exenatide|treats|patients|21574000
exenatide|treats|type 2 diabetes mellitus|21595277
exenatide|treats|patients|21595277
insulin|treats|type 2 diabetes mellitus|21601480
exenatide|treats|type 2 diabetes mellitus|21601480
medicaments|stimulates|GLP-1 receptor|21612070
agonists|treats|type 2 diabetes|21612070
agonists|treats|type 2 diabetes mellitus|21612070
exenatide|compared_with|glucose|21615670
drugs|affects|cell function|21615670
exenatide|compared_with|liraglutide|21641071
drug|treats|type 2 diabetes mellitus|21641071
GLP-1|isa|drug|21641071
GLP-1|treats|type 2 diabetes mellitus|21641071
exenatide|compared_with|glimepiride|21645507
exenatide|associated_with|insulin resistance|21645507
exenatide|higher_than|glimepiride|21645507
exenatide|coexists_with|blood glucose|21645806
Exenatide|affects|gastric emptying|21645806
exenatide|affects|insulin secretion|21645806
exenatide|affects|hyperglycemia|21645806
exenatide|part_of|cat|21645806
insulin|stimulates|exenatide|21645806
exenatide|affects|pancreatic beta cells|21645806
exenatide|augments|insulin secretion|21645806
drugs|treats|infection|21652029
Exenatide|treats|insulin sensitivity|21652029
agonists|treats|type 2 diabetes|21663496
liraglutide|treats|people|21663496
liraglutide|treats|type 2 diabetes|21663496
agonist|treats|participants|21663496
agonist|compared_with|placebo|21663496
HbA|compared_with|placebo|21663496
agonists|coexists_with|HbA|21663496
liraglutide|compared_with|drugs|21663496
liraglutide|compared_with|placebo|21663496
agonists|compared_with|placebo|21663496
HbA|stimulates|GLP-1|21663496
agonist|treats|type 2 diabetes mellitus|21719364
Exenatide|stimulates|GLP-1 receptor|21719364
insulin glargine|treats|type 2 diabetes mellitus|21719364
agonist|compared_with|insulin glargine|21719364
agonist|same_as|insulin glargine|21719364
exenatide|treats|T2DM|21719364
IG|treats|patients|21719364
IG|treats|T2DM|21719364
exenatide|treats|obese|21719364
exenatide|treats|patients|21719364
exenatide|compared_with|IG|21719364
IG|treats|obese|21719364
Exenatide|compared_with|IG|21719364
Exenatide|treats|patients|21719364
IG|treats|patients|21719364
exenatide|treats|type 2 diabetes mellitus|21719364
insulin glargine|treats|patients|21719364
insulin glargine|treats|type 2 diabetes mellitus|21719364
exenatide|treats|obesity|21719364
exenatide|compared_with|insulin glargine|21719364
insulin glargine|treats|obesity|21719364
exenatide|treats|type 2 diabetes|21730278
exenatide|treats|patients|21730278
exenatide|compared_with|exenatide|21730278
exenatide|associated_with|type 2 diabetes mellitus|21730278
agonists|compared_with|exenatide|21730278
glucose|associated_with|type 2 diabetes mellitus|21732798
agonists|treats|T2DM|21732798
exenatide|treats|type 2 diabetes mellitus|21742605
exenatide|treats|patients|21742605
insulin glargine|treats|patients|21742605
insulin glargine|treats|type 2 diabetes mellitus|21742605
exenatide|treats|type 2 diabetes|21751887
Exenatide|affects|glucose homeostasis|21751893
Exenatide|compared_with|glimepiride|21751893
exendin-4|stimulates|glucagon-like peptide-1 receptor|21810596
GLP-1R|part_of|neurons|21810596
exendin-4|neg_interacts_with|blood glucose|21810596
exendin-4|neg_interacts_with|HbA|21810596
exendin-4|treats|mice|21810596
exendin-4|treats|DPN|21810596
exendin-4|affects|polyneuropathy|21810596
insulin|part_of|patients|21856602
Glucagon-like peptide-1|augments|insulin secretion|21871831
agonists|inhibits|enzymatic|21871831
exenatide|associated_with|T2DM|21871831
exenatide|part_of|patients|21871831
exenatide|compared_with|liraglutide|21871831
liraglutide|associated_with|T2DM|21871831
liraglutide|part_of|patients|21871831
agonists|neg_predisposes|hypoglycaemia|21871831
agonists|affects|pleiotropic|21871831
agonist|interacts_with|exendin-4|21901364
Ex-4|treats|rats|21901364
Ex-4|compared_with|saline|21901364
kinase|associated_with|DM|21901364
glucagon|augments|insulin secretion|21902291
agonists|inhibits|systolic blood pressure|21902291
exenatide|stimulates|GLP-1 receptor|21902291
agonists|treats|type 2 diabetes|21902291
analogues|treats|Type 2 diabetes mellitus|21902291
Exenatide|treats|type 2 diabetes mellitus|21904106
Exenatide|treats|patients|21904106
exenatide|treats|type 2 diabetes|21904106
agonists|treats|type 2 diabetes|21905764
agonists|stimulates|GLP-1R|21905764
exenatide|treats|type 2 diabetes|21905764
liraglutide|stimulates|GLP-1R|21905764
agonists|causes|weight loss|21905764
Exenatide|isa|analogue|21920963
exenatide|treats|patients|21920963
exenatide|treats|ST-segment elevation myocardial infarction|21920963
Exenatide|disrupts|reperfusion injury|21920963
exendin-4|isa|analog|21957486
exendin-4|causes|apoptosis|21957486
fatty acids|causes|Steatosis|21957486
agonist|treats|high fructose diet|21957486
agonist|augments|insulin secretion|21961484
agonist|treats|Type 2 diabetes|21961484
exenatide|stimulates|glucagon-like peptide-1 receptor|21961484
exenatide|affects|parameters|22040840
exenatide|affects|weight loss|22040840
agonists|interacts_with|incretin|22051096
liraglutide|associated_with|T2DM|22051096
liraglutide|compared_with|therapies|22051096
basal insulin|associated_with|type 2 diabetes mellitus|22051096
exenatide|treats|type 2 diabetes|22056400
exenatide|treats|patients|22056400
oral hypoglycaemic|isa|medications|22056400
exenatide|affects|type 2 diabetes|22056400
drug|treats|type 2 diabetes|22067476
exenatide|stimulates|glucagon-like peptide 1 receptor|22067476
exenatide|interacts_with|haemoglobin A1c|22074017
insulin|coexists_with|sulphonylureas|22074017
exenatide|treats|obesity|22076596
exenatide|treats|youth|22076596
Exenatide|treats|weight-loss|22076596
cannabinoid CB1 receptor|stimulates|glucagon-like peptide-1 (GLP-1) receptor|22100840
agonist|affects|consumption|22100840
exendin-4|affects|consumption|22100840
endocannabinoids|interacts_with|neurotransmitters|22100840
CB1 receptor|affects|consumption|22100840
exendin-4|part_of|Wistar rats|22100840
CB1 receptor|stimulates|GLP-1 receptor|22100840
cannabinoid CB1 receptor|stimulates|glucagon-like peptide-1 receptor|22100840
agonist|treats|patients|22146227
agonist|treats|type 2 diabetes|22146227
Exenatide|stimulates|GLP-1 receptor|22146227
glucagon|interacts_with|incretin|22146227
exenatide|treats|type 2 diabetes|22146227
exenatide|treats|patients|22146227
exendin-4|isa|drug|22150224
agonists|treats|diabetes|22150224
exenatide|affects|endothelial dysfunction|22155457
Drugs|treats|type 2 diabetes mellitus|22158421
glucagon-like peptide-1|affects|cells|22158421
exendin-3|part_of|Rats|22170618
exendin-3|affects|sucrose intake|22170618
Exendin-4|affects|sucrose intake|22170618
Exenatide|treats|type 2 diabetes|22209597
Exenatide|treats|obesity|22209597
Exenatide|treats|patients|22209597
Exenatide|isa|analogue|22209597
exenatide|treats|type 2 diabetes|22209597
exenatide|treats|obesity|22209597
exenatide|treats|patients|22209597
HbA|isa|treatment|22209597
Exenatide|isa|drug|22209597
exenatide|treats|type 2 diabetes mellitus|22209597
pioglitazone|treats|type 2 diabetes|22210563
pioglitazone|treats|patients|22210563
exenatide|compared_with|metformin|22210563
HbA|compared_with|MET|22210563
exenatide|treats|cohort|22216894
metformin|treats|T2D|22227407
sulphonylureas|treats|T2D|22227407
exenatide|treats|poor glycaemic control|22227407
exenatide|treats|diabetes|22227407
exenatide|treats|patient|22227407
agonists|stimulates|glucagon-like peptide-1|22232377
glucagon|inhibits|gastric emptying|22232377
GLP-1|augments|insulin secretion|22232377
dipeptidyl peptidase-IV|interacts_with|GLP-1|22232377
agents|compared_with|agents|22232377
agonists|treats|patients|22232377
agonists|compared_with|agents|22232377
agonists|treats|adults|22232377
agonists|treats|weight loss|22236411
agonist|treats|patients|22236411
agonist|treats|diabetes|22236411
agonists|affects|weight loss|22236411
exenatide|treats|type 2 diabetes|22246377
exenatide|treats|patients|22246377
drug|interacts_with|favourable|22246377
exenatide|treats|diabetic|22246377
exenatide|treats|CHF|22246377
medications|predisposes|ARF|22268550
exenatide|compared_with|medications|22268550
exenatide|predisposes|ARF|22268550
exenatide|treats|diabetic|22268550
Exenatide|predisposes|acute renal failure|22268550
insulin glargine|treats|patients|22321776
insulin glargine|treats|type 2 diabetes mellitus|22321776
glargine|part_of|patients|22321776
exenatide|part_of|patients|22321776
exendin-4|treats|monkeys|22338110
exendin-4|treats|rats|22338110
exendin-4|interacts_with|insulin|22338110
exendin-4|treats|humans|22338110
exenatide|affects|pharmacokinetics|22344551
exenatide|inhibits|glucose|22344551
exenatide|compared_with|placebo|22354133
exenatide|higher_than|placebo|22354133
Exenatide|compared_with|placebo|22354133
exendin-4|interacts_with|GK|22356440
exendin-4|coexists_with|alloxan|22356440
exendin-4|affects|liver|22356440
exendin-4|affects|pancreas|22356440
exendin-4|part_of|mice|22356440
exendin-4|affects|glucose homeostasis|22356440
Exendin-4|treats|symptoms|22356440
exenatide|compared_with|insulin glargine|22357185
metformin|treats|patients|22357185
IG|treats|patients|22357185
insulin glargine|treats|patients|22357185
exenatide|treats|patients|22357185
exendin-4|interacts_with|Sirt1|22363635
Lkb1|part_of|hepatic|22363635
exendin-4|treats|fatty liver|22363635
drugs|treats|diabetes|22365085
exenatide|associated_with|type 2 diabetes|22365085
exenatide|affects|weight reduction|22365085
hypoglycemic agent|treats|diabetic|22365085
hypoglycemic agent|treats|patients|22365085
exenatide|compared_with|placebo|22365085
agonist|inhibits|glucose|22369345
Exenatide|stimulates|GLP-1 receptor|22369345
pioglitazone|treats|T2DM|22369345
pioglitazone|treats|patients|22369345
pioglitazone|treats|type 2 diabetes|22369345
exenatide|treats|type 2 diabetes|22369345
exenatide|treats|patients|22369345
metformin|treats|Type 2 diabetes|22375612
exenatide|treats|type 2 diabetes|22375612
exenatide|treats|patients|22375612
exenatide|compared_with|exenatide|22375612
Liraglutide|isa|analogue|22382611
liraglutide|treats|patients|22382611
liraglutide|interacts_with|exenatide|22405265
liraglutide|interacts_with|peptidase (DPP-4) inhibitors|22405265
antidiabetic agents|treats|weight loss|22405265
agonists|treats|diabetic|22405265
peptidase-4 (DPP-4) inhibitors|treats|patients|22405266
agonists|treats|patients|22405266
agonists|treats|type 2 diabetes|22405266
peptidase-4 (DPP-4) inhibitors|treats|type 2 diabetes|22405266
glucose|isa|medications|22405266
glucose|stimulates|GLP-1 receptor|22405266
GLP-1 RAs|causes|weight loss|22405266
DPP-4 inhibitors|associated_with|infections|22405266
liraglutide|compared_with|exenatide|22405266
liraglutide|compared_with|anti-hyperglycaemic agents|22405266
exenatide|neg_predisposes|pancreatitis|22416857
exenatide|compared_with|medications|22416857
insulin|associated_with|pancreatitis|22416857
medications|predisposes|pancreatitis|22416857
exenatide|predisposes|pancreatitis|22416857
medication|compared_with|medication|22416857
exenatide|isa|medication|22416857
exenatide|compared_with|medication|22416857
exenatide|compared_with|exenatide|22416857
medication|isa|exenatide|22416857
incretin|compared_with|therapies|22420869
agonists|causes|weight loss|22420869
oral contraceptive|treats|women|22429273
oral contraceptive|interacts_with|exenatide|22429273
drugs|inhibits|maximum|22429273
exenatide|affects|gastric emptying|22429273
ethinyl estradiol|isa|oral contraceptive|22429273
drugs|administered_to|patients|22429273
insulin glargine|part_of|participants|22432107
agonists|stimulates|glucagon-like peptide- 1 (GLP-1) receptor|22432846
saxagliptin|stimulates|glucagon-like peptide- 1 (GLP-1) receptor|22432846
glucagon|augments|insulin secretion|22432846
exenatide|interacts_with|GLP-1 receptor|22432846
liraglutide|interacts_with|GLP-1 receptor|22432846
GLP-1|augments|satiety|22432846
agonists|inhibits|blood glucose|22432846
agonists|treats|patients|22432846
agonists|treats|diabetic|22432846
basal insulin|treats|T2DM|22435393
insulin|treats|T2DM|22435393
GLP-1|interacts_with|GLP-1|22435393
insulin|associated_with|type 2 diabetes mellitus|22435393
exenatide|treats|patients|22446132
antihyperglycemic|isa|medications|22446132
exenatide|administered_to|patients|22464691
insulin|compared_with|exenatide|22464691
insulin|higher_than|exenatide|22464691
insulin|administered_to|Patients|22464691
insulin|interacts_with|exenatide|22464691
incretin|compared_with|metformin|22471248
metformin|treats|patients|22471248
metformin|treats|type 2 diabetes|22471248
agonist|stimulates|GLP-1 receptor|22471248
insulin|part_of|brain|22476196
insulin|predisposes|cognitive deficits|22476196
GLP-1|disrupts|food intake|22492036
Exendin-4|interacts_with|agonist|22492036
GLP-1Rs|part_of|nodes|22492036
GLP-1Rs|disrupts|motivation|22492036
exendin-4|isa|analogue|22492036
exenatide|part_of|patients|22496084
exenatide|causes|smaller infarct size|22496084
Exenatide|treats|patients|22496084
Exenatide|treats|ST-segment-elevation myocardial infarction|22496084
GLP-1|affects|diabetic|22496442
exenatide|interacts_with|analogues|22496442
liraglutide|interacts_with|analogues|22496442
incretin|isa|peptidic incretin hormones|22503954
exendin-4|treats|diabetes|22503954
therapeutic protein|treats|diabetes|22503954
exenatide|treats|type 2 diabetes|22510305
exenatide|treats|patients|22510305
exenatide|treats|weight loss|22510305
HbA|part_of|patients|22510305
exenatide|treats|type 2 diabetes mellitus|22510305
glargine|treats|T2DM|22519390
OADs|predisposes|hypoglycemia|22530845
RAs|treats|patients|22530845
exenatide|inhibits|hemoglobin (A1C|22530845
RAs|affects|cardiovascular risk factors|22530845
RAs|affects|adverse events|22530845
RAs|treats|T2DM|22530845
exenatide|treats|type 2 diabetes mellitus|22533526
liraglutide|treats|type 2 diabetes mellitus|22533526
exenatide|compared_with|liraglutide|22533526
exenatide|treats|T2DM|22533526
liraglutide|treats|T2DM|22533526
exenatide|treats|type 2 diabetes|22533526
exenatide|treats|patients|22533526
liraglutide|treats|type 2 diabetes|22533526
liraglutide|treats|patients|22533526
insulin|treats|insulin resistance|22540883
adiponectin|compared_with|metformin|22540883
palmitic-acid|interacts_with|exendin-4|22561689
palmitic-acid|causes|Hypoglycemia|22561689
exendin-4|treats|type 2 diabetes|22561689
exenatide|stimulates|GLP-1R|22566747
insulin|neg_affects|systolic BP|22566747
insulin|treats|type 2 diabetes|22566747
antibodies|coexists_with|HbA|22608106
exenatide|associated_with|type 2 diabetes|22608106
exenatide|inhibits|glipizide|22644981
losartan|treats|high blood pressure|22644981
glipizide|treats|patient|22644981
glipizide|treats|type 2 diabetes mellitus|22644981
drugs|treats|type 2 diabetes|22675341
agonists|compared_with|placebo|22675341
exenatide|stimulates|GLP-1 receptor|22675341
exenatide|treats|renal injury|22687869
exenatide|interacts_with|albumin|22687869
exenatide|administered_to|patients|22687869
exenatide|inhibits|TGF-beta|22687869
Exenatide|inhibits|transforming growth factor-beta1|22687869
Exenatide|disrupts|sleepiness|22716195
Exenatide|treats|excessive daytime sleepiness|22716195
exenatide|treats|type 2 diabetes|22732108
exenatide|compared_with|glimepiride|22732108
exenatide|affects|brachial artery|22732108
exenatide|treats|dilation|22732108
Exenatide|isa|medication|22735035
non-steroidal anti-inflammatory drugs|isa|medications|22762797
exenatide|treats|Type 2 diabetes mellitus|22762797
exenatide|treats|patient|22762797
dopamine|part_of|extracellular|22774922
dopamine|disrupts|striatum|22774922
noradrenaline|disrupts|striatum|22774922
noradrenaline|disrupts|frontal cortex|22774922
dopamine|disrupts|frontal cortex|22774922
agonist|treats|people|22789767
agonist|treats|type 2 diabetes|22789767
Exenatide|stimulates|glucagon-like peptide 1|22789767
insulin glargine|part_of|patients|22793669
insulin glargine|associated_with|type 2 diabetes mellitus|22793669
exenatide|compared_with|insulin glargine|22793669
exenatide|associated_with|type 2 diabetes mellitus|22793669
exenatide|part_of|patients|22793669
IG|treats|patients|22793669
IG|treats|T2DM|22793669
exenatide|treats|type 2 diabetes|22793669
insulin glargine|treats|patients|22793669
insulin glargine|treats|type 2 diabetes|22793669
exenatide|treats|patients|22793669
liraglutide|compared_with|exenatide|22804841
exenatide|augments|renal excretion|22808453
Exenatide|augments|kaliuresis|22808453
exenatide|associated_with|type 2 diabetes|22825226
agonists|treats|obesity|22827554
agonists|treats|type II diabetes|22827554
exendin-4|affects|eating|22827554
Ex-4|associated_with|SDA|22827554
Ex-4|stimulates|c-Fos|22827554
exendin-4|treats|diabetes|22831885
drug|treats|hypothalamic obesity|22831885
exendin-4|treats|type 2 diabetes|22831918
Exenatide|causes|weight loss|22831918
Exenatide|treats|patient|22831918
Exenatide|treats|severe hypothalamic obesity|22831918
exenatide|treats|patients|22831918
exendin-4|treats|patient|22831918
exendin-4|treats|hypothalamic obesity|22831918
exenatide|neg_administered_to|patients|22845701
liraglutide|treats|type 2 diabetes mellitus|22862847
liraglutide|compared_with|therapies|22862847
agonist|treats|patients|22884767
agonist|treats|type 2 diabetes|22884767
exenatide|stimulates|glucagon-like peptide-1 receptor|22884767
insulin glargine|treats|patients|22884767
insulin glargine|treats|type 2 diabetes|22884767
insulin glargine|coexists_with|HbA|22884767
HbA|part_of|patients|22884767
insulin|treats|patients|22884767
insulin|treats|type 2 diabetes|22884767
drug|treats|type 2 diabetes|22884767
exenatide|treats|type 2 diabetes|22884767
exenatide|treats|patients|22884767
exenatide|compared_with|insulin|22884767
Exenatide|stimulates|glucagon-like peptide-1 receptor|22913891
exenatide|treats|patients|22913892
medications|administered_to|patients|22913892
Exenatide|treats|type 2 diabetes mellitus|22913892
neurotoxin|causes|rodent model|22921965
Exendin-4|stimulates|glucagon-like peptide-1 receptor|22921965
exenatide|treats|type 2 diabetes|22925173
exenatide|treats|patients|22925173
Exenatide|treats|type 2 diabetes|22925173
exenatide|administered_to|patients|22931974
exenatide|treats|Patients|22931974
GLP-1|disrupts|appetite|22945360
agonists|stimulates|GLP-1 receptor|22945360
agonists|inhibits|blood glucose|22945360
agonists|treats|type 2 diabetes mellitus|22945360
Ex4|treats|fatty livers|22960075
Exendin 4|associated_with|injury|22960075
Exendin 4|associated_with|steatotic liver|22960075
agonist|treats|type 2 diabetes|22960288
Exenatide|stimulates|glucagon-like peptide-1 receptor|22960288
exenatide|affects|motility|22960288
exenatide|affects|gallbladder emptying|22960288
CCK|compared_with|placebo|22960288
exenatide|compared_with|placebo|22960288
Exenatide|neg_affects|pancreatic|22960288
pramlintide acetate|coexists_with|dodecyl maltoside|22960403
Exenatide|coexists_with|dodecyl maltoside|22960403
exenatide|administered_to|Mice|22960403
pramlintide acetate|administered_to|mice|22960403
pramlintide acetate|neg_affects|weight gain|22960403
exenatide|disrupts|Food intake|22960403
exenatide|neg_affects|Water intake|22960403
pramlintide acetate|disrupts|water intake|22960403
exenatide|coexists_with|blood glucose|22960403
pramlintide acetate|coexists_with|blood glucose|22960403
pramlintide acetate|coexists_with|DDM|22960403
exenatide|coexists_with|DDM|22960403
synthetic peptide|isa|amide|22960403
leptin|interacts_with|exenatide|22960403
leptin|interacts_with|pramlintide acetate|22960403
basal insulin|treats|patients|22982784
basal insulin|treats|type 2 diabetes mellitus|22982784
exenatide|treats|type 2 diabetes mellitus|22982784
exenatide|treats|patients|22982784
medications|treats|patients|22982784
exenatide|disrupts|blood pressure|22982784
exendin-4|part_of|rats|22983684
exendin-4|prevents|hyperglycemia|22983684
exendin-4|treats|mice|23000581
exendin-4|isa|drug|23000581
exendin-4|predisposes|infection|23000581
agonists|treats|patients|23010561
agonists|affects|serious adverse events|23010561
exenatide|predisposes|AP|23010561
liraglutide|predisposes|AP|23010561
exenatide|associated_with|cancer|23010561
Liraglutide|predisposes|thyroid cancer|23010561
agonists|affects|cancer|23010561
HbA|stimulates|insulin|23019799
metformin|neg_treats|patients|23031623
TZD|neg_treats|patients|23031623
exenatide|administered_to|patients|23031623
exenatide|coexists_with|HbA|23031623
HbA|coexists_with|HbA|23031623
thiazolidinedione|treats|type 2 diabetes mellitus|23031623
exenatide|treats|type 2 diabetes mellitus|23031623
exenatide|treats|patients|23031623
exenatide|part_of|patients|23039898
exenatide|administered_to|patients|23039898
exenatide|part_of|Patients|23039898
exenatide|treats|patients|23039898
exenatide|compared_with|regimens|23039898
neuroprotective agent|interacts_with|exendin-4|23059457
Exendin-4|stimulates|glucagon-like peptide-1 receptor|23059457
basal insulin|interacts_with|glucose|23061470
agonist|treats|patients|23061886
basal insulin|treats|type 2 diabetes|23061886
agonist|treats|type 2 diabetes|23061886
exenatide|stimulates|glucagon-like peptide 1 receptor|23061886
Exenatide|stimulates|insulin|23061886
Glucagon-like peptide|augments|insulin secretion|23078126
glucose|augments|hypoglycaemia|23078126
exendin-4|produces|cholera toxin B subunit|23078126
EX4|augments|insulin secretion|23078126
EX4|neg_causes|hypoglycaemia|23078126
exendin-4|part_of|chloroplasts|23078126
agonists|treats|type 2 diabetes|23094590
GLP-1-RA|augments|tachyphylaxis|23094590
proinsulin|part_of|cells|23099275
exendin-4|part_of|cells|23099275
biopharmaceuticals|part_of|human|23099275
glucagon|affects|glucose homeostasis|23122871
glucagon|isa|peptide hormones|23122871
Oxyntomodulin|isa|peptide hormones|23122871
peptide hormones|affects|glucose homeostasis|23122871
exendin-4|isa|peptide hormones|23122871
exendin-4|affects|glucose homeostasis|23122871
Oxyntomodulin|affects|glucose homeostasis|23122871
glucagon receptors|interacts_with|glucagon|23122871
OXM|interacts_with|GLP-1|23122871
glucagon|interacts_with|GLP-1|23122871
glucagon receptors|interacts_with|OXM|23122871
hormones|treats|cattle|23122871
OXM|interacts_with|insulin|23122871
Oxyntomodulin|treats|hypoglycemia|23122871
agonist|treats|type 2 diabetes|23139373
HbA|compared_with|exenatide|23139373
HbA|higher_than|exenatide|23139373
exenatide|treats|type 2 diabetes|23139373
agonist|compared_with|exenatide|23139373
exenatide|augments|free water clearance|23155627
Exenatide|augments|excretion|23155627
exenatide|treats|hyperglycemia|23186969
glucose|part_of|patients|23186969
exenatide|compared_with|INT|23186969
Exenatide|treats|patients|23186969
exenatide|administered_to|patients|23186969
glucose|treats|patients|23186969
exenatide|coexists_with|glucose|23186969
metformin|treats|patients|23186975
metformin|treats|type 2 diabetes|23186975
exenatide|treats|type 2 diabetes|23186975
exenatide|treats|patients|23186975
exenatide|compared_with|metformin|23186975
exenatide|part_of|patients|23186975
liraglutide|compared_with|exenatide|23186975
liraglutide|part_of|patients|23186975
exenatide|treats|weight loss|23191935
exenatide|treats|adult|23191935
exenatide|treats|adults|23191935
Exenatide|associated_with|overweight|23191935
Exenatide|treats|patients|23191935
drug|treats|type 2 diabetes|23220706
Exendin-4|stimulates|glucagon-like peptide-1 receptor|23220706
exendin-4|interacts_with|exendin-4|23220706
Exendin-4|inhibits|TNFalpha|23220706
drugs|treats|vascular diseases|23220706
agonists|treats|vascular diseases|23220706
agonist|treats|hyperplasia|23220706
exenatide|treats|humans|23229855
exenatide|part_of|human|23229855
HbA|interacts_with|lipid|23236362
HbA|part_of|patients|23236362
metformin|treats|Patients|23236362
HbA|coexists_with|IHL|23236362
agonists|prevents|liver fat|23236362
exendin-4|stimulates|glucagon- like peptide-1 receptor|23256660
agonist|treats|diabetes|23256660
exenatide|treats|T2DM|23256660
glucagon|inhibits|gastric emptying|23256660
exenatide|treats|diabetes|23256660
metformin|treats|type 2 diabetes|23275363
sulfonylureas|treats|type 2 diabetes|23275363
exenatide|treats|type 2 diabetes|23275363
insulin detemir|treats|patients|23275363
exenatide|treats|patients|23275363
insulin detemir|treats|type 2 diabetes|23275363
exenatide|compared_with|insulin detemir|23275363
Exenatide|stimulates|glucagon-like peptide-1 receptor|23291680
glucagon-like peptide-1|affects|satiation|23295502
agonists|causes|weight loss|23295502
exenatide|treats|hyperglycemia|23295502
liraglutide|treats|hyperglycemia|23295502
exenatide|treats|type 2 diabetes|23340146
exenatide|treats|patients|23340146
cAMP-dependent protein kinase|augments|PKA activity|23349500
PKA|augments|insulin secretion|23349500
incretins|neg_interacts_with|PKA|23349500
proteins|affects|exocytosis|23349500
PKA|affects|insulin secretion|23349500
insulin|interacts_with|glucose|23349500
agonists|treats|type 2 diabetes mellitus|23357334
glucagon-like peptide-1|associated_with|nausea|23357334
glucagon-like peptide-1|associated_with|vomiting|23357334
GLP-1 receptor|affects|emesis|23357334
Exendin-4|stimulates|GLP-1 receptor|23357334
exendin-4|causes|emesis|23357334
emetic|affects|brainstem|23357334
exendin-4|interacts_with|GLP-1 receptors|23357334
exendin-4|stimulates|GLP-1 receptor|23357334
GLP-1|affects|injury|23364453
exenatide|isa|analog|23364453
vildagliptin|treats|diabetes|23364453
NADPH oxidase|produces|reactive oxygen species|23364453
GLP-1|associated_with|diabetes|23364453
GLP-1|stimulates|Rho|23364453
agonists|affects|gastrointestinal disorders|23365557
exenatide|associated_with|type 2 diabetes|23365557
liraglutide|associated_with|type 2 diabetes|23365557
drugs|compared_with|drugs|23433305
drugs|treats|type 2 diabetes|23433305
liraglutide|isa|drugs|23433305
liraglutide|treats|type 2 diabetes|23433305
liraglutide|treats|type 2 diabetes|23433305
liraglutide|compared_with|drugs|23433305
drugs|isa|liraglutide|23433305
liraglutide|compared_with|liraglutide|23433305
exenatide|interacts_with|exenatide|23433305
exenatide|isa|drugs|23433305
exenatide|compared_with|liraglutide|23433305
liraglutide|interacts_with|liraglutide|23433305
liraglutide|interacts_with|exenatide|23433305
drugs|interacts_with|liraglutide|23433305
drugs|interacts_with|exenatide|23433305
exenatide|interacts_with|liraglutide|23433305
exenatide|compared_with|placebo|23433305
exenatide|inhibits|systolic blood pressure|23433305
liraglutide|compared_with|placebo|23433305
liraglutide|inhibits|SBP|23433305
glimepiride|treats|patients|23433305
glimepiride|treats|T2DM|23433305
exenatide|predisposes|pancreatitis|23440284
medications|treats|type 2 diabetes|23471935
Exenatide|compared_with|exenatide|23471935
exenatide|treats|patients|23471935
exenatide|part_of|patients|23471935
exenatide|compared_with|placebo|23473527
exenatide|treats|type 2 diabetes mellitus|23473527
exenatide|treats|patients|23473527
agonist|treats|patients|23553357
exenatide|stimulates|glucagon-like peptide-1|23553357
exenatide|isa|drug|23553357
exenatide|inhibits|hemoglobin A1c|23553357
agonist|treats|type 2 diabetes mellitus|23553357
GLP-1|affects|energy expenditure|23562866
GLP-1|augments|energy expenditure|23562866
agonism|neg_affects|energy expenditure|23562866
glucose|treats|patients|23578605
glucose|treats|type 2 diabetes|23578605
Exenatide|stimulates|glucagon-like peptide-1 receptor|23578605
exenatide|inhibits|glucose|23578605
Glucagon-like-peptide-1|affects|food intake|23613987
Glucagon-like-peptide-1|affects|glucose metabolism|23613987
GLP-1|part_of|Wistar rats|23613987
GLP-1|inhibits|GLP-1 receptors|23613987
liraglutide|disrupts|food intake|23616105
incretin hormone|treats|T2DM|23640454
GLP-1 analogs|augments|insulin secretion|23640454
GLP-1 analogs|augments|plasticity|23640454
net|stimulates|drug|23640454
exenatide|neg_affects|brain metabolism|23640454
exenatide|affects|cognition|23640454
Exenatide|treats|mice|23640454
exenatide|compared_with|insulin glargine|23640946
Exenatide|compared_with|insulin glargine|23640946
Exenatide|interacts_with|favorable|23640946
Exenatide|treats|T2DM|23640946
exenatide|treats|type 2 diabetes mellitus|23640946
insulin glargine|treats|patients|23640946
insulin glargine|treats|type 2 diabetes mellitus|23640946
exenatide|treats|patients|23640946
exenatide|compared_with|injections|23645886
metformin|treats|type 2 diabetes|23645886
exenatide|associated_with|type 2 diabetes|23645886
exenatide|treats|diabetes mellitus|23659201
exenatide|compared_with|insulin glargine|23659201
insulin glargine|treats|patients|23659201
exenatide|treats|diabetes|23659201
exenatide|treats|patients|23659201
insulin glargine|treats|diabetes|23659201
exenatide|compared_with|exenatide|23659201
exenatide|affects|cell function|23744726
exenatide|administered_to|patients|23744726
resistin|compared_with|metformin|23744726
exendin-4|treats|type 2 diabetes|23747732
exendin-4|part_of|individual|23747732
anti-diabetic agent|treats|type 2 diabetes|23747732
Exenatide|stimulates|glucagon-like peptide-1 receptor|23748506
agonist|predisposes|hypoglycemia|23748506
exenatide|treats|type 2 diabetes mellitus|23748506
exenatide|treats|patients|23748506
exenatide|stimulates|GLP-1 receptor|23748507
exenatide|treats|type 2 diabetes mellitus|23748507
exenatide|treats|patients|23748507
RAs|inhibits|glucose|23748861
GLP-1|part_of|patients|23748861
exenatide|compared_with|insulin glargine|23784159
exenatide|higher_than|insulin glargine|23784159
exenatide|treats|patients|23784159
exenatide|treats|hemorrhagic pancreatitis|23784159
exenatide|treats|type 2 diabetes|23784159
exenatide|treats|type 2 diabetes mellitus|23784159
exenatide|isa|incretin|23865382
liraglutide|isa|incretin|23865382
GLP-1 RAs|treats|hyperglycemia|23865382
GLP-1 RAs|treats|T2DM|23865382
exenatide|administered_to|patients|23868944
insulin|part_of|rat|23891516
exendin-4|stimulates|insulin|23891516
bovine insulin|causes|glucose-lowering effect|23891516
hypoglycemic|affects|ingestion|23891516
exendin-4|treats|NPs|23891516
bovine insulin|treats|NPs|23891516
exenatide|treats|type 2 diabetes mellitus|23895999
liraglutide|treats|type 2 diabetes|23971789
GLP-1 RAs|treats|T2D|23971789
GLP-1 RAs|treats|hyperglycemia|23971789
agonists|treats|Type 2 diabetes|23971789
hypoglycemic|treats|mice|23976850
exendin-4|treats|type 2 diabetes|23976850
antihyperglycemic|isa|drugs|23981106
exendin-4|treats|type 2 diabetes mellitus|23984340
exendin-4|stimulates|glucagon-like peptide-1 receptor|23984340
GLP-1|associated_with|T2D|23986202
GLP-1|interacts_with|insulin|23986202
peptidase-4 (DPP-4) inhibitors|interacts_with|insulin|23986202
exendin-4|disrupts|signaling|23986202
GLP-1|coexists_with|glucose|23986202
exendin-4|interacts_with|insulin|23986202
insulin|affects|insulin secretion|23986202
agonist|prevents|symptoms|24101584
Exendin-4|stimulates|GLP-1|24101584
agonist|prevents|cachexia|24101584
Exendin-4|treats|symptoms|24101584
Exendin-4|treats|tumor growth|24101584
Exendin-4|treats|cachexia|24101584
Exendin-4|treats|cancer cachexia|24101584
exenatide|affects|clotting|24107779
drug combinations|inhibits|serious adverse events|24107779
drugs|treats|serious adverse events|24107779
drug combinations|treats|adverse event|24107779
Basal insulin|treats|patients|24113668
Basal insulin|treats|poor glycemic control|24113668
b-INS|treats|patients|24113668
b-INS|treats|type 2 diabetes mellitus|24113668
insulin glargine|compared_with|insulin detemir|24113668
b-INS|compared_with|b-INS|24113668
b-INS|treats|adverse events|24113668
metformin|treats|patients|24113668
metformin|treats|poor glycemic control|24113668
Exenatide|compared_with|basal insulin|24113668
exenatide|isa|antidiabetic peptide drug|24114868
exendin-4|treats|diabetes|24140611
agonists|treats|type 2 diabetes mellitus|24156868
GLP-1 RAs|affects|glucose homeostasis|24156868
GLP-1 RAs|affects|parameters|24156868
liraglutide|compared_with|exenatide|24156868
exenatide|coexists_with|FPG|24156868
GLP-1 RAs|stimulates|GLP-1 RAs|24156868
GLP-1|causes|tachyphylaxis|24156868
liraglutide|inhibits|glucagon|24156868
exenatide|treats|T2DM|24156868
exenatide|treats|individuals|24156868
agonists|treats|individuals|24156868
Exendin-4|stimulates|glucagon-like peptide-1 receptor|24201448
Ex-4|affects|hippocampus|24201448
Ex-4|affects|neurons|24201448
Ex-4|affects|cell line|24201448
GLP-1R|disrupts|neurons|24201448
GLP-1R|disrupts|cell line|24201448
exendin-4|associated_with|transient global ischemia|24201448
agonists|treats|weight loss|24249759
agonists|causes|weight loss|24249759
exenatide|interacts_with|agonists|24249759
liraglutide|interacts_with|agonists|24249759
liraglutide|causes|weight loss|24249759
agonists|treats|patients|24249759
agonists|treats|type 2 diabetes mellitus|24263424
liraglutide|treats|patients|24263424
GLP-1|affects|weight loss|24263424
Exendin-4|augments|apoptosis|24351817
oxaliplatin|treats|subcutaneous tumors|24351817
therapeutic agents|treats|diabetes mellitus|24353307
exenatide|affects|diabetes|24353307
exenatide|treats|rats|24353307
fragments|part_of|pancreatic|24353307
GLP1 receptor|augments|pancreas|24353307
insulin|administered_to|patients|24369764
exenatide|administered_to|patients|24369764
exenatide|affects|vascular endothelial injury|24371833
glucose|causes|injury|24371833
glucose|stimulates|inducible nitric oxide synthase|24371833
exenatide|disrupts|stress|24371833
exenatide|interacts_with|blood glucose|24402015
metformin|treats|Patients|24402015
exenatide|treats|Patients|24402015
metformin|treats|NAFLD|24402015
Exenatide|treats|type 2 diabetes|24402015
Exenatide|isa|incretin|24558765
exendin-4|compared_with|exendin-4|24565847
exendin-4|lower_than|exendin-4|24565847
glucose|disrupts|food intake|24565847
drug|treats|type 2 diabetes|24565847
exenatide|interacts_with|exenatide|24584550
exenatide|isa|drug|24584550
drug|interacts_with|exenatide|24584550
exenatide|administered_to|patients|24584550
exenatide|augments|hyperglycemia|24800522
drugs|treats|breakthrough pain|11000661
Conantokin-G|associated_with|cerebral ischemia|16112094
NMDA receptor antagonist|affects|depolarizations|16112094
NMDA receptor antagonist|affects|injury|16112094
anticoagulant|treats|patients|11504572
anticoagulant|treats|ACS|11504572
anticoagulant|treats|HIT|11504572
direct thrombin inhibitors|treats|patients|11504572
direct thrombin inhibitors|isa|anticoagulant|11504572
direct thrombin inhibitors|treats|HIT|11504572
PCI|associated_with|ACS|11504572
direct thrombin inhibitor|compared_with|UFH|15282656
venom|associated_with|pathogenesis|17324135
venom|part_of|rats|17324135
melatonin|treats|control groups|17324135
melatonin|treats|rats|17324135
Melatonin|treats|rats|17324135
venom|administered_to|Wistar rats|19663823
saline|isa|injections|19663823
saline|uses|saline|19663823
saline|administered_to|cohorts|19663823
Rho|affects|parameters|19663823
venom|causes|inflammatory response|18687300
F(ab|disrupts|leukocytosis|18687300
Cilengitide|inhibits|alphavbeta5 integrin|16729916
Cilengitide|inhibits|EMD121974|16729916
Integrins|isa|cell surface receptors|16729916
integrins|augments|apoptosis|16729916
integrins|associated_with|metastases|16729916
basic fibroblast growth factor|predisposes|neovascularization|16729916
vascular endothelial growth factor|predisposes|neovascularization|16729916
cilengitide|inhibits|basic fibroblast growth factor|16729916
Cilengitide|disrupts|tumor growth|16729916
cilengitide|treats|patients|16729916
cilengitide|treats|prostate cancer|16729916
cilengitide|treats|metastatic prostate cancer|16729916
cilengitide|treats|asymptomatic|16729916
gemcitabine|treats|patients|17156477
gemcitabine|compared_with|gemcitabine|17156477
gemcitabine|treats|unresectable pancreatic cancer|17156477
Cilengitide|isa|angiogenesis inhibitor|17156477
Cilengitide|neg_interacts_with|gemcitabine|17156477
Cilengitide|associated_with|unresectable pancreatic cancer|17156477
Mojave toxin|coexists_with|venom|22316204
Mojave toxin|part_of|authors|22316204
SNX-111|disrupts|voltage-sensitive calcium channels|10666519
ziconotide|affects|heat hyperalgesia|10666519
ziconotide|neg_affects|pain thresholds|10666519
ziconotide|compared_with|morphine|10666519
ziconotide|higher_than|morphine|10666519
formalin|inhibits|N-type calcium-channel|10692631
ziconotide|associated_with|cancer|10692631
calcium channel blocker|disrupts|neurotransmitter release|15212625
Ziconotide|isa|calcium channel blocker|15212625
calcium channel blocker|affects|primary nociceptive afferents|15212625
Ziconotide|disrupts|neurotransmitter release|15212625
Ziconotide|affects|primary nociceptive afferents|15212625
ziconotide|administered_to|patients|15212625
ziconotide|treats|refractory pain|15212625
calcium|stimulates|voltage-gated calcium channels|16489373
drugs|affects|pain|16489373
drugs|affects|calcium channel activity|16489373
ziconotide|administered_to|patients|16503720
Ziconotide|treats|severe chronic pain|16503720
ziconotide|associated_with|pain|16716870
ziconotide|isa|nonopioid analgesic|16716870
ziconotide|treats|adults|16716870
ziconotide|treats|severe chronic pain|16716870
ziconotide|treats|severe chronic pain|16849624
ziconotide|treats|chronic pain|16849624
Ziconotide|isa|calcium-channel blocker|16849624
Ziconotide|predisposes|meningitis|16849624
morphine|treats|severe chronic pain|16849624
Ziconotide|isa|treatment|16849624
ziconotide|isa|pain therapies|16849624
ziconotide|treats|refractory chronic pain|16849624
analgesic|treats|chronic intractable pain|17063978
Ziconotide|isa|toxin|17063978
Ziconotide|causes|analgesia|17063978
Ziconotide|compared_with|placebo|17063978
Ziconotide|isa|treatment|17063978
Ziconotide|higher_than|placebo|17063978
ziconotide|isa|analgesic|17063978
calcium channel blocker|treats|severe chronic pain|17063978
Ziconotide|treats|chronic pain|17078783
Ziconotide|isa|treatment|17078783
Ziconotide|treats|severe chronic pain|17078783
Ziconotide|inhibits|N-type calcium channels|17078783
ziconotide|treats|patients|17078783
Ziconotide|isa|analgesic|17078783
nonopioid intrathecal analgesic|treats|chronic pain|17078783
Ziconotide|isa|peptide|17131701
peptide|coexists_with|poison|17131701
Ziconotide|coexists_with|poison|17131701
Ziconotide|inhibits|N-type calcium channels|17131701
drug|treats|severe chronic pain|17131701
ziconotide|isa|analgesic|18685354
creatine kinase|stimulates|creatine kinase|18715748
ziconotide|treats|chronic pain|18715748
opioids|treats|pain|19500276
opioids|treats|severe chronic pain|19500276
Ziconotide|isa|nonopioid analgesic|19500276
ziconotide|treats|patients|19500276
ziconotide|treats|CRPS|19500276
ziconotide|treats|complex regional pain syndrome|19500276
ziconotide|treats|severe chronic pain|19563256
ziconotide|compared_with|supportive care|19563256
Ziconotide|treats|patients|19563256
nonopioid intrathecal (IT) analgesic|treats|patients|19682321
nonopioid intrathecal (IT) analgesic|treats|neuropathic pain|19682321
Ziconotide|isa|nonopioid intrathecal (IT) analgesic|19682321
Ziconotide|treats|patients|19682321
ziconotide|treats|neuropathic pain|19682321
ziconotide|affects|AEs|19682321
drugs|treats|patients|19682321
drugs|treats|neuropathic pain|19682321
Ziconotide|treats|severe chronic pain|20119460
nonopioid intrathecal analgesic|treats|severe chronic pain|20119460
Ziconotide|isa|nonopioid intrathecal analgesic|20119460
ziconotide|prevents|pain|20413151
Ziconotide|treats|severe chronic pain|20413151
ziconotide|treats|pain|21041028
Ziconotide|treats|chronic pain|21267038
Ziconotide|isa|therapy|21267038
ziconotide|treats|Patients|21267038
drugs|interacts_with|calcium channels|21740292
Ziconotide|inhibits|N-type neuronal voltage-sensitive calcium channels|21992243
ziconotide|part_of|patients|21992243
ziconotide|associated_with|panic disorder|21992243
Ziconotide|inhibits|N-type calcium channels|22748108
Ziconotide|isa|peptide|22748108
peptide|inhibits|N-type calcium channels|22748108
ziconotide|treats|dog|22748108
ziconotide|compared_with|inulin|22748108
ziconotide|higher_than|inulin|22748108
gabapentin|treats|mice|24369063
ziconotide|treats|mice|24369063
analgesic|stimulates|ziconotide|24369063
venom|inhibits|ion channels|15279578
peptides|coexists_with|venom|15279578
conotoxins|inhibits|nicotinic acetylcholine receptors|15279578
sodium channel|part_of|cell types|15578999
sodium channel|part_of|tissues|15578999
toxins|interacts_with|sodium channels|15578999
Conotoxins|isa|toxins|17640618
toxins|inhibits|sodium channels|21419143
peptides|coexists_with|venoms|22204425
drug|treats|pain|22204425
Xen2174|treats|neuropathic pain|22204425
Integrins alpha v beta 3|associated_with|tumor growth|16863930
Cilengitide|augments|cells|16863930
alpha v beta 3 integrin|coexists_with|endothelial|16863930
alpha v beta 3 integrin|coexists_with|Cilengitide|16863930
C-type lectin|interacts_with|integrin|17323383
lectin|disrupts|angiogenesis|17323383
MCF-7|disrupts|growth|22349023
analgesics|treats|pain|19640231
peptides|causes|cell degranulation|21971370
therapeutic agents|interacts_with|ion-channel|11476408
pesticides|interacts_with|ion-channel|11476408
Lhcgr|part_of|Transgenic mice|19261682
H-CGbeta-c|part_of|adrenal tumors|19261682
H-CGbeta-c|inhibits|GnRH-a|19261682
H-CGbeta-c|disrupts|tumor cells|19261682
H-CGbeta-c|inhibits|gonadotropin|19261682
T antigen|part_of|Simian Virus 40|19261682
T antigen|part_of|transgenic mice|19261682
Hecate-CGbeta|treats|transgenic mice|19261682
T antigen|interacts_with|Hecate-CGbeta|19261682
Hecate-CGbeta|disrupts|cells|12779076
estrogen|stimulates|Hecate-CGbeta|12779076
LHRH|treats|nude mice|17382461
drugs|affects|sensitivity|17382461
FSH|interacts_with|drugs|17382461
FSH|interacts_with|LH/CG receptor|17382461
LH/CG receptor|isa|drugs|17382461
cardiotoxin|isa|injection|12477723
venom|part_of|mice|12575843
venom|associated_with|suicide attempt|16553103
crotalidae polyvalent immune Fab|isa|antivenom|20920516
CroFab|isa|Antivenom|22963729
Crotalidae Polyvalent Immune Fab|isa|Antivenom|22963729
lysines|interacts_with|DNA|12666187
EMD 121974|inhibits|integrins alphavbeta3|12706360
Cilengitide|treats|patients|12706360
Cilengitide|treats|solid tumours|12706360
cilengitide|inhibits|integrin|12901235
Integrins|isa|cell surface adhesion molecules|16507218
receptors|affects|cell migration|16507218
Cilengitide|isa|angiogenesis inhibitor|17277694
Cilengitide|treats|mice|17277694
cilengitide|treats|patients|17470857
cilengitide|treats|malignant glioma|17470857
cilengitide|administered_to|Patients|17470857
cilengitide|isa|antiangiogenesis agent|18281665
EMD 121974|inhibits|integrin|18281665
cilengitide|administered_to|children|18281665
cilengitide|treats|children|18281665
cilengitide|treats|brain tumors|18281665
Integrins|part_of|GBM|18616418
Cilengitide|inhibits|alphavbeta5 integrin|18616418
cilengitide|treats|GBM|18616418
Cilengitide|treats|glioblastoma multiforme|18616418
alphavbeta5 integrin|administered_to|adults|18981465
Cilengitide|administered_to|adults|18981465
cilengitide|treats|patients|18981465
cilengitide|treats|GBM|18981465
aspartic acid|associated_with|glioblastoma multiforme|18981465
cilengitide|isa|antiangiogenic agent|19114005
cilengitide|disrupts|integrin binding|19114005
Integrins|part_of|malignant glioma|19114005
cilengitide|interacts_with|endothelial|19114005
cilengitide|part_of|cells|19114005
promotor|part_of|cells|19114005
endothelial|disrupts|phosphorylation|19114005
cilengitide|disrupts|phosphorylation|19114005
Cilengitide|causes|apoptosis|19114005
endothelial|inhibits|integrin|19114005
Cilengitide|coexists_with|endothelial|19114005
Integrins|associated_with|prostate cancer metastasis|20336348
cilengitide|treats|patients|20336348
Cilengitide|interacts_with|favor|20336348
Cilengitide|treats|patients|20336348
Cilengitide|treats|metastatic castration resistant prostate cancer|20336348
temozolomide|treats|glioblastoma|20371685
cilengitide|associated_with|glioblastoma|20439646
cilengitide|treats|Patients|20439646
cilengitide|treats|patients|20439646
cilengitide|treats|glioblastoma|20439646
cilengitide|compared_with|MGMT|20439646
cilengitide|affects|bone metastases|20648558
cilengitide|treats|bone metastases|20648558
cilengitide|treats|rats|20648558
Cilengitide|disrupts|bone metastases|20648558
EMD121974|inhibits|integrin|20839028
Cilengitide|associated_with|malignant gliomas|20839028
cilengitide|treats|patients|20839028
cilengitide|treats|solid tumors|20839028
Integrins|associated_with|prostate cancer bone metastases|21049281
integrins|associated_with|metastatic castration resistant prostate cancer|21049281
cilengitide|treats|patients|21049281
cilengitide|treats|metastatic castration resistant prostate cancer|21049281
integrin alphaVbeta5|associated_with|lung metastasis|21636344
Cilengitide|prevents|lung metastasis|21636344
cilengitide|treats|patients|21739168
cilengitide|treats|glioblastoma|21739168
cilengitide|administered_to|Patients|21739168
cilengitide|associated_with|glioblastoma|21739168
Cilengitide|treats|patients|21739168
Cilengitide|treats|glioblastoma|21739168
cilengitide|affects|cells|21788343
Cilengitide|causes|autophagy|21788343
cilengitide|part_of|GSCs|21788343
cilengitide|causes|autophagy|21788343
Cilengitide|causes|autophagy-mediated cell death|21788343
Cilengitide|inhibits|integrin|22517399
temozolomide|treats|patients|22517399
temozolomide|treats|glioblastoma multiforme|22517399
cilengitide|part_of|patients|22517399
cilengitide|treats|run|22517399
Cilengitide|treats|patients|22517399
EMD 121974|inhibits|integrins alphavbeta3|22668797
Cilengitide|treats|metastatic melanoma|22668797
cilengitide|treats|patients|22668797
cilengitide|treats|metastatic melanoma|22668797
docetaxel|treats|patients|22752690
docetaxel|treats|non-small-cell lung cancer|22752690
EMD 121974|inhibits|integrins alphaVbeta3|22752690
integrins alphaVbeta3|part_of|cell-surface|22752690
cilengitide|treats|patients|22752690
cilengitide|treats|non-small-cell lung cancer|22752690
cilengitide|compared_with|docetaxel|22752690
Integrins|part_of|tumor cells|22976135
integrins|disrupts|tumor growth|22976135
alphavbeta5 integrins|affects|cell adhesion|22976135
drugs|treats|cancer|22976135
cilengitide|inhibits|integrin|22976135
cilengitide|isa|treatment|22976135
cilengitide|affects|vasculature|22976135
Cilengitide|treats|patients|22976135
Cilengitide|treats|glioblastoma multiforme|22976135
Cilengitide|treats|malignant glioma|22976135
Integrins|part_of|tumor cells|22989076
EMD121974|inhibits|integrin|22989076
integrin|part_of|cells|22989076
integrin|part_of|tumor endothelial cells|22989076
vascular endothelial growth factor|interacts_with|rapamycin|23060541
receptor|interacts_with|rapamycin|23060541
epidermal growth factor receptor|interacts_with|rapamycin|23060541
integrin|interacts_with|rapamycin|23060541
glycoprotein|part_of|cells|23060541
glycoprotein|part_of|transmembrane|23060541
glycoprotein|affects|cell-cell interactions|23060541
glycoprotein|affects|cell matrix|23060541
integrins|isa|glycoprotein|23060541
integrins|affects|cell-cell interactions|23060541
integrins|part_of|cells|23060541
integrins|affects|cell matrix|23060541
integrins|part_of|transmembrane|23060541
integrins|part_of|vasculature|23060541
glycoprotein|part_of|vasculature|23060541
integrins|affects|angiogenesis|23060541
cilengitide|treats|glioblastoma|23060541
EMD 121974|inhibits|alpha-V integrins|23152080
Cilengitide|affects|tumor|23152080
cilengitide|part_of|i.p.|23152080
melphalan|associated_with|tumor|23152080
cilengitide|stimulates|melphalan|23152080
cilengitide|disrupts|cell attachment|23152080
temozolomide|treats|glioblastoma|23354807
cilengitide|treats|glioblastoma|23354807
drug|augments|apoptosis|23354807
cilengitide|compared_with|drug|23354807
cilengitide|augments|apoptosis|23354807
cilengitide|inhibits|angiogenesis|23354807
cilengitide|disrupts|cell migration|23948974
cilengitide|associated_with|malignant meningiomas|23948974
cilengitide|affects|cell motility|23948974
Cilengitide|inhibits|alphav integrin|24014381
cilengitide|isa|treatment|24014381
cilengitide|treats|children|24014381
cilengitide|treats|glioma|24014381
cilengitide|administered_to|patient|24014381
cilengitide|treats|HGG|24014381
Hecate-betaCG|disrupts|cells|17101210
agonists|inhibits|dipeptidyl peptidase IV|17076997
hemoglobin A|associated_with|Diabetes|17724013
inhibitors|isa|medications|17724013
incretin|treats|type 2 diabetes|17622601
medication|isa|placebo|17622601
hemoglobin A|compared_with|placebo|17622601
Incretins|inhibits|hemoglobin A|17622601
analogues|compared_with|placebo|17622601
insulin|inhibits|DPP4|17622601
peptidase 4 inhibitors|predisposes|infection|17622601
incretin|treats|patients|20631270
incretin|treats|type 2 diabetes|20631270
agonists|affects|hyperglycemia|20631270
peptidase 4 (DPP4) inhibitors|affects|hyperglycemia|20631270
peptidase 4 (DPP4) inhibitors|neg_predisposes|hypoglycemia|20631270
agonists|neg_predisposes|hypoglycemia|20631270
agonists|interacts_with|hemoglobin A|20631270
drugs|treats|type 2 diabetes mellitus|23489968
Medications|inhibits|insulin|20107300
insulin|affects|weight loss|20107300
amiodarone|treats|children|20414522
amiodarone|treats|left ventricular dysfunction|20414522
calcium|causes|dysfunction|23247061
SNX-185|coexists_with|CO2|23247061
venomous|part_of|family|19495521
diclofenac|treats|analgesia|19495521
Snake Venom|part_of|patient|24014571
allergen|augments|wheal|15662966
allergen|augments|erythema|15662966
hormone|associated_with|fat deposition|17192476
Ghrelin|associated_with|fat deposition|17192476
Exendin (Ex)-4|stimulates|glucagon-like peptide (GLP)-1 receptor|17192476
Ex-4|inhibits|ghrelin|17192476
Ex-4|stimulates|ghrelin|17192476
Ex-4|associated_with|type 2 diabetes|17192476
Ex-4|interacts_with|ghrelin|17192476
Ex-4|treats|PWS|17192476
Ex-4|treats|syndromes|17192476
Exendin-4|inhibits|ghrelin|17192476
CM|interacts_with|CM|16038768
CM|augments|macrophages|16038768
CM|prevents|infection|16038768
CM|affects|infection|16038768
Immunomodulatory|interacts_with|medication|16038768
CM|affects|host-parasite relationship|20433834
medication|affects|parameters|20433834
clonidine|treats|neuropathic pain|16154696
Xen2174|treats|allodynia|16154696
morphine|treats|rats|16154696
Xen2174|treats|rats|16154696
Xen2174|administered_to|patients|16154696
Glucagon-like peptide-1|interacts_with|insulin|16188169
Glucagon-like peptide-1|interacts_with|glucagon|16188169
Glucagon-like peptide-1|augments|glucose homeostasis|16188169
GLP-1|inhibits|GLP-1|16188169
drugs|augments|signaling|16188169
insulin|predisposes|hypoglycemia|18473757
metformin|neg_treats|patients|19579421
analogues|treats|type 2 diabetes|19579421
Glucagon-like peptide 1|interacts_with|osteogenic|21372151
GLP-1|inhibits|glucose|21372151
GLP-1|inhibits|total cholesterol|21372151
GLP-1|inhibits|triglycerides|21372151
exendin-4|treats|osteopenia|21372151
agonists|compared_with|therapies|21484979
agonists|treats|diabetes|21484979
glucose|stimulates|sulfonylureas|21484979
agonists|treats|patients|21484979
agonists|treats|renal impairment|21484979
agonists|stimulates|antibodies|21484979
agonists|treats|signs|21484979
agonists|treats|type 2 diabetes|21484979
drugs|treats|diabetes|23258125
antidiabetic drugs|augments|protection|23258125
analogues|treats|obesity|23392214
analogues|treats|severe hypothalamic obesity|23392214
analogues|treats|hypothalamic obesity|23392214
glucagon-like peptide 1|neg_interacts_with|GLP-1|23775764
agonism|augments|weight loss|23775764
agonism|neg_treats|weight loss|23775764
fenofibrate|affects|glucose metabolism|23827952
analogs|treats|type 2 diabetes|24092637
analogs|affects|pulmonary function|24092637
ovalbumin|part_of|mice|24092637
GLP-1R|part_of|lung tissue|24092637
agonists|treats|Mice|24092637
agonists|treats|chronic obstructive pulmonary disease|24092637
agonists|treats|pulmonary diseases|24092637
Glucagon-Like Peptide-1|affects|Lung Function|24092637
allergens|coexists_with|vaccines|21370719
sIgE|neg_part_of|patients|21370719
cardiotoxin|interacts_with|G-CSF|16459191
incretin|associated_with|DM|16971704
Complementary|associated_with|multiple sclerosis|16635436
GsMTx-4 toxin|associated_with|stretch|18367236
nAChRs|associated_with|pathophysiology|17101979
nAChRs|affects|peripheral nerve injury|17101979
transmembrane semaphorin proteins|affects|axonal guidance|17498836
Sema3A|part_of|extracellular|23384361
medications|treats|patient|22098810
medications|treats|obese|22098810
medications|causes|weight loss|22098810
antidiabetic drugs|causes|weight loss|22098810
Drug|treats|obesity|22098810
voltage gated calcium channel|associated_with|pathogenesis|23537331
insulin|treats|mice|20800631
oligonucleotides|isa|drugs|21609675
omega-3 fatty acids|treats|neurological disorders|17659472
epidermal growth factor receptor|associated_with|tumor|21434348
vascular endothelial growth factor|associated_with|tumor|21434348
EGFR|associated_with|tumor|21434348
VEGF|associated_with|tumor|21434348
glucagon-like peptide-1|inhibits|hemoglobin (A1C|18820816
peptidase-4 (DPP-4) inhibitors|stimulates|GLP-1|18820816
H3 receptor|interacts_with|histamine|22220205
histamine|affects|neuron|22220205
neurotoxin|interacts_with|anticonvulsant|18587450
c-Fos|affects|seizure|18587450
anticonvulsant|disrupts|seizures|18587450
sodium channels|affects|epilepsy|18587450
neurotoxin|interacts_with|Anticonvulsant|18587450
omalizumab|treats|patients|18596592
omalizumab|treats|systemic mastocytosis|18596592
omalizumab|treats|allergic reactions|18596592
beta-blockers|isa|medications|18596592
omalizumab|prevents|anaphylaxis|19610266
urea|part_of|blood|18930073
local anaesthetics|isa|analgesic|19558072
idiotype|part_of|Lymphoma|19749091
vaccines|neg_part_of|antigen-presenting cells|19749091
vaccines|augments|cell immunity|19749091
toxin action|affects|toxin binding|20682774
dexamethasone|treats|Generalized edema|21206257
diphenhydramine|treats|Generalized edema|21206257
immunomodulator|part_of|Animals|21811552
crotamine|disrupts|tumor|21834748
Crotamine|affects|neurotransmission|23460475
crotamine|compared_with|neostigmine|23460475
crotamine|part_of|rats|23460475
neostigmine|treats|rats|23460475
crotamine|higher_than|neostigmine|23460475
nonsteroidal anti-inflammatory drug|treats|pain|22188869
drugs|treats|eclampsia|22774506
antimicrobial|treats|fibrosarcoma|23015777
pardaxin|affects|membrane|23015777
interferon (IFN)-gamma|treats|mice|23015777
pardaxin|causes|apoptosis|23015777
pardaxin|treats|mice|23015777
pardaxin|treats|fibrosarcomas|23015777
medroxyprogesterone acetate|affects|endometriosis|23827690
leuprolide acetate|affects|endometriosis|23827690
medroxyprogesterone acetate|compared_with|leuprolide acetate|23827690
